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VSUMMARY
Satisfactory seizure control in epileptic patients may be 
difficult to achieve when anticonvulsant drug dosage is 
adjusted empirically. This may be due, in part, to individual 
variations in metabolism or distribution. Section 1 of this 
thesis includes studies of how serum concentrations of anti­
convulsants may vary in different patients and the relation­
ship between serum concentrations and therapeutic effects.
As shown in Chapter 3, serum concentrations of phenytoin show 
wide variations between different patients. Chapter 4 
describes a study to investigate the value of a nomogram 
(Richens and Dunlop, 19 75) in adjusting serum concentrations. 
Control of major seizures, but not minor seizures, improved 
when the serum concentrations were raised into the postulated 
therapeutic range in patients on multiple drug therapy. The 
nomogram was found to be of only limited value in predicting 
serum concentrations, apparently because the phenobarbitone 
that these patients were receiving inhibits phenytoin 
metabolism and may alter the relationship between dose and 
serum concentration.
The interactions between phenytoin and phenobarbitone are 
complex since, as shown in Chapter 3, administration of 
phenytoin inhibits phenobarbitone metabolism and increases 
phenobarbitone serum concentrations in patients receiving 
phenobarbitone as the drug itself or as a metabolic product 
of primidone. In addition, in the study described in 
Chapter 5, phenytoin was found to lower serum concentrations 
of primidone by inducing its conversion to phenylethyl- 
raalonamide (PEMA). The relationship between primidone dose 
and serum concentration is non-linear, apparently due to 
induction by primidone of its own metabolism.
Serum concentrations and therapeutic effect of a new benzo­
diazepine anticonvulsant, clonazepam, are described in 
Chapter 6. Improvement in seizure control was greater and 
side-effects were less in patients who were receiving
VI
clonazepam alone or low doses of other drugs. There was no 
effect of clonazepam on serum concentrations of other anti­
convulsants, but administration of other anticonvulsants 
appeared to induce the metabolism of clonazepam, possibly 
to a toxic derivative.
A comparative trial of clonazepam against another recently 
introduced anticonvulsant, sodium valproate, is reported in 
Chapter 7. Neither drug significantly reduced the frequency 
of major seizures but sodium valproate therapy significantly 
improved control of minor seizures. Sodium valproate admini­
stration produced an increase in phenobarbitone serum con­
centrations in some patients and in this trial phenobarbitone 
doses were reduced where necessary to ensure that the 
therapeutic action of sodium valproate was not mediated via 
this effect. Serum concentrations of sodium valproate were 
similar in different patients and there was no apparent 
effect of administration of other drugs-
valproate
In Chapter 7 it is also shown that sodium^administration 
reduces serum concentrations of phenytoin and it is suggested 
that this may be due to displacement of phenytoin from its 
plasma protein binding sites. Tissue concentrations of drugs 
depend on the free concentrations in serum and studies of 
protein binding of phenytoin and other anticonvulsants was 
described in Section 2 of this Thesis. In Chapter 8 it is 
shown that protein binding of phenytoin may vary signifi­
cantly between different patients and Chapters 9 and 10 
describe methods which may be used to measure protein 
binding routinely in epileptic patients. Saliva concen­
trations of phenytoin were measured by a new radioimmuno­
assay technique and are shown to be dependent on the free 
concentration in serum. In addition, measurement of 
phenytoin in red blood cells may be a useful index of 
protein binding.
Section 3 of this Thesis includes studies of some of the 
biochemical effects of anticonvulsants. Serum and CSF 
concentrations of folate are lowered by anticonvulsant 
therapy and in Chapter 11 a trial is reported of the effects 
of administration of folate either as folic acid or 
5-formyltetrahydrofolate to epileptic patients. Both groups
vil
of patients showed increases in serum and CSF concentrations 
of folate but there were no significant effects on brain 
amine metabolism, as measured by CSF concentrations of HVA 
and HIAA, or on seizure control. There was, however, a 
significant fall in serum concentrations of phenytoin and 
this may account for an increase in major seizures found in 
some patients in this study and in studies by other workers.
The effects of anticonvulsants on liver enzyme induction 
were studied in Chapter 12 by measuring serum levels of 
y -glutamyl-transpepticfe.seThe metabolism of primidone, 
clonazepam and folate were found to be related to the com­
bined doses of enzyme-inducing drugs. No evidence was, 
however, found between enzyme induction and serum concen­
trations of calcium or triglyceride. It is also possible, 
as described in Chapter 13, that the effect of phenytoin in 
lowering serum concentrations of IgA may be explained by an 
induction of its breakdown but it is suggested that the low 
folate concentrations in patients on anticonvulsant therapy 
may antagonise this effect.
Vlll
LIST OF TABLES
No Page
1.1 International classification of epileptic 3
seizures
1.2 Currently available anticonvulsants 5
3.1 Anticonvulsants received by patients 19
studied for this thesis
3.2 Frequencies of occurrence of various drugs 19
3.3 Phenytoin concentrations and seizure control 23
3.4 Reported effects of phenobarbitone 27
on phenytoin serum concentrations
4.1 Effects of increasing phenytoin concen- 33
trations on seizure frequencies
5.1 Relationship between serum concentrations 59
of primidone and its metabolites and 
primidone dose, serum primidone concen­
trations and serum phenytoin concen­
tration
6.1 Concurrently used anticonvulsants in 59
patients on double-blind trial of 
clonazepam
6.2 Effects of clonazepam therapy on seizure 52
control in patients in double-blind trial
6.3 Effects of clonazepam therapy on seizure 53
control in patients in open trial
7.1 Effects of treatment with sodium valproate 74
and clonazepam on seizure frequencies in
all patients who were treated with one or 
both drugs in comparative trial
7.2 Effects of treatment with sodium valproate 75
and clonazepam on seizure frequencies in 
patients who completed comparative trial
8.1 Summary of previous data on phenytoin 85
binding
9.1 Phenytoin concentration ratios in 95
biological fluids
XX
10.1 Relationships between whole blood and 100
plasma concentrations of anticonvulsants
10.2 Uptake of phenytoin and phenobarbitone 101
by RBCs
11.1 Serum folate concentrations in patients 108
on anticonvulsants
11.2 Effects of folate therapy on serum and 109
CSF concentrations of folate and CSF 
concentrations of HVA and 5-HIAA
11.3 Effects of folate therapy on seizure n o
frequencies
11.4 Effects of folate therapy on serum anti- 112
convulsant concentrations
12.1 Serum y GT levels in patients on anti- 123
convulsants
13.1 Serum immunoglobulin levels in patients 2 3 3
on anticonvulsants
13.2 Serum anticonvulsant concentrations in 234
patients in whom serum IgA was measured
XLIST OF FIGURES
No Page
3.1 Serum phenytoin concentrations in a group 20
of outpatients
3.2 Scrum phenytoin concentrations in a group 20
of inpatients
3.3 Relationship between serum phenytoin 20
concentrations and the weight of the
patient
3.4 Relationship between serum phenytoin 20
concentrations and the weight-related dose
of the drug
3.5 Relationship between serum phenytoin 21
concentrations and the age of the patient
3.6 Serum phenytoin concentrations in patients 22
receiving the drug alone or combined
therapy with phenobarbitone
3.7 Relationship between phenobarbitone dose 22
and serum concentration
4.1 Kinetics of phenytoin metabolism 30
4.2 Nomogram for adjusting phenytoin dosage 30
4.3 Design of study of effect of increasing 32
phenytoin dose on serum concentrations
and seizure control
4.4a,b Effect of increasing serum phenytoin 32
concentrations on frequencies of major 
and minor seizures
4.5 Graphical estimation of individual Vmax 34
and Km values for phenytoin metabolism
4.6 Effect of increasing phenytoin concen- 34
trations on serum phenobarbitone concen­
trations
4.7 Possible effects of competitive inhibition 37
by phenobarbitone on the kinetics of 
phenytoin
XI
4A.1 Serum phenytoin concentrations in a 40
group of geriatric patients
4A.2 Graphical estimation of mean Vmax and Km 4 0
values for phenytoin metabolism in the 
elderly
4A.3 Relationship between dose and serum con- 40
centration of phenytoin in the elderly
4B.la Percentage of phenytoin dose recovered 44
as HPPH
4B.lb Relationship between urine HPPH:phenytoin 44
ratio and serum phenytoin concentration
5.1 Structures of primidone and its metabolites 47
5.2 Serum concentrations of phenobarbitone 48
in patients receiving primidone
5.3 Relationship between dose and serum con- 50
centrations of primidone
5.4 Serum concentrations of PEMA plotted against 51
primidone concentrations
6.1 Chemical structure of clonazepam 57
6.2a,b,c Effects of clonazepam therapy on serum 55
concentrations of phenytoin, phenobarbitone 
and primidone
6.3 Serum clonazepam concentrations in patients 65
on double-blind trial
6.4 Relationship between serum clonazepam and 65
phenobarbitone concentrations
6.5 Serum clonazepam concentrations and the 65
therapeutic effect
6.6 Serum clonazepam concentrations after one 66
year of therapy
7.1 Chemical structure of sodium valproate 72
7.2 Design of cross-over trial of sodium 72
valproate and clonazepam
7.3 Effects of sodium valproate and clonazepam 7 3
on seizure frequency
7.4 Serum clonazepam concentrations and the 77
therapeutic effect
XXX
7.5 Effect of clonazepam on frequency of minor ^7
seizures in an individual patient
7.6a,b,c Effects of sodium valproate therapy on 73
serum concentrations of phenytoin, pheno­
barbitone and primidone
7.7 Effects of sodium valproate on serum con- 81
centrations of other drugs and seizure 
frequency in an individual patient
8.1a,b,c Relationship between serum and CSF con- 87
centrations of phenytoin, phenobarbitone 
and primidone
8.2 Relationship between percentage free 88
phenytoin in serum and the albumin con­
centration
8.3 Effect of plasma dilution on protein binding 88
of phenytoin and phenobarbitone
8.4 Effect of temperature on protein binding 88
of phenytoin and phenobarbitone
8.5 Effect of sodium valproate on protein 89
binding of phenytoin and phenobarbitone
8.6 Sephadex fractionation of protein bound 89
phenytoin
9.1 Relationship between saliva and CSF con- 95
centrations of phenytoin
10.1 Effect of plasma dilution on RBC uptake of 101
phenytoin and phenobarbitone
11.1 Effect of folate therapy on serum phenytoin 112
concentrations
12.1 Relationship between serum y GT levels and 123
'Drug Units'
12.2 Relationship between serum folate and yGT 125
levels
12.3 Relationship between the serum PEMA:primidone 127
ratio and 'Drug Units'
12.4 Relationship between serum clonazepam con- 127
centrations and 'Drug Units'
13.1 Serum IgA levels in patients on anticon- 134
vulsants
ABBREVIATIONS
X l l l
DPH
PB
PEMA
HPPH
CSF
GLC
5-HIAA 
HVA 
y GT
ig
EEG
TMAH
TMPAH
RBC
SD
r
P
diphenylhydantoin (phenytoin)
phenobarbitone
phenylethylraalonamide
p-hydroxy-phenytoin
cerebrospinal fluid
gas liquid chromatography
5“hydroxy-3-indole acetic acid
homovanillic acid
y  -glutamyl transpeptidase
immunoglobulin
electroencephalogram
trimethylammonium hydroxide
trimethylphenylammonium hydroxide
red blood cell
standard deviation
regression coefficient
probability
UNITS USED
sec
kg
mg
m
ml
pi
pU/1
mmol/1
jamol/1
nmol/1
o^
second
3
kilogram 1 x 10 gram
milligram 1 x 10  ^ gram
-6microgram 1 x 10 gram
-31 x 10
- 6
millilitre 
microlitre 1 x 10 
micro Units per litre 
millimoles per litre 
micromoles per litre 
na nomoles per litre
degrees centrigrade
litre
litre
1 X 10 
1 X 10
-  6
-3
1 x 10
-9
1 X  10 ^
-  6
Units per litre 
moles per litre 
moles per litre 
moles per litre
CHAPTER 1 
INTRODUCTION
Historically, epilepsy is a term which was introduced by the 
Ancient Greeks to describe the phenomenon in which a man was 
apparently "seized" by mysterious forces. Hippocrates 
(460-357 BC) suggested that epilepsy was due to a disturbance 
of the brain, and in the seventeenth century Willis 
attributed epileptic fits to an explosion of animal spirits 
within the brain. Scientific understanding of epilepsy did 
not begin until the nineteenth century however. In 18 70, the 
experiments of Tritsh and Hitzig showed that electrical stimu­
lation of the dog's cortex produced fits and in the same year 
Hughlings Jackson suggested that epilepsy was due to occasional 
discharges of neurones, beginning at and spreading from a 
focus in the brain. The introduction of electroencephalo­
graphy (Berger, 19 29) permitted the electrical recording of 
the discharge and has been a major tool in the study of 
seizures.
Epilepsy is among the most common of chronic'neurological 
disorders, the incidence being reported as 1 in 200 of the 
population (Lennox, 1960). In 75% of the patients it begins 
before the age of 20 and in tv70 thirds of all patients it is 
a chronic recurring problem despite drug therapy which must, 
therefore, be lifelong (Rodin, 1968).The aetiologic factors 
in epilepsy have not been precisely established, but it is 
known that damage to the brain such as produced by infections 
(meningitis, encephalitis), cerebral injuries sustained in 
association with birth or from other causes, and metabolic 
disorders (hypoglycaemia, hypernatraemia) predispose some 
individuals to the development of the disease.
Epileptic attacks differ widely in their clinical presenta­
tion. There may be only a momentary suspension of activity, 
as in a petit mal attack. In others, complex alterations of 
behaviour characterise the attack. Consciousness is usually, 
but not always, affected; some seizures consist of nothing
more than an altered sensation. The manifestations of the 
seizures depend upon several factors, foremost among which 
are the site of origin of the epileptic discharge and the 
pattern of spread of the discharge within the brain. The 
most generally accepted classification of seizures is that 
proposed by the International League against Epilepsy 
(Gastaut, 19 70) which is shown in Table 1.1.
Seizures may be divided into two groups; those that begin 
as local processes in relatively restricted populations of 
neurones are described as focal or partial seizures; and 
those that are primarily : generalised, having a diffuse
and unspecific influence upon cerebal function. Secondary 
generalisation also occurs, when this same diffuse system 
is activated by spread from an epileptic discharge that is 
initiated in a focus.
The tonic-clonic or grand mal attack is a generalised 
seizure and is the type of attack most likely to be equated 
with epilepsy by the layman. The patient loses con­
sciousness and the sequence of motor events usually proceeds 
from tonic muscular stiffening to clonic fits. The body 
initially goes rigid and the patient falls, this being 
followed by a period of symmetrical jerking and relaxation 
of the extremities. By contrast, the absence attack is a 
generalised seizure in which the main characteristic is 
simply a brief suspension of consciousness and may be so 
mild as to make recognition difficult. Myoclonic seizures 
which may occur singly or repetitively, are sudden brief 
muscular contractions.
The nature of the clinical symptoms in a partial seizure 
depends to a great extent upon the functional importance of 
the area of the brain from which the discharge emanates. 
Usually such foci are in the cerebral cortex. Partial 
seizures may be separated into hvo major categories; those 
with elemental and those with complex symptoms. Seizures 
with complex symptomatology, including psychomotor attacks, 
characteristically arise from temporal lobe foci on one or 
both sides. The psychomotor attack (or automatism) is a 
seizure involving a period of altered behaviour for which
1. Partial Seizures (local onset)
A. With elementary symptomatology - generally 
without impaired consciousness
1. With motor symptoms (includes Jacksonian 
seizures)
2. With special sensory or somatosensory symptoms
3. With autonomic symptoms
4. Cbirpound forms
B. Partial seizures with complex symptomatology - 
generally with impairment of consciousness
1. Impaired consciousness only
2. Cognitive symptomatology
3. Affective symptomatology
4. Psychosensory symptomatology
5. Psychomotor symptomatology (automatisms)
6. Compound forms
C. Partial seizures secondarily generalised - 
usually tonic-clonic in type
2. Generalised Seizures (bilaterally symmetrical without 
local onset)
1. Absences (including petit mal)
2. Bilateral massive epileptic myoclonus
3. Infantile spasms
4. Clonic seizures
5. Tonic seizures
6. Tonic-clonic seizures (grand mal)
7. Atonic seizures
8. Akinetic seizures
3. Unilateral Seizures
4. Unclassified Seizures
Table 1.1 International Classification of Epileptic
Seizures (1970)
the patient is amnesic and during which he appears to 
respond in a limited fashion to his environment. Partial 
seizures with elementary symptoms include motor seizures 
with characteristic movements (including Jacksonian 
seizures) or with inhibition of movement, and various forms 
of sensory seizures, in which the patient experiences 
somatic, visual, auditory and vertiginous symptoms.
The first effective drug treatment came in 1857, when 
Locok- introduced bromides, on the erroneous supposition 
that epilepsy was caused by sexual overactivity and would 
thus be relieved by an anti-aphrodisiac. Prior to this 
time, treatment of epilepsy was generally bizarre and 
included trephination of the skull to let the evil spirits 
escape or, in Roman times, drinking the fresh blood of a 
gladiator. Bromide salts remained the only successful 
treatment until, with the introduction of phenobarbitone 
by Hauptman in 1912, a truly effective anticonvulsant 
therapy arrived. This was followed by the introduction of 
diphenylhydantoin by Merritt and Putman in 19 38, and a wide 
range of anticonvulsants is now available (Table 1.2).
Most patients are, however, still treated with combinations 
of phenytoin, phenobarbitone and primidone. Primidone is, 
in fact, converted in the body partly to phenobarbitone 
(Bogue, 19 56) and this may be the basis of its anticon­
vulsant action.
The use of these drugs is empirically based and the 
mechanisms of their actions remain little understood. The 
primary action of phenytoin appears to be in stabilising 
excitable membranes, possibly due to a decrease in intra­
cellular sodium and an increase in the extracellular to 
intracellular Na^ (Woodbury, 19 55). Phenobarbitone is a 
sedative and has a depressing effect on synaptic activity. 
It may also act via a blocking effect on cation transport 
through the cellular membrane, with a resulting decrease 
in the Na*** and fluxes which accompany excitation and 
inhibition (Bunker and Vandam, 1965). Phenytoin, pheno­
barbitone and primidone are all wide spectrum anticonvul­
sants and are effective against most types of seizures, 
although only minimally so in petit mal which is usually
GENERIC NAME TRADE NAME
A. BARBITURATES
1. Phenobarbitone Gardenal
2. Primidone Mysoline
B. HYDANTOINATES
1. Diphenylhydantoin Epanutin
2. Methoin Mesontoin
3. Ethotoin Peganone
C. 0XA20LIDINIDI0NES
1. Trimethadione Tridione
2. Paramethadione Paradione
D. SUCCINIMIDES
1. Ethosuximide Zarontin
2. Phensuximide Milontin
3. Methosuximide Cilontin
E. BENZODIAZEPINES
1. Diazepam Valium
2. Nitrazepam Mogadon
3. Clonazepam Rivotril
F. MISCELLANEOUS
1. Carbamazepine Tegretol
2. Sodium Valproate Epilim
3. Sulthiame Ospolot
4. Pheneturide Benuride
Table 1.2 Some Currently Available Anticonvulsants
treated with ethosuximide.
The ideal anticonvulsant drug should be capable of complete 
suppression of all types of seizure at a doseage level that 
does not cause sedation or other toxic effects. No such 
drug exists and, with the aim of maximising seizure control, 
with the minimum of toxic effects, it has become standard 
practice to utilise multiple drug therapy in the management 
of epilepsy. It is, therefore, important to know if one 
drug will alter the action of another where they are taken  ^
together.
Drug interactions may occur as a result of alteration of the 
absorption, distribution or elimination of one drug by 
another, or from combination of their actions or effects.
In particular, interactions involving anticonvulsants may 
involve a rise or fall of the serum concentration of the 
primary drug, after addition of a second agent. In order 
for a drug to act it must reach the site of its action 
(receptor), presumably the central nervous system in the 
case of anticonvulsants. The concentration of drug that 
reaches receptor, and hence the effect, depends upon the 
serum level. It would be expected that measurement of 
serum concentration will give a more accurate guide to the 
therapeutic or toxic effects of a drug than will the daily 
dose. Improved techniques for the assay of drugs, 
particularly using gas chromatography, have made their 
routine measurement possible and the value of determining 
serum concentrations of anticonvulsant drugs in the clinical 
management of patients with epilepsy has been emphasised in 
numerous publications (reviewed in Woodbury et al, 19 72; 
Eadie and Tyrer, 1974; Kutt and Penry, 1974).
The aim of Section 1 of this thesis is to study further the 
value of the measurement of serum anticonvulsant concen­
trations in the treatment of epileptic patients and how 
various factors, particularly the administration of other 
drugs, affect the relationship between dose and serum con­
centration. After a review of methods used for the 
measurement of anticonvulsant drugs in Chapter 2, a survey 
is described in Chapter 3 of an inpatient and an outpatient
epileptic population which had the aim of investigating 
what drugs these patients were receiving and how well 
patients were managed without the availability of 
information on drug levels. It was found that patients 
on phenytoin, which is the most commonly used anticon­
vulsant, showed serum concentrations below the commonly 
accepted therapeutic range; a study was therefore 
designed and is described in Chapter 4 to investigate 
whether increasing serum concentrations into the thera­
peutic range improves seizure control. In Chapter 3 it 
is also shown that serum concentrations of phenytoin may 
increase with age; the possible effects of age on 
phenytoin metabolism are examined in Chapter 4A.
Many patients receive combined therapy of phenytoin with 
phenobarbitone or primidone, and interactions between 
these drugs may be of major therapeutic importance.
Chapter 3 includes an investigation of the possible 
effects of phenobarbitone or primidone on serum concen­
trations of phenytoin and the possible importance of 
these interactions is examined further in Chapter 4. 
Conversely, phenytoin administration may affect serum con­
centrations of phenobarbitone and studies in Chapters 3 
and 4 show that phenytoin may inhibit phenobarbitone metab­
olism. The effects of phenytoin on primidone metabolism 
are more complex and appear to involve both inhibition and 
induction effects; this is described in Chapter 5.
The use of information on serum drug levels may be 
particularly valuable in the evaluation of new drugs. 
Chapters 6 and 7 describe trials of two newly introduced 
anticonvulsants, clonazepam and sodium valproate, which 
were designed to study the possibility of drug interactions 
and define therapeutic ranges of serum concentrations for 
these drugs.
Tissue concentrations of drugs depend on the free rather 
than the total concentration in plasma. Drugs such as 
phenytoin may be highly bound to proteins in plasma, and 
variations in protein binding may affect the therapeutic 
response. Section 2 of this thesis is concerned with the 
study of protein binding of anticonvulsants. In Chapters
the possible effects of various other factors (including 
plasma albumin concentration, administration of other drugs 
and the effect of temperature) on protein binding of 
phenytoin are examined, and the protein binding is shown 
to vary significantly between different patients. However, 
standard methods for measuring protein binding of drugs are 
generally too tedious to be used routinely in the clinical 
management of epileptic patients; Chapters 9 and 10 are 
concerned with the evaluation of simple new methods for 
studying binding. In Chapter 9 the concentration of 
phenytoin in saliva is shown to be equivalent to the free 
concentration in plasma and Chapter 10 describes how the 
uptake of phenytoin and other anticonvulsants by red blood 
cells is related to the free concentration of plasma.
The study of the pharmacokinetics of anticonvulsant drugs 
is important not only because it offers a means of 
improving seizure control, but also because it offers 
useful insights into the mechanisms of some of the bio­
chemical effects of anticonvulsants. Section 3 of this 
thesis is concerned with an examination of the relationship 
of some of the biochemical effects of anticonvulsants to 
their serum concentrations and to their effects on the drug- 
metabolising system in the liver. Chapter 11 is concerned 
with a study of the reduced folate levels found in patients 
on anticonvulsant therapy and offers an interesting example 
of a link between a biochemical effect of a drug and its 
metabolism - it is found that administration of folate may 
decrease phenytoin serum concentrations, presumably due to 
increased metabolism of the drug, but conversely it is 
suggested that the effect of phenytoin and other anticon­
vulsants in reducing serum folate concentrations may be 
due to induction of folate metabolism. Evidence that 
folate metabolism may be induced by anticonvulsants is 
described in Chapter 12, there being a significant relation­
ship between serum folate and levels of y-glutamyltranspep- 
tidase (y  GT). The action of anticonvulsant drugs in raising 
y GT levels has been used as an index of their ability to 
induce activity of the drug-metabolising system in the liver 
and a method is described in Chapter 12 whereby the potential 
enzyme-inducing effect of a given drug regime can be
quantified in terms of 'Drug Units'. The relationship 
is described between the Drug Units that a patient is 
receiving and the metabolism of clonazepam and primidone 
and the possible effects of anticonvulsants on calcium 
metabolism, which may cause osteomalacia, are investigated. 
In Chapter 13 it is suggested that the low serum IgA levels 
obtained in patients on anticonvulsant therapy may be due to 
induction of breakdown of the protein; in addition, it is 
suggested that the lowered folate concentrations antagonise 
this effect and that folate therapy also increases immuno­
globulin catabolism.
SUMMARY
1. The history of the understanding of epilepsy and
the nature of the disease are briefly described.
The types of epileptic seizure and the drugs 
available for treatment are tabulated.
2. The reasons for embarking on this study are given
along with an outline of the structure of the thesis
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CHAPTER 2
MEASUREMENT OF ANTICONVULSANT DRUGS
The major part of the work described in this thesis 
involves measurement of anticonvulsant drugs, either in 
serum or in other biological fluids. In this Chapter 
the techniques available for the assay of anticonvulsant 
drugs are reviewed and the methods used for the studies 
in this thesis are summarised. Details of these methods 
are included in the appendix.
Techniques for Measuring Anticonvulsant Drugs
A variety of methods for measuring concentrations of 
phenytoin and other drugs have been developed over the 
last 20 years. The major methods that have been used can 
be divided into six basic types ;
1. Spectrophotometric techniques such as that of 
Olesen, 1967. These show a lack of specificity and 
sensitivity and tend to give unreliable results 
(Richens, 1975).
2. Thin-layer chromatography techniques. That developed 
by Pippenger (1969) allows the measurement of 
approximate levels of phenytoin, phenobarbitone 
primidone and phenylethylmalonamide (PEMA) and such 
techniques may be useful for routine screening of 
large numbers of specimens.
3. Gas-liquid chromatographic (GLC) techniques, in which 
the drug may be chromatographed directly or a 
derivative is formed.
4. High-pressure chromatographic methods such as that 
of Adams and Vandemark (19 76) which allows the 
simultaneous determination of phenytoin, pheno­
barbitone, primidone, carbamazepine and ethosuximide. 
These methods provide good sensitivity without the 
derivatisation that may be necessary in GLC techniques, 
but require equipment that is not readily available
in most laboratories.
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5. Radioimmunoassay. This is a particularly sensitive 
technique and is useful for assaying drugs such as 
clonazepam whose concentrations in serum are low or 
for assaying drugs in small volumes of biological 
fluids such as saliva. However, there may be 
difficulties in obtaining a specific antibody; in 
the radioimmunoassay for clonazepam other benzo­
diazepines interfere. Only one drug may be assayed 
at a time and the cost involved is likely to be 
greater than with gas chromatography.
6. Enzyme immunoassay. This is an analogous method to 
radioimmunoassay and also suffers from the dis­
advantage that it is expensive to use. Also, it 
cannot be readily adapted to assay new drugs unless 
antibodies against these drugs are available.
However, it is a particularly simple technique to 
use.
Gas Chromatography of Anticonvulsant Drugs
The generally most useful technique for measurement of 
anticonvulsants appears to be GLC. This can be used to 
measure most anticonvulsants, often several simultane­
ously, uses equipment which is readily available in most 
laboratories, and provides reliable and accurate results 
(Richens, 19 75). The methods which have been developed 
are summarised in the accompanying table (Table 2.1).
Some workers chromatograph the unchanged drugs 
(Pippinger and Gillen, 1969; Evenson et al, 1970;
Van Meter, 19 70; Gardner-Thorpe et al, 19 72; Toseland 
et al, 1972), while others form derivatives to reduce 
polarity and subsequent absorption and peak tailing. The 
commonest approach is the formation of 1,3-dimethyl 
derivatives of the drugs. Méthylation prior to chroma­
tography (Sandberg et al, 1968) increases the number of 
manipulative steps following extraction. On-column 
méthylation with tétraméthylammonium hydroxide (TMAH)
(McGee, 19 70) or trimethylphenylammonium hydroxide (TMPAH) 
(Hammer et al, 19 70; Kupferberg, 1970; Goudie and 
Burnett, 19 72; Kananen et al, 1972; Perchalski et al, 1973;
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Roger et al, 1973; Midha et al, 1976; Nishina et al,
19 76) provides a simple technique; the latter reagent 
appears to give the better quantitative performance. 
Results of a quality control scheme (Richens, 1975) 
suggested that GLC with méthylation was more accurate, 
at least for assay of phenytoin, than GLC without 
derivatisation. Other methods utilise trimethylsilyl 
(Chang and Glazco, 1970; Baume1 et al, 19 72; Least 
et al, 1975), ethylated (Kumps and Mardens, 1974; Friel 
and Troupin, 19 75) hexylated (Giovanniello and Pecci,
1976) and butylated (Hooper et al, 1975) derivatives.
Since most epileptic patients receive various combinations 
of phenytoin, phenobarbitone and primidone, it is 
desirable that any routine method for measurement of 
serum levels should measure these drugs simultaneously.
In the present study it was intended to investigate the 
metabolism of phenytoin and primidone and it was 
desirable that the method used could be adapted as 
easily as possible to the measurement of HPPH (in urine) 
and PEMA (in serum and urine). Also, a significant 
number of patients receive carbaraazepine and ideally the 
method should also be capable of measuring this drug. 
However, there is no single method available which is 
capable of measuring phenytoin, phenobarbitone, primidone, 
carbamazepine, HPPH and PEMA. A method using on-column 
méthylation with TMPAH has been described for the 
simultaneous measurement of phenytoin, phenobarbitone, 
primidone and carbamazepine (Roger et al, 1973), but the 
present author did not find that a reproducible carbama­
zepine peak was obtained. Carbamazepine is measured as 
a decomposition product but it was found that under the 
conditions used (without automatic sampler as in the 
original publication) the degree of decomposition was 
variable, and this has been confirmed by other workers.
A method in which the trimethylsilyl derivatives are 
chromatographed has been suggested for the simultaneous 
measurement of phenytoin, primidone, PEMA and carbama­
zepine (Least et al, 1975). However, the trimethylsilyl
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derivative of phenobarbitone is unstable and this drug 
cannot be assayed by this procedure. Routine use of this 
method would require a separate determination of pheno­
barbitone, by méthylation, in all patients receiving this 
drug or primidone. Thus in this study the routine method 
used for analysis of phenytoin, phenobarbitone and 
primidone involved méthylation with TMPAH; the method 
was extended to include simultaneous measurement of 
HPPH in urine samples. Since this method could not be 
used for the assay of PEMA, this compound was determined 
separately as its trimethylsilyl derivative.
Extraction of Anticonvulsant Drugs
A considerable number of methods for extraction of drugs 
from serum have been used by different investigators, 
but they can be divided into two basic types : 
those in which the drugs are extracted into organic 
solvent and the solvent then evaporated; and those in 
which the methylating (or ethylating) agent is added to 
the solvent to extract the drugs so that no solvent 
evaporation is necessary. The latter technique offers 
advantages in terms of rapidity but has disadvantages in 
that the methylating agent used must be TMAH rather than 
TMPAH and the extracting solvent generally incorporates 
ether (Perchalski et al, 1973; Friel and Troupin, 1975; 
Joern, 1975), which is relatively dangerous to handle. 
Also, this method is not suitable for the extraction of 
PEMA. Therefore, the method used for extraction of drugs 
in this study was one in which the solvent was evaporated 
after extraction; before evaporation it was possible to 
split the extract into two parts - one for the assay of 
PEMA and one for the assay of phenytoin, phenobarbitone, 
primidone and PEMA. It would also be possible to com­
bine the assay of PEMA, as its trimethylsilyl derivative, 
with assay of carbamazepine according to the method of 
Least et al (1975).
The extraction method used was based on that of Goudie 
and Burnett (1972), which was found to give satisfactory 
extraction for all these drugs and metabolites. The
15
conditions used for chromatography of the methylated 
derivatives (with addition of p-tolyl-phenytoin as 
internal standard) were also those used by these workers 
(but a flame ionisation detector was used rather than a 
nitrogen detector), while the trimethylsilyl derivative 
of PEMA was chromatographed according to the method of 
Baumel et al (197 2). No internal standard was added for 
assay of PEMA, the peak height being measured in relation 
to the peak height of primidone, which can also be 
measured by this method.
Assay of HPPH
Chapter 6 describes measurement of HPPH in the urine, 
which is present mainly as the glucuronide conjugate 
rather than the free drug. GLC assay of HPPH initially 
requires hydrolysis of this conjugate. This can be done 
by acid hydrolysis - boiling in HCl but this causes 
problems in that the pH must be adjusted before extraction 
by adding saturated NaOH and this is somewhat tedious.
Thus in this study enzymatic hydrolysis with ^ -glucuroni­
dase was used.
Assay of Sodium Valproate and Clonazepam
The other drug which was measured by GLC in this study 
was sodium valproate. This is a fatty acid which is 
present in the serum at fairly high levels at thera­
peutic doses and can be readily assayed as the 
underivatised compound and only a simple extraction into 
organic solvent is necessary. The measurement of 
clonazepam in serum presents considerably greater 
difficulties, since the drug is present only in 
nanogram quantities, and an electron capture detector 
is necessary. Since this piece of apparatus was not 
available, clonazepam was measured in this study by 
radioimmunoassay.
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Blood Sampling
Blood samples for measurement of serum anticonvulsants 
were obtained by venepuncture from an ant.ecubital vein. 
Blood was collected into plain plastic tubes and the 
serum separated and stored at -20C.until the time of 
assay. Half-lives in the body for phenytoin and 
phenobarbitone are relatively long and serum levels of 
these drugs vary little throughout 24 hours; blood 
samples for assay of these drugs in the study described 
in Chapter 3 were taken between 2 and 12 hours after the 
last drug dose. Primidone and sodium valproate have short 
half-lives and the blood samples taken for assay of these 
drugs, and also of clonazepam, were generally taken soon 
( 2 - 4  hours) after the last drug dose.
SUMMARY
1. Methods used for the assay of anticonvulsant drugs 
are surveyed.
2,. Gas chromatographic techniques for the assay of 
anticonvulsant drugs, including the particular 
methods used for the work described in this thesis, 
are described.
Note :A11 measurements of anticonvulsants described in this 
thesis were carried out by the author personally 
except for radioimmunoassays of phenytoin and clonzepam. 
The phenytoin radioimmunoassay was done by Dr J W Paxton 
of the Department of Materia Medica and the clonazepam 
radioimmunoassay was done by Dr D A O'Kelly at the 
Psychoendocrine Centre, St James's Hospital, Dublin.
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CHAPTER 3
SURVEY OF ANTICONVULSANTS USED AND THEIR SERUM 
CONCENTRATIONS IN PATIENTS STUDIED FOR THIS THESIS
- ' , INTRODUCTION
The chief reason for measuring serum drug concentrations 
is that concentrations produced by standard doses of some 
drugs vary widely from patient to patient. This variation 
is due to differences in absorption, distribution, 
metabolism or excretion of the drug. For most drugs this 
pharmokinetic variation is much greater than the pharmo- 
codynamic variation (differences in tissue response to a 
given circulating concentration of the drug). It would 
be expected that the ability to monitor the serum con­
centration will enable the clinician to tailor the patient's 
dose to produce a concentration within the therapeutic 
range.
This Chapter describes a study which was conducted in 
order to examine what anticonvulsant drugs two groups of 
epileptic patients (inpatients and outpatients) were 
receiving and how the serum concentrations varied. It was 
found that serum concentrations of phenytoin in particular 
showed a high degree of variability. How does this 
variability arise? It was attempted to identify how various 
parameters (including the weight, age and sex of the patient 
and the administration of other drugs) altered the relation­
ship between dose and serum concentration.
PATIENTS AND METHODS
The investigations carried out for this and succeeding 
Chapters were on patients receiving anticonvulsant therapy 
for various forms of epilepsy. They were mainly inpatients 
at the Epilepsy Centre, Quarriers' Homes, Bridge of Weir, 
Renfrewshire and outpatients attending the Institute of
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Neurological Sciences, Southern General Hospital, Glasgow.
A survey was carried out of what drugs these patients were 
receiving and blood samples for anticonvulsant analysis 
were obtained from most patients, on at least one occasion.
In all patients the age and sex were recorded at the time 
of sampling and in the inpatients and some of the outpatients 
the weight was also obtained. Seizure control in the in­
patients was evaluated by calculating the average number of 
major or minor seizures per month during the period prior 
to blood sampling (3-12 months) in which the drug regime 
had remained unchanged. Serum concentrations of phenytoin, 
phenobarbitone and primidone were determined by GLC (see 
Chapter 2 and Appendix),
RESULTS
Frequency of Drug Use
The drugs which were being received by 124 inpatients and 
430 outpatients are listed in Table 3.1. The outpatients 
were receiving a mean of 1.8 drugs and the inpatients, who 
were generally suffering from more severe epilepsy, were 
receiving a mean of 2.0 drugs. Phenytoin, phenobarbitone 
and primidone were by far the most commonly used anticon­
vulsants and Table 3.2 gives the frequencies of combina­
tions of these drugs.
Reproducibility of Serum Concentrations
In order to determine to what extent measured serum con­
centrations varied on different occasions, blood samples 
for analysis of phenytoin, phenobarbitone or primidone were 
obtained on two occasions, the drug regime being unchanged. 
Approximately half the samples were obtained from inpatients, 
the other half from outpatients. Correlating the results 
obtained on the first and second occasions, for 86 patients 
on whom serum phenytoin was measured r ~ 0.89 2, for 59 
patients in whom phenobarbitone was measured r = 0.7 76, for 
37 patients in whom primidone was measured r = 0.7 05.
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DRUG .INPATIENTS OUTPATIENTS
Phenytoin 86 333
Phenobarbitone 61 202
Primidone 57 116
Diazepam 8 17
Ethosuximide 1 8
Clonazepam 4 27
Carbamazepine 21 34
Sodium Valproate 2 19
Sulthiame 4 4
Pheneturicte 2 7
Total 248 767
Table 3.1 Anticonvulsant Drugs Received by 124 Inpatients 
and 430 Outpatients
DRUG COMBINATIONS INPATIENTS OUTPATIENTS
Phenytoin 13 125
Hienobarbitone 12 48
Primidone 19 30
Phenytoin + Phenobarbitone 42 136
Phenytoin + Primidone 31 68
Phenobarbitone tPrimidone 5 9
Phenytoin + Primidone +
Phenobarbitone 2 9
Total 124 425
Table 3.2 Combinations of Phenytoin, Phenobarbitone and 
Primidone received by 124 Inpatients and 430 
Outpatients {5 of the Outpatients were 
receiving Clonazepam only)
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There was no significant difference between reproducibility 
for outpatients and inpatients. The low correlation 
obtained for phenobarbitone concentrations as compared to 
phenytoin concentrations was due to the relatively small 
variation in phenobarbitone concentrations between 
different patients; in fact, there was a mean variation 
in phenobarbitone concentrations between the two occasions 
of only 10%. The low correlations for primidone concen­
trations can be explained by its short half-life and the 
fact that variations in the time of sampling in relation 
to the previous dose may produce widely different results. 
For further discussion of serum primidone concentrations, 
see Chapter 5.
Serum Phenytoin Concentrations
Serum phenytoin concentrations plotted against dose are 
shown in Fig 3.1 for 262 outpatients and in Fig 3.2 for 
85 inpatients. There was no significant difference 
between the results for the two groups of patients, except 
that a few outpatients showed zero phenytoin concentrations 
on reasonably high doses of the drug and this was not found 
in the inpatients. There was a wide scatter of phenytoin 
concentrations in patients on the same dose and the 
distribution appeared to be log-normal; for the 83 in­
patients, correlating serum concentrations against dose 
r = 0.240 (p<0.05) and correlating log serum concentrations 
against dose r = 0.283 (p<0.01).
The weight of the patient was obtained in 7 0 patients (in­
patients and outpatients) who were receiving 300mg phenytoin 
daily. The serum concentrations were plotted against the 
weight and the results are shown in Fig 3.3. A significant 
negative relationship was found between the weight and log 
serum concentrations (r = 0.368, p<0.01). The weight of 
the patient was also obtained for 76 patients on doses of 
phenytoin other than 300mg, and Fig 3.4 shows the serum 
concentration plotted against the weight-related dose for 
a total of 146 patients. As can be seen, there was no 
significant difference between men and women for the
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relationship between phenytoin concentration and weight 
related dose. Fig 3.5 shows the serum phenytoin concen­
tration plotted on a logarithmic scale against age for 
patients receiving 300mg phenytoin. A small but signifi­
cant positive relationship was found (r = 0.251, p<0.01).
It is also possible that the drug interactions may cause an 
increase or decrease in serum phenytoin concentrations and 
may increase variability. A higher correlation between 
phenytoin dose and log serum concentration was obtained 
for 6 8 patients on single drug therapy with phenytoin 
(r = 0. 389, p<0.01) compared to the 83 inpatients described 
above, who were mainly on combination therapy with pheno­
barbitone or primidone. Serum concentrations of phenytoin 
in patients on single therapy and combined therapy with 
phenobarbitone are shown in Fig 3.6. There is slightly 
more variation in serum concentrations in patients on com­
bined therapy. There is no difference in the mean serum 
concentrations between the two groups of patients, comparing 
patients receiving 300mg phenytoin daily; 27 patients on 
single therapy showed a geometric mean phenytoin serum con­
centration of 35.8 pmol/1 and 46 patients receiving pheno­
barbitone showed a geometric mean phenytoin serum concen­
tration of 33.9 pmol/1. 36 patients receiving 300mg phenytoin
and receiving primidone, however, showed a lower geometric 
mean phenytoin serum concentration of 2 6.9 pmol/1; comparing 
phenytoin serum concentrations in patients receiving 
phenytoin alone and patients receiving primidone, the difference 
between the means did not quite reach significance (t = -1.616, 
p < 0.1 , comparing the log values of the serum concentrations).
Phenobarbitone serum concentrations were plotted against 
phenytoin serum concentrations for the 5 8 patients on combined 
therapy and on a standard dose of 300mg phenytoin daily.
There was no significant correlation between the serum pheno­
barbitone concentration and the log serum concentration of 
phenytoin. However, there is evidence that, at least in 
patients on phenytoin, the phenobarbitone serum concentrations 
show an approximately log - normal distribution (see 
following section). Correlating the logarithms of the 
serum concentrations of phenytoin and phenobarbitone, a
Serum Phenytoin 
(jumol/l )
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Fig 3.5 The relationship between serum phenytoin 
concentrations plotted on a logarithmic 
scale and the age of the patient for 135 
patients receiving 300mg phenytoin daily 
A significant positive relationship 
( p < 0.01) is shown
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significant positive relationship was found (r = 0.358, 
p < 0.Oil.
Serum Phenobarbitone Concentrations
Phenobarbitone showed less variability in serum concen­
trations than phenytoin with the weight-related dose.
For 49 patients in whom the weight was obtained, 
correlating serum concentrations with dose r =0.793 
There was a particularly high correlation between dose and 
serum concentration for patients receiving phenobarbitone 
alone. This can be seen in Fig 3.7, where results for 22 
patients receiving single therapy and 7 8 patients receiving 
combined therapy are plotted; none of these patients were 
receiving any other drugs. The equation of the line for 
patients receiving phenobarbitone alone was 
serum concentration = 12.6 + 0.46 x dose (r = 0.813) 
and for patients receiving phenytoin was 
serum concentration = 2.5 + 0.78 x dose (r = 0.663)
Patients receiving phenytoin had significantly higher 
phenobarbitone serum concentrations and the lower r value 
shows that there was greater variability. In fact, in 
patients on phenytoin there was evidence that the serum 
concentrations did not show a normal distribution but 
rather approximated to a log-normal distribution.
Seizure Control
Seizure frequency was assessed in 57 patients who were on 
a standard dose of 30 0mg phenytoin daily. All but two were 
receiving phenobarbitone or primidone also and a number were 
receiving other drugs - carbamazepine (7), diazepam (3), 
clonazepam (1) and sulthiame (1). The seizure frequency 
in relation to serum concentration of phenytoin is shown 
in Table 3.3, There was no significant relationship 
between serum concentration and seizure frequency but 
patients showing concentrations below 40 pmol/1 were having 
more major seizures.
On Phenobarb
Serum  
Level 
M m ol/l
120-
80-
40- •b
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Phenytoin Dose mg
Fig 3.6 The relationship between phenytoin dose and 
serum concentration, for patients receiving 
the drug alone and patients receiving 
combined therapy with phenobarbitone
On Phenytoin
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Fig 3.7 The relationship between phenobarbitone dose 
and serum concentration, for 22 patients 
receiving the drug alone and 7 8 patients on 
combined therapy with phenytoin
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Phenytoin
Concentration
Range
No of 
Patients
Major
Seizures
,,
Minor
Seizures
0 - 4 0  pmol/1 38 1 . 82 8.0
40 - 80 16 1.04 10.1
> 80 3 0.3 2.2
Table 3.3 Mean Seizure Frequency Per Month Per 
Patient for Groups of Patients Showing 
Phenytoin Serum Concentrations Below, In 
and Above the Therapeutic Range
DISCUSSION
By far the most commonly used drugs in the patients described 
in this study were phenytoin, phenobarbitone and primidone. 
Combinations of phenytoin with phenobarbitone or primidone 
were particularly common. Since phenytoin, phenobarbitone 
and primidone were,by far the most commonly used drugs, 
these drugs were selected for studies of their serum con­
centrations which are described.in this and the succeeding 
two Chapters. Although clonazepam and sodium valproate 
were infrequently used in these patients, studies of these 
drugs were conducted and are described in Chapters 6 and 7 
because they had only recently been introduced at the time 
this survey was carried out and it is likely that they will 
be of increasing importance. Note that the patients in 
this study were all over 16 years of age; it is likely that 
a younger population would be receiving ethosuximide more 
frequently, for treatment of petit mal epilepsy.
The combination drug therapy in these patients is notable. 
Similar findings were obtained in a recent survey of 11,720 
patients in 15 centres in 4 European countries (Guelen et 
al, 1975) , it being found that the patients were receiving 
a mean of 2.7 anticonvulsant drugs s h o r v o n  an d  R e y n o l d s  (1977) 
recently drawn attention to this tendency towards poly-
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pharmacy as an unsatisfactory aspect of the drug treatment 
of epilepsy. There is a lack of evidence that, for 
instance, the widely practiced treatment of epilepsy with 
phenytoin and phenobarbitone offers advantages over single 
drug therapy. This and succeeding Chapters present 
evidence that the apparent potentiation when phenytoin 
and phenobarbitone (Chen and Ensor, 1954; Weaver et al, 
1955) and possibly also when phenytoin and primidone are 
used in combination may be due to drug interactions which 
increase serum concentrations of one or both drugs. In 
Chapter 6 it is shown that administration of other drugs 
may reduce the value of clonazepam therapy and in Chapter 7 
it is shown that a drug interaction between sodium valproate 
and phenobarbitone may cause toxic effects.
Serum Phenytoin Concentrations
Serum concentrations of phenytoin showed particularly 
wide variation between different patients. This is in line 
with a large number of other studies (eg Lascalles et al, 
1970; Kutt, 1971; Buchthal et al, 1972). It appears that 
the enzyme responsible for phenytoin metabolism becomes 
saturated at higher serum concentrations (Bochner et al, 
1972) and this exaggerates the variation in the rate of 
metabolism in different patients which is produced by 
genetic influences. As the dose of phenytoin is increased, 
the increments in serum concentration become larger.
The distribution of serum phenytoin concentrations was log­
normal, as found by other workers (Houghton et al, 1975), 
with most patients showing serum concentrations below the 
proposed therapeutic range of 4 0 - 80 pmol/1 (Buchthal 
et al, 1960). It is unlikely that the low concentrations 
in most instances were due to failure of compliance since 
inpatients, in whom drug intake was closely supervised, 
showed similar concentrations; however, a few outpatients 
showed zero concentrations on fairly high doses which may 
have been due to failure to take the drug. A retrospective 
study was carried out to determine whether patients showing 
serum phenytoin concentrations below the therapeutic range 
showed poorer control - a trend towards a higher frequency
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of major but not minor seizures was found in patients with 
low concentrations below 40 jumol/1, A study was carried out 
and is described in the following Chapter which shows that 
increasing serum concentrations into the therapeutic range 
improves control of major seizures.
Thus the variation in serum concentrations of phenytoin 
may be of therapeutic importance. It is of course possible 
to adjust serum concentrations into the therapeutic range 
by routine assay, but it would be desirable to predict more 
accurately the serum concentration that would be obtained 
on a given phenytoin dose. It might be expected that this 
would be made easier if one could allow for the effect of 
various parameters which alter the relationship between 
phenytoin dose and serum concentration. Such parameters 
include the weight and age of the patient and the effects 
of administration of other drugs.
Serum phenytoin concentrations measured in patients 
receiving 300mg of the drug daily showed a negative 
correlation with body weight, similar to that found by 
Houghton et al (1975). However, the low value of the 
correlation coefficient indicates that this accounts for 
only a small part of the variation in serum phenytoin con­
centrations between patients. Triedman et al (19 60) found 
similar results and concluded that an accurate estimate of 
the serum phenytoin concentration could not be made from the 
weight-related dose.
A positive correlation between age and serum concentrations 
of phenytoin was found in patients on a standard dose of 
300 mg daily. A similar finding was reported by Houghton 
et al (1975) and in another study it was shown that a group 
of young patients showed considerably lower phenytoin con­
centrations than a group of older patients (H aerer and Grace, 
19 69) . Other workers have also found that children require 
a larger dose of phenytoin/kg of body weight than adults in 
order to obtain therapeutic concentrations (Jailing et al, 
1970; Dawson and Jamieson, 1971) . The most likely 
explanation for the finding of increased phenytoin in the 
aged is a reduction in the rate of metabolism. This is 
examined in Chapter 4A.
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Patients receiving phenobarbitone in this study showed 
similar serum phenytoin concentrations to those receiving 
phenytoin alone, suggesting that there is a significant 
overall effect of phenobarbitone on phenytoin metabolism. 
Interaction between phenobarbitone and phenytoin has been 
studied by a number of workers with varying results 
(Table 3,4). Some patients show an increase and some a 
decrease in phenytoin serum concentrations when pheno­
barbitone is added. It is likely that two opposing effects 
occur - competitive inhibition of phenytoin metabolism occurs 
with the start of phenytoin therapy, but a more slowly 
developing induction of the liver metabolising enzymes 
reverses this effect. Phenobarbitone serum concentrations 
were correlated with phenytoin serum concentrations in 58 
patients on combined therapy and on a standard dose of 300mg 
phenytoin daily. Correlating the logarithms of the serum 
concentrations of both phenytoin and phenobarbitone, a 
significant positive relationship was found. This would 
suggest that serum concentrations are increased by inhibition 
of metabolism in patients with high concentrations of pheno­
barbitone. However, it is likely that the opposite effect 
also occurs and that serum phenobarbitone concentrations 
are increased in patients with high serum phenytoin concen­
trations - see the following section and Chapter 4.
Although there is no overall effect of phenobarbitone on 
serum concentrations of phenytoin, a possible effect of 
primidone was found. Patients receiving primidone showed 
generally lower serum phenytoin concentrations than patients 
receiving phenytoin alone and this almost reached signifi­
cance. It is possible that in patients receiving primidone 
there is a greater induction effect on phenytoin metabolism 
relative to the inhibition produced by the derived pheno­
barbitone than for patients receiving phenobarbitone.
Evidence that this is indeed likely is presented in Chapter 
11, where it is shown that patients receiving primidone have 
a higher level of enzyme induction than patients with com­
parable serum concentrations of phenobarbitone who are 
receiving phenobarbitone itself.
In conclusion, the weight and age of the patient and the
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administration of other drugs may all affect the relation­
ship between serum concentration and dose of phenytoin. 
However, even allowing for these factors there is a great 
deal of variability in serum concentrations of phenytoin 
in different patients on the same dose. It is possible 
that serum concentrations may be more predictable in a 
given patient at a range of doses if the serum concen­
tration is measured at one dose - this is examined in the 
following Chapter.
Serum Phenobarbitone Concentrations
By contrast with phenytoin, phenobarbitone serum concen­
trations showed a high correlation with dose, particularly 
with the weight-related dose.
Patients receiving phenytoin in this study showed 
significantly higher concentrations of phenobarbitone than 
patients receiving phenobarbitone alone. A similar finding 
has been reported by other workers (Morselli et al, 1971) 
and it is likely that phenytoin acts as a competitive 
inhibitor of phenobarbitone metabolism. Further evidence 
for this interaction is given in the following Chapter, 
it being found that increase in phenytoin dose and serum 
concentrations also caused increased serum phenobarbitone 
concentrations. The interactions between phenytoin and 
primidone, which is partly metabolised to phenobarbitone, 
are complex and these are discussed separately in 
Chapter 5.
SUMMARY
1. A survey was made of the anticonvulsant drugs that 
two groups of epileptic patients (inpatients and 
outpatients) were receiving and of the serum con­
centrations of the drugs. The seizure control in 
the inpatients was also assessed,
2. Serum concentrations of phenytoin showed 
particularly wide variation between different 
patients. There was no significant relationship 
between serum concentrations and seizure control.
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although patients showing concentrations below the 
accepted therapeutic range C40 - 80 jumol/l) had 
more major seizures,
3. The effects of various parameters on serum con­
centrations of phenytoin in patients on a fixed 
dose (300mg) of the drug were studied. A significant 
negative correlation was found between serum concen­
tration and the weight of the patient and a positive 
correlation was found with age. There was no 
difference in serum concentrations between patients 
receiving phenobarbitone and patients receiving 
phenytoin alone, although patients receiving primidone 
showed lower concentrations.
4. Serum phenobarbitone concentrations were significantly 
higher in patients receiving phenytoin than in 
patients receiving phenobarbitone alone. There was
a significant positive correlation between pheno­
barbitone and phenytoin serum concentrations in 
patients receiving both drugs, probably due to 
both an inhibition by phenytoin of phenobarbitone 
metabolism and inhibition by phenobarbitone of 
phenytoin metabolism.
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CHAPTER 4
HOW DO. SEIZURE CONTROL AND SERUM CONCENTRATIONS ALTER 
AS PHENYTOIN DOSE IS INCREASED?
“You may object that it is not a trial at all, 
you are quite right, for it is only a trial 
if I recognise it as such."
from "The Trial" by Fraiz Kafka
INTRODUCTION
Two prospective studies of phenytoin in the treatment of 
epilepsy have suggested that maximum seizure control is 
obtained only when its concentration in serum is greater 
than 40 pmol/1 (Buchthal et al, 1960; Lund, 1974) and 
the therapeutic range is commonly regarded as 
40 - 80 )amol/l (10 - 20 jjmol/1) (Lancet, 1975) . However, 
as has been shown in Chapter 3, wide variation of serum 
concentrations of phenytoin is found in different 
individuals on the same dose and in most instances serum 
concentrations lie outside the therapeutic range unless 
adequate monitoring is performed.
Difficulties in achieving therapeutic serum concen­
trations of phenytoin can be explained by its pharma­
cokinetics. There is a non-linear relationship between 
dose and serum concentration of phenytoin so that serum 
concentration may rise rapidly with increasing dose.
The relationship can be described by the Ilichaelis- 
Menten equation and defined in terms of the serum con­
centration at which metabolism is 50% saturated 
(Michaelis constant. Km) and the maximum rate of phenytoin 
metabolism (V max) ( Fig 4.1). A nomogram has been 
produced which can be used to predict the therapeutic 
dose of phenytoin (Richens and Dunlop, 1975) (Fig 4.2).
The nomogram depends upon the assumption that Km remains 
relatively constant in different individuals, whereas
Serum
Concn.
m
V.m axDose
Fig 4.1 Kinetics of phenytoin described by the 
Michaelis-Menten relationship. Vmax is 
the maximum velocity of the reaction (ie 
the maximum dose which can be metabolised) 
and Km is the serum concentration at h Vmax
Fig 4.2 Nomogram for adjusting phenytoin dosage,
described by Richens and Dunlop (1975).
Given a single serum concentration on a 
given daily dose of the drug, the dose 
required to achieve a serum concentration of 
60jimol/l or 80pmol/l can be predicted. A line 
is drawn connecting the measured serum concer 
tration (left hand scale) with the dose 
administered (centre scale), and then by 
extending this line to the right hand scale t 
dose required to produce a therapeutic con­
centration of the drug can be read off
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Vmax values vary considerably because of variation in the 
degree of enzyme induction.
The therapeutic range of phenytoin serum levels has been 
established mainly in patients receiving phenytoin alone, 
but many patients receive phenytoin in combination with 
other anticonvulsants, particularly phenobarbitone or 
primidone. Also, previous studies have supported the 
relationship between serum levels and control of grand 
mal seizures (Buchthal et al, 19 60; Lund, 19 73;
Lund 1974); there has been no assessment of the value 
of adjusting serum levels in the control of absences or 
focal seizures. In this Chapter the relationship 
between phenytoin level and therapeutic effect against 
different types of seizure, in patients on multiple drug 
therapy, is examined. The value of the nomogram for 
predicting therapeutic dose has been assessed and the 
assumption on which it is based have been studied.
Also, in Chapter 3, the possible effects of administration 
of phenobarbitone or primidone on serum concentrations 
of phenytoin were discussed; in this Chapter the effect 
of administration of these drugs on the relationship 
between phenytoin dose and serum concentration in indiv­
idual patients has been investigated.
PATIENTS AND METHODS
Patients
Twenty epileptic inpatients with serum levels of 
phenytoin below 4 0 |imol/l were selected for study. There 
were seventeen males and three females aged 19 - 63 years. 
Nine patients had generalised tonic-clonic epilepsy, 
nine had temporal-lobe epilepsy and two had myoclonic- 
atonic epilepsy. All patients were having an average of 
at least one minor seizure per month and sixteen patients 
were having one or more major seizures per month. All 
patients were receiving phenytoin (200 - 350mg daily) 
and either phenobarbitone (90 - 180mg daily) or primidone 
(750 - lOOOmg)daily.
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Methods
Fig 4.3 shows the design of the study, which lasted eight 
months. During the first four months the drug regimen 
was unchanged and control observations were made of fit 
frequencies. All seizures were recorded throughout the 
trial by the nursing staff as major (tonic-clonic) or 
minor seizures. Serum concentrations of phenytoin,and 
also of phenobarbitone and primidone, were measured at 
the beginning and end of the contrd. period. In the 
second four months the phenytoin doses were increased 
and blood samples for anticonvulsant analysis were 
obtained at monthly intervals. In fifteen patients a 
therapeutic serum concentration of phenytoin was obtained 
after one dose increase of 50 - lOOmg and in five patients 
further dose increases were required. The doses of drugs 
other than phenytoin remained unaltered throughout the 
study.
RESULTS
Seizure Frequency
The effects of increased phenytoin therapy on the 
frequencies of major and minor seizures in twenty patients 
on multiple drug therapy are shown in Figs 4.4a and 4.4b.
In patients in whom a second dose increase was necessary, 
seizure frequency was assessed over the last two months 
only. Minor seizures were unchanged but there was a 
reduction in major seizures in the sixteen patients 
affected. Seven patients with major seizures had no 
further seizures when the serum concentrations of phenytoin 
were increased above 40 ^mol/1. Three other patients 
showed a reduction in frequency of major seizures. In 
three patients major seizures increased and three patients 
showed no change. The overall changes in seizures are 
summarised in Table 4.1. Toxic effects of phenytoin 
therapy were observed in one patient, who had the highest 
serum concentration of 104 pmol/1.
Month
Phenytoin
Dose
Blood
Sample
Seizures
Recorded
Fig 4.3 Design of the trial to investigate 
how altering dose of phenytoin affected 
serum drug concentrations and seizure 
control
Major 
Seizures I 
Month
4-
3- 
2- 
1
O-J
5-1
4-
( n = 20 )
3-
2-
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Therapeutic
Range
118
BEFORE
INCREASE
AFTER
INCREASE
40 80
Serum Phenytoin { M/ L
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Fig 4.4a Effect of increasing serum concentrations
of phenytoin into the therapeutic range 
on frequency of major seizures in a group 
of 20 inpatients. Each vertical line 
represents one patient
Minor
Seizures/
Month
40-1
30-
20 -
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30-
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( n = 20 )
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F ig  4 . 4 b  Effect of increasing serum concentrations
of phenytoin into the therapeutic range 
on frequency of minor seizures in a group 
of 20 inpatients
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Serum Anticonvulsant Concentrations
The patients in the trial initially received total daily 
doses of 200 - 350mg of phenytoin and doses of 250 - 
450mg daily were required to attain serum concentrations 
above 40 jumol/l. In a number of patients the dose 
required to attain therapeutic serum concentrations was 
considerably less than that predicted from the nomogram 
(Richens and Dunlop, 1975). For the eight patients who 
showed initial serum concentrations of phenytoin below 
20 /Jimol/l, the predicted doses (of up to 650mg) were 
considerably greater than required. An average Km in 
twenty patients of 2.2mg/l (range 1.4 - 4.8 mg/1) was 
found. The Km values for the five patients in the study 
who required two dose increases are shown by the slopes 
of the continuous lines plotted in Fig 4.5. The slope of 
the interrupted line in this Figure indicates the Km on 
which the nomogram was based (Km 3.1), which is somewhat 
higher than the mean observation in this study. The Vmax 
values in these five patients are given by the intercepts 
on the y-axis. A mean Vmax in twenty patients of 375mg/day 
(range 250 - 550mg/day) was found; the Vmax values were 
generally less variable than the Km values, with fifteen 
of the twenty patients showing Vmax values in the range 
350 - 450mg/day.
Not only phenytoin concentrations but also phenobarbitone 
concentrations in serum increased as the phenytoin dose 
was increased in these patients. Serum phenobarbitone 
levels, both in patients receiving phenobarbitone and 
patients receiving primidone, significantly increased 
from a mean of 10 3 ^mol/1 to a mean of 140 jamol/1 
(P<C0.01, Wilcoxon signed-ranks test) as phenytoin dose 
was raised. This effect was most marked in patients in 
whom particularly high serum phenytoin levels were 
obtained and is shown graphically in Fig 4,6. All twenty 
patients in this trial were receiving either phenobarbitone 
or primidone in addition to phenytoin and, as this might 
affect the relationship between dose and serum level of 
phenytoin, a comparison was made with five patients
mg Phenytoin / Day 
( =Rq)
600-1
600-
200
100 15050
Rq/S erum Concentration ( litre s /d a y )
Fig 4.5 Graphic estimations of individual Vmax 
and Km values for phenytoin metabolism 
in five patients in whom serum phenytoin 
concentrations were measured at three 
doses. The y-intercept is the value of 
Vmax and the slope is the negative value 
of Km
%  Change in
Phenobarbitone Concentration n» 20
+50964
04 p < 0  05
12040 80
Serum Phenytoin /umol/l
Fig 4.6 Percentage change in phenobarbitone 
concentrations, plotted against final 
serum phenytoin concentration, for 20 
patients in whom serum phenytoin 
concentration was increased from below 
40pmol/l
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receiving phenytoin alone. Five outpatients were studied, 
phenytoin doses being increased from 200 - 400mg daily to 
300 “ SOOrag daily and the serum level of phenytoin 
measured at both doses. The mean Km in these patients 
was 4.4 (range 2.0 - 5.6) and the mean Vmax was 410 
(range 340 - 520).
DISCUSSION
The results presented here are in line with a therapeutic 
range for serum phenytoin concentrations of 40 - 80 pmol/1. 
It was found that increase of serum concentrations above 
40 ^mol/1 in patients on combined therapy with phenobarbi­
tone or primidone, improved control of major seizures 
although minor seizures were unaffected. That major but 
not minor seizures are reduced by increased phenytoin 
therapy has also been found recently by other workers in 
patients receiving phenytoin alone (Reynolds et al, 1976). 
The patients in the present study who showed improved 
control of major seizures with raised phenytoin dose were 
those with generalised activity in their EEC's; there 
was no overall effect in patients with temporal lobe 
epilepsy.
In assessing the effect of increased phenytoin therapy 
in these patients it should be taken into consideration 
that there was also an increase in phenobarbitone serum 
levels. While it seems likely that the increase in 
phenobarbitone serum concentrations was of less thera­
peutic importance than the increase in phenytoin serum 
concentrations, this finding is of interest in view of 
the fact that treatment of epilepsy with a combination of 
these drugs, which is often recommended (Schmidt and 
Wilder, 1968; Aird and Woodbury 1974) and widely 
practised (see Table 3.2), is based on a suggested 
synergistic action between these two drugs. The effect 
of phenytoin in increasing serum concentrations of 
phenobarbitone as found here may account for an apparent 
synergistic action. Conversely, a recent study (Leppik 
and Sherwin, 1977) has shown that an apparent potentiation 
of anticonvulsant activity against electroshock seizures
f-
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in rats when these drugs were administered simultaneously 
could be accounted for by the effect of phenobarbitone in 
increasing serum concentrations of phenytoin. The effect 
of phenytoin on metabolism of phenobarbitone is discussed 
further in Chapter 5.
In Chapter 3 it was found that comparison of serum 
phenytoin concentrations in patients receiving phenytoin 
alone and patients receiving phenytoin plus phenobarbitone 
did not show any significant effect of the administration 
of phenobarbitone. Because of the wide scatter of con­
centrations even in patients on the same dose it is 
possible that an effect might not be detected; and this 
trial was therefore designed also to examine the effect 
of phenobarbitone on the relationship between phenytoin 
dose and serum levels in individual patients. All the 
twenty patients in the trial were receiving either 
phenobarbitone or primidone, and comparison was made with 
five patients receiving phenytoin alone who also had their 
doses increased and the Km and Vmax values determined. 
Patients receiving phenytoin alone showed generally higher 
Km values; there was no difference in Vmax values 
between the two groups of patients. Also, the patients 
on whom the nomogram (Richens and Dunlop, 197 5) was based, 
most of whom were receiving phenytoin alone, showed a 
higher mean Km than the patients in the present study on 
combined therapy.
The finding of a lower Km in the patients receiving 
phenobarbitone, either as the drug itself or as primidone, 
is somewhat surprising. There is evidence that pheno­
barbitone may act as a competitive inhibitor of phenytoin 
metabolism in vitro (Kutt and Verebely, 1970) and this 
would be expected to increase Km. In addition, studies 
both of serum half-lives (Cucinell et al, 1963; Frey et al, 
1968; Buchanan et al, 1969; Kristensen et al, 1969), 
and of metabolism by rat liver microsomes (Kutt and Fouts,
1971) have suggested that pre-treatment with phenobarbitone 
induces phenytoin metabolism; this would be expected to 
increase Vmax, which was not found in the present study.
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It appears that, with chronic administration of pheno­
barbitone and phenytoin, the inducing and inhibitory 
effects of phenobarbitone on phenytoin metabolism tend 
to cancel. As was discussed in Chapter 3, there have 
been a number of conflicting reports of a raising or 
lowering of phenytoin serum levels when phenobarbitone 
is administered but the general effect appears to be 
slight.
It might still be expected that phenobarbitone admini­
stration would raise the Km and Vmax for phenytoin 
metabolism, although serum levels are unaffected.
However, it should be taken into consideration that, in 
this study, phenobarbitone serum levels increased as 
phenytoin dose and serum level were raised. Fig 4.7 
shows the expected relationship between dose and serum 
concentration of phenytoin graphed as a reciprocal plot 
(Lineweaver - Burk), which is an alternative method to 
that shown in Fig 4.5 for determination of Km and Vmax.
The effect of a competitive inhibitor such as pheno­
barbitone is shown by the interrupted line - Km is 
increased while Vmax is unaffected. The slope of the 
line, and hence Km, is increased as inhibitor concen­
tration increases; however, in this case the concen­
tration of the inhibitor (phenobarbitone) does not stay 
constant. In this study the increase in serum phenytoin 
caused an increase in serum phenobarbitone, either due 
to inhibition of phenobarbitone metabolism or stimulation 
of conversion of primidone to phenobarbitone. This 
combined interaction of phenytoin and phenobarbitone might 
produce a non-linear relationship in the reciprocal plot 
as shown. The effect of this would be to produce 
apparently lower values of Km and Vmax. As was stated 
above, phenobarbitone may also act as an inducer of 
phenytoin metabolism and this would raise Vmax. The 
inhibitory and inducing effects of phenobarbitone may 
cancel and produce no overall change in Vmax.
m a x
m
Fig 4.7 Possible kinetics of phenytoin metabolism 
in the presence of phenobarbitone. Simple 
competitive inhibition is shown by the 
interrupted line; a more complex inter­
action may produce a curve similar to 
that shown
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It should be noted that, if administration of drugs such 
as phenobarbitone produce effects on phenytoin metabolism 
as described here, then not only might the nomogram not 
be valid but even determination of the individual Km and 
Vmax would not accurately predict the relationship 
between dose and serum concentration of phenytoin. It is, 
therefore, important to adjust the dose in small 
increments, with constant measurement of serum concen­
trations, or toxic effects due to high concentrations 
may result.
SUMMARY
1. A study has been conducted to asse%the value of 
a nomogram proposed by Richens and Dunlop (19 75) 
for predicting therapeutic doses of phenytoin.
This nomogram attempted to predict the relation­
ship between dose and serum concentration of 
phenytoin in individual patients from a single 
measured serum concentration.
2. Twenty poorly controlled epileptic patients 
receiving anticonvulsant therapy were investigated. 
All were receiving phenytoin and showed low serum 
concentrations of the drug.
3. Increase of serum concentrations of phenytoin to 
above 4 0 pmol/1 improved control of major but not 
minor seizures.
4. Phenobarbitone serum concentrations were found to 
increase as the phenytoin dose was raised.
5. The nomogram was found to be of only limited value 
in predicting serum concentrations in these patients. 
It is suggested that this may be because pheno­
barbitone alters the relationship between dose and 
serum concentration of phenytoin due to inhibition 
of phenytoin metabolism.
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CHAPTER 4A
HOW DOES AGEING AFFECT THE RELATIONSHIP BETWEEN PHENYTOIN 
DOSE AND SERUM CONCENTRATION?
INTRODUCTION
Epilepsy is a common clinical problem in old age (Hildick- 
Smith, 1974):, cerebrovascular disease and dementia of 
unknown aetiology being the most frequent causes 
(British Medical Journal, 1975). Good control of fits can 
usually be established with anticonvulsants and, since 
phenobarbitone is often regarded as a potentially toxic 
drug in the elderly, phenytoin is the anticonvulsant of 
choice.
In Chapter 3 it was shown that, in patients receiving 
the same dose of phenytoin, the serum concentration is 
significantly increased with age. The doses of phenytoin 
recommended for the elderly are generally lower than those 
used for younger patients (Exton-Smith and Windsor, 1971; 
Balme, 1977). This Chapter describes a study which was 
conducted to determine whether there is a rationale for 
reducing phenytoin doses in the elderly based on a reduced 
ability to metabolise the drug.
PATIENTS AND METHODS
Seventeen patients aged 6 7 to 96 years (3 male and 14 
female) were studied. The cause of seizures was cerebral 
infarction in eight cases, 'senile dementia' in four, 
intracranial tumour in two and uncertain in two. In 
addition to phenytoin, three patients were also being 
treated with benzodiazepines, two with phenobarbitone and 
two with thioridazine.
Serum phenytoin was measured on blood samples taken 
between 0900 and 1100 hours. Single measurements were 
made on six patients, two measurements on two patients,
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three on four patients, and four or more on four patients 
on different dose levels. All patients but one (two weeks 
only) had been taking phenytoin for three weeks before the 
first determination, and each dose level had been main­
tained for at least seven days before blood was taken.
RESULTS
Fig 4A.1 shows the relationship between phenytoin dose and 
serum concentration for the 4 2 samples obtained. No serum 
concentration was in the range 40 - 80 pmol/1 on any dose 
less than 300mg/day. Of 13 measurements on doses of 
300mg/day, three were over 40 pmol/1. Four of five 
measurements on patients receiving 350mg/day or more were 
substantially higher (64 - 133 jumol/1) but there was no 
clear evidence of toxicity in any patient.
Fig 4A.2 shows a plot of dose against dose/mean serum
concentration for four dose levels, of 150mg/day and over; 
the serum concentrations for lower doses, of 75 and 
lOOmg/day, do not appear to fit the Michaelis-Menten 
relationship and have been excluded. The mean values 
obtained for Vmax (375mg/day) and Km (2.5 jug/1 ; 12 ;amol/l)
are very close to those which were previously found in
Chapter 4 for younger patients on multiple drug therapy 
[vmax : mean 375mg/day, ranger 250 - 550mg/day;
Km : mean 2.2 pg/1 (8.8 ;umol/l) range 1.4 - 4.8 pig/1 
(5.6 - 19.2 yUmol/1)] , although they are somewhat lower 
than younger patients on single drug therapy with phenytoin. 
Fig 4A. 3 shows the curve relating dose to serum concen­
tration derived from the values for Vmax and Km in the 
elderly.
DISCUSSION
This study shows that, similar to findings in younger 
patients, doses of phenytoin of less than 300mg/day do 
not produce serum concentrations in the range 40 - 80 /amol/1 
and even doses of 300mg/day do so relatively infrequently.
It is of course possible that in old age increased 
sensitivity of the brain to drugs might be accompanied by 
a reduction in the lower limit of the therapeutic range,
ju mol/1
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Fig 4A.1 Relationship between phenytoin dose
and serum concentrations for 4 3 
samples obtained at different dose 
levels from 17 geriatric patients
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Fig 4A.2 Plot of phenytoin dose against dose/
serum concentration for samples obtained 
from geriatric patients on doses of 150- 
350mg/day ( ® ). Crosses represent doses 
of 100 and 75mg/day. This plot allows 
determination of Vmax (intercept on the 
y-axis) and Km (the negative slope of 
the line)
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Fig 4A.3 Serum phenytoin concentrations (mean ± SE)
in relation to dose in the elderly. The 
curve has been derived from the values of 
Vmax and Km obtained from the previous 
figure
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but in the only instance of such a phenomenon at present 
documented, nitrazepam (.Castleden et al, 1977) , the 
increase in sensitivity was modest. In the present study 
none of the patients displayed symptoms of phenytoin 
toxicity even with fairly high serum concentrations. It 
must be concluded that the phenytoin doses of less than 
300mg/day often advised for the elderly (Exton-Smith and 
Windsor, 1971; Balme, 1977) are likely to be inadequate.
A reasonable maintenance dose would seem to be 300mg/day.
The data are consistent with the view that the kinetics 
of phenytoin metabolism are not substantially different 
in the elderly from those in younger patients. An age- 
related reduction in the hepatic metabolism of other 
drugs has been suggested for antipyrine (O’Malley et al, 
1971; Vestal et al, 1975), phenylbutazone (O'Malley et al,
1971), amylobarbitone (Irvine et al, 1974), diazepam 
(Klotz et al, 1975) and propranolol(Castleden et al, 1975), 
but a wider scatter about the mean values is striking, and 
age is certainly not the main determinant of the rate of 
metabolism of any of these drugs.
Apart from reduced metabolism in the elderly, it is 
possible that there might be reduction in protein- 
binding of phenytoin. It would in fact be expected that 
a lowered degree of protein binding would produce an 
increased elimination of the drug, and it may be that 
there is a decreased capacity for drug metabolism in the 
elderly which could not be observed in this study because 
of this effect. The relationship between age and protein 
binding of phenytoin is discussed in Chapter 8, but it 
appears that the protein binding is reduced only if there 
is a low serum albumin level.
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SUMMARY
1. Serum phenytoin concentrations were measured in 
17 elderly patients, a total of 42 samples being 
obtained at different dose levels.
2. Therapeutic phenytoin concentrations were not 
produced by doses of less than 300mg/day. 
Determination of mean values for Vmax and Km 
showed little difference from values obtained 
for younger patients, suggesting that phenytoin 
metabolism is not greatly altered in old age.
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CHAPTER 4B
HOW DOES PHENYTOIN METABOLISM ALTER WITH INCREASING DOSE?
INTRODUCTION
In Chapter 4 a non-linear relationship between dose and 
serum concentration of phenytoin has been described. This 
is probably due to saturation of the enzyme system involved 
in metabolism. The metabolism of phenytoin involves con­
version in the liver to p-hydroxy-phenytoin (HPPH) which is 
conjugated with glucuronic acid before excretion in the 
liver (Noach et al, 1958). Since the non-linear relation­
ship between dose and serum concentration makes it difficult 
to obtain therapeutic serum concentrations, a method of 
predicting serum concentrations is desirable. One method 
which has been proposed is the nomogram (Richens and Dunlop, 
1975) which was described and evaluated in Chapter 4.
Another possible method is the use of the HPPH/phenytoin 
ratio in a 24-hour urine sample after a single oral dose 
(Toseland and Albani, 19 74); it was suggested that this 
gives an index of the steady state serum concentration that 
will be achieved with chronic therapy.
It has been shown that the urine HPPH/phenytoin ratio 
correlates negatively with the serum phenytoin concen­
tration in a group of 'steady state' patients (Houghton 
and Richens, 1974). However, in that study no allowance 
was made for the possibility that the fraction of the 
phenytoin dose which is excreted as phenytoin plus HPPH may 
alter with increasing dose; for example, it has been 
suggested that the proportion of the dose excreted as HPPH 
may alter due to conversion of phenytoin to a secondary 
metabolite (Eadie et al, 1976)., This possibility should 
perhaps be taken into consideration in describing the 
relationship between the HPPH/phenytoin ratio in urine and 
the serum phenytoin concentration. This Chapter describes
an initial study which was carried out to determine how the
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proportion of the phenytoin dose excreted as HPPH and 
phenytoin alters with increasing serum concentration.
PATIENTS AND METHODS
24-hour urine samples were obtained from 12 epileptic in­
patients on chronic phenytoin therapy. All were in addition 
receiving either phenobarbitone or primidone. Completeness 
of urine collection was determined by measuring creatinine 
production. Concentrations of phenytoin and HPPH in urine 
were determined by GLC, the HPPH conjugate being first 
hydrolysed with glucuronidase (see Chapter 2).
Blood samples were also obtained from these patients for 
measurement of serum phenytoin.
RESULTS
Fig 4A.la shows the percentage recovery of the phenytoin 
dose (free acid) as HPPH correlated against the serum 
phenytoin concentrations in these patients. One patient 
showed a very low HPPH recovery of 22% of the dose (this 
result proving repeatable when a second 24-hour urine sample 
was obtained); this patient was suffering from psoriasis. 
Excluding this patient, there was a negative trend between 
the output of HPPH and the serum phenytoin concentration 
but this did not reach significance. The negative trend 
in HPPH production as the serum concentration is increased 
can be explained at least partly by the increased excretion 
of phenytoin; correlating the percentage of the dose 
excreted as phenytoin with the serum concentration, a 
positive relationship was found, as would be expected. A 
significant negative linear relationship was found between 
the HPPH/phenytoin concentration ratio in urine and the 
serum phenytoin concentration (r = 0.619, p < 0.05) as shown 
in Fig 4A.lb
DISCUSSION
A negative relationship was found between the HPPH/phenytoin 
ratio in urine and the serum phenytoin concentration. This 
is in line with the hypothesis that the hydroxylation of 
phenytoin by hepatic microsomal enzymes is a saturable
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Fig 4B.la Percentage of phenytoin dose recovered 
in the urine as HPPH in relation to 
serum phenytoin concentration, for 12 
patients in steady-state. A patient 
who was suffering from psoriasis is 
shown by an open circle
Fig 4B.lb The HPPHrphenytoin concentration ratio 
in the urine plotted against serum 
phenytoin concentration. A significant 
negative relationship (p<0.05) is 
shown
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process (Arnold and Gerber, 19 70). The proportion of the 
dose recovered in the urine as HPPH plus phenytoin was 
approximately constant with increasing serum concentration; 
this suggests that no significant fraction of the dose is 
converted to a metabolite other than HPPH. A mean of 
72% of the phenytoin dose was recovered as HPPH, which is 
in line with a single dose study in which about 70% of the 
dose was recovered as HPPH (Chang and Glazco, 1970).
One patient showed a considerably lower excretion of HPPH 
in the urine than other patients. This patient suffered 
from psoriasis, a skin disease with which there has been 
reported to be associated a malabsorption in the small 
intestine which causes increased excretion of faecal fat and 
of D-xylose (Shuster et al, 1967). It seems unlikely that 
this patient showed a defect in absorption of phenytoin, 
since serum levels on 3 5Qmg daily showed a reasonably high 
level of 64 pmol/1. In addition, the patient was receiving 
primidone and serum levels and urinary excretion of this 
drug and its metabolites were normal. It is more likely 
that there was reduced reabsorption of HPPH - the metabolite 
is released into the bile after formation in the liver and 
absorted in the small intestine before excretion by the 
kidney (Noach et al, 1958). Measurement of the HPPH/ 
phenytoin ratio to predict serum phenytoin concentrations 
would be expected to give an erroneous result in this patient.
In conclusion, the urinary excretion of HPPH and phenytoin 
normally accounts for most of the dose even in patients 
showing high serum concentrations of phenytoin. However, it 
is possible that some patients may show reduced'
HPPH production due to reduced reabsorption in the small 
intestine. If this effect is common then it may produce 
errors in the use of the urine HPPH/phenytoin ratio 
(Toseland and Albani, 19 74) as a method to predict
serum phenytoin concentrations.
SUMMARY
1. Excretion of phenytoin and its major metabolite
(HPPH) have been measured in 24-hour urine samples 
obtained from 12 patients on chronic phenytoin therapy
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There was a significant negative correlation 
between the HPPH/phenytoin ratio and the serum 
phenytoin concentration. There was no evidence 
that the percentage of the phenytoin dose excreted 
as the drug itself plus HPPH is altered with 
increasing dose.
A patient suffering from psoriasis showed reduced 
excretion of HPPH. It is suggested that this may 
be due to reduced reabsorption of the metabolite 
from the small intestine.
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CHAPTER 5
PRIMIDONE METABOLISM AND THE EFFECTS OF PHENYTOIN UPON IT
INTRODUCTION
Primidone (Mysoline R) is a desoxybarbiturate which was 
reported to be clinically effective by Handley and Stewart 
in 19 52 and is now widely used in the treatment of epilepsy. 
Primidone has two major metabolites both in animals and 
man - phenobarbitone and phenylethymalonamide (PEMA)
Bogue et al, 1956; Butler and Waddell, 1956). The structure 
of primidone and its metabolites are shown in Fig 5.1. 
Phenobarbitone has been employed as an anticonvulsant since 
1912 and primidone exerts its anticonvulsant activity at 
least partly via oxidation to phenobarbitone. In addition, 
PEMA has been shown to have anticonvulsant activity in rats 
(Baumel et al, 1972). Since primidone is converted in vivo 
to two active metabolites, variations in the metabolism of 
the drug between different individuals may be of thera­
peutic importance. In Chapter 4 it was shown that phenytoin 
may increase serum concentrations of phenobarbitone in 
patients receiving either phenobarbitone or primidone and 
other workers have suggested that phenytoin increases serum 
concentrations of phenobarbitone in patients receiving 
primidone (Wilson and Wilkinson, 1973; Fincham et al, 1974; 
Reynolds et al, 1975). In this Chapter further observations 
on the effects of phenytoin on primidone metabolism are 
described, particularly with reference to the metabolism of 
primidone to PEMA which has been little studied previously. 
Serum concentrations of the drug and its metabolites have 
been measured in patients receiving primidone alone and 
patients receiving primidone plus phenytoin; in addition, 
concentrations in urine have been measured to determine 
how accurately serum concentrations reflect the metabolism.
Primidone has a fairly short half-life of about six hours 
(Gallagher and Baumel, 1972) and therefore serum concen­
trations of primidone are usually measured shortly after
C H g C H a ^  \ C —  
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Fig 5.1 Structures of primidone and its 
metabolites
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the previous dose. However, it would be expected that serum 
concentrations measured in this way would depend mainly on 
the peak serum concentration obtained with this previous 
dose and would not reflect to any great extent the rate of 
metabolism of primidone. Therefore, in this study serum 
concentrations of primidone have also been measured some 
considerable time (12 hours) after the previous dose.
PATIENTS AND METHODS
The subjects studied were 58 male and 36 female patients, 
with ages ranging from 16 to 66 years. Of these, 59 were 
outpatients attending the epilepsy clinic at the Institute 
of Neurological Sciences, Glasgow, and 35 were inpatients 
at the Epilepsy Centre, Bridge of Weir. All patients were 
receiving primidone, in doses ranging from 250-1500mg daily, 
and 55 patients were also receiving phenytoin.
Blood samples for anticonvulsant analysis were obtained 
from 60 patients between 2 ard 4 hours after the last drug 
dose and from the other 34 patients blood samples were 
obtained 12 hours after the last drug dose. Concentrations 
of phenytoin and primidone were determined by gas chroma­
tography (see Appendix).
Urine was collected over a period of 24 hours from 10 of 
these patients of whom 6 were receiving primidone plus 
phenytoin and 4 were receiving primidone alone. Completeness 
of urine collection was assessed by measuring 24-hour 
creatinine production. Drug analyses were performed as in 
serum but it was necessary to dilute uring containing high 
concentrations of drug. Any drug or metabolite which might 
exist as the glucuronide derivative rather than the free 
drug was measured by hydrolysing the conjugates with 
glucuronidase,
RESULTS
Serum Concentrations of Phenobarbitone
The serum concentrations of phenobarbitone in relation to 
the dose of primidone are shown in Fig 5.2 for 19 patients 
receiving primidone alone and 52 patients receiving primidone
Serum Phenobarbitone 
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Primidone Dose m g
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Fig 5.2 Serum concentrations of derived 
phenobarbitone in patients receiving 
primidone. 19 patients were receiving 
primidone alone and 52 were receiving 
phenytoin also
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and phenytoin (no patients receiving other drugs have been 
included). There were significant correlations between 
dose and serum concentration for both groups of patients 
(Table 5.1). Patients receiving phenytoin showed slightly 
higher concentrations.Although there is little difference 
between the slopes of the lines, it is noticeable that in 
several patients receiving primidone alone showed very low 
serum phenobarbitone concentrations in relation to dose.
Serum Concentrations of Primidone
The serum concentrations of primidone in relation to dose 
are shown in Fig 5.3 for 52. patients from whom blood samples 
were obtained 2-4 hours after the previous drug dose (15 
were receiving primidone alone) and 29 patients from whom 
blood samples were obtained 12 hours after the previous dose 
(5 were receiving primidone alone). For the former group 
of patients there were significant correlations between dose 
and serum concentrations (Table 5.2). Considering only the 
24 patients who were receiving 300mg phenytoin daily, a 
higher correlation was found (r = 0.693) than when all 34 
patients receiving phenytoin were considered (r = 0.566). 
There was some evidence, at least in the patients receiving 
phenytoin, that increase of the primidone dose above lOOOmg 
did not produce the expected rise in primidone serum con­
centrations. Evidence for non-linearity was also found from 
measurement of serum concentrations of primidone 12 hours 
after the previous dose ~ particularly for patients receiving 
primidone alone, the serum concentrations were not increased 
with increasing dose.
The Phenobarbitone/Primidone Ratio
The patients receiving primidone alone showed slightly 
elevated primidone serum concentrations and in a number of 
cases lower phenobarbitone serum concentrations than patients 
receiving phenytoin; this would suggest that the pheno­
barbitone concentrations are higher at least in relation to 
primidone concentrations in patients receiving phenytoin.
This was confirmed when the phenobarbitone/primidone ratios 
were compared, for concentrations measured 2-4 hours after
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Fig 5.3 Serum concentrations of primidone in 
samples obtained from 52 patients 2-4 
hours after the previous dose and from 
29 patients 12 hours after the previous 
dose of the drug. Patients were either 
receiving primidone alone or combined 
therapy with phenytoin
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the dose; 31 patients on phenytoin showed a significantly 
higher ratio than 14 patients receiving primidone alone 
(t = 4.513, p <  0.001, comparing the log values for the 
ratio). In the 22 patients receiving 300mg phenytoin 
daily there was a trend towards higher phenobarbitone/ 
primidone ratios with increasing serum concentrations of 
phenytoin and this just failed to reach significance 
(Table 5.1) (correlating the log values for the ratio and 
for serum phenytoin concentration).
Serum Concentrations of PEMA
Serum concentrations of PEMA were measured in 40 of the
patients receiving primidone, 31 of whom were receiving 
phenytoin also. The relationship between serum concen­
trations of primidone and PEMA is shown in Fig 5.4 and 
Table 5.1. There was a significant correlation between the 
serum concentrations both for patients receiving phenytoin 
and patients receiving primidone alone; patients receiving 
phenytoin showed generally higher levels of PEMA in relation
to primidone, although the slopes of the lines were the same.
Comparing the PEMA/primidone ratios in patients receiving 
phenytoin to those in patients receiving primidone, a 
significant difference was indeed found (t ~ 3.04, p<0.005) 
There was, in addition, a possible trend towards a higher 
PEMA/primidone ratio in patients receiving higher doses, but 
this did not reach significance (Table 5.1).
Urinary Excretion of Primidone and its Metabolites
Measurement of excretion of primidone and its metabolites 
was carried out in 24-hour urine samples obtained from 10 
patients receiving primidone. Measurements were carried out 
by gas chromatography as before, but any drug or metabolite 
which might exist as a glucuronide conjugate was first 
hydrolysed enzymatically (see Chapter 2 and Appendix); no 
evidence was found, however, for significant conjugation of 
primidone or PEMA in urine, comparing the free with the total 
concentrations.
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4jmol/l
100
50
• o’»
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Fig 5.4 Serum concentrations of PEMA plotted 
against primidone concentrations for 
40 patients receiving primidone, 31 
of whom were also receiving phenytoin
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The percentage of primidone dose which was recovered 
in urine as the drug itself or as its metabolites was 
72.5% ± 12.3 SD. In line with the findings from 
serum concentrations, the PEMA : primidone ratio and pheno­
barbitone : primidone ratio were higher in patients receiving 
phenobarbitone - in four patients receiving primidone 
alone the PEMA : primidone and phenobarbitone : primidone 
ratios showed means of 0.58 ± 0.41 SD and 1.00 ± 0.04 SD 
respectively and for patients receiving phenytoin the means 
were 0.9 8 ± 0.08 SD and 0.21 ± 0.0 8 SD respectively. There 
were reasonably high correlations between these ratios in 
serum and urine, r = 0.7 81 for the PEMA : primidone ratio 
and r = 0.712 for the phenobarbitone : primidone ratio 
(note that the serum concentrations of primidone and its 
metabolites were measured 12 hours after the previous dose 
in these patients). The actual values for the PEMA : 
primidone ratios in serum and urine were almost identical 
but the phenobarbitone : primidone ratio in serum was 
twelve times that in urine.
For comparison, measurements of phenobarbitone concen­
trations were carried out in 24-hour urine samples obtained 
from 5 patients receiving phenobarbitone (all of these were 
also receiving phenytoin). A mean fraction of 0.41 ± 0,11 SD 
of the dose was recovered as phenobarbitone in the urine. 
Using this value it was possible to calculate approximately 
how much of the primidone dose is converted to each of its 
metabolites - in the 10 patients studied, 18% ± 7 SD of the 
dose recovered in the urine was phenobarbitone (pheno­
barbitone itself plus its hydroxylated metabolite) and 35%
± 10 SD was PEMA. In the only other study of urinary 
excretion of primidone and both its metabolites, in rabbits, 
the extents of conversion of primidone to phenobarbitone 
and PEMA were 25% and 65% respectively (Fujimoto et al, 1968)
DISCUSSION
Many patients receive combined therapy of phenytoin and 
primidone (see Chapter 3) and interactions between these 
drugs may be of therapeutic significance. The results in 
this study suggest that phenytoin may have an effect on the
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metabolism of primidone which causes higher serum concen­
trations of derived phenobarbitone. This effect may be 
related to the serum concentrations of phenytoin, since 
in the patients receiving 300mg phenytoin daily there was 
a positive trend which almost reached significance between 
the phenobarbitone : primidone ratio and the serum phenytoin 
concentration. The latter finding was described previously 
(Reynolds et al, 1975) and itwas suggested that the effect 
of phenytoin may be an inhibition of the metabolism of 
phenobarbitone. Other workers have shown that an increased 
phenobarbitone ; primidone ratio in patients on phenytoin 
(Fincham et al, 19 74; Callaghan et al, 19 77) and have 
suggested that phenytoin induces the liver enzyme system 
responsible for the oxidation of primidone to phenobarbi­
tone, An inhibitory effect of phenytoin on phenobarbitone 
metabolism, as at least a contributory factor, appears 
likely since a similar greater effect of phenytoin on 
phenobarbitone concentrations was described in Chapter 3 in 
patients receiving phenobarbitone rather than primidone. 
Also, in the study described in Chapter 4, phenobarbitone 
concentrations increased in individual patients receiving 
either phenobarbitone or primidone, in whom the phenytoin 
dose and serum concentrations were increased.
Enzyme induction may nonetheless be important in the 
metabolism of primidone. There appears to be a non-linear 
relationship between dose and serum concentrations of 
primidone which might be explained as a self-induction of 
its own metabolism, presumably mainly to PEMA rather than 
phenobarbitone. This is confirmed by measurement of serum 
conventrations of PEMA and it appears that, in addition, 
phenytoin may induce primidone metabolism to PEMA. Auto­
induction by primidone of its metabolism has been found by 
other workers during acute administration (Gallagher et al,
1972) but in this case the drug appeared to induce its own 
metabolism to phenobarbitone rather than to PEMA ; pheno­
barbitone did not appear in the serum until 24 to 96 hours 
after the initiation of primidone therapy whereas PEMA 
appeared within 24 hours. However, a patient in whom the 
appearance of phenobarbitone was delayed for 96 hours showed 
only low levels of PEMA within this period. A study of
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primidone metabolism in perfused rat liver (Alvin et al,
1975) showed that pretreatment with phenobarbitone or 
primidone induced metabolism both to phenobarbitone and 
PEMA, It appears from the present study that, in patients 
on chronic therapy, the inducing effect of primidone on 
its own metabolism to PEMA^ and possibly also to pheno­
barbitone, may increase with increasing dose of the drug.
It has previously been suggested that there is a linear 
relationship between dose and serum concentrations of 
primidone (Gallagher and Baumel, 1972), but the evidence 
in the present studv suacests that this mav not be entirelv 
true and another recent study has similarly found the serum 
levels of primidone levelled off at about 30 pmol/1 in adult 
patients (Dekaban et al. 1974).
The possible inducing effect of primidone on its own 
metabolism and the effects of phenytoin may be of clinical 
importance and this depends upon the relative therapeutic 
effects of primidone and its metabolites. It has been 
found that doses of primidone required to obtain an anti­
convulsant effect comparable to a given dose of pheno­
barbitone result in comparable serum concentrations of 
phenobarbitone (Bogan and Smith, 1968). Olesen and Dam (1967) 
found no difference in the clinical effectiveness of the two 
anticonvulsants when similar serum concentrations of pheno­
barbitone were obtained and they suggested that the anticon­
vulsant activity of primidone is simply due to the derived 
phenobarbitone. If this were the case it might be expected 
that combined therapy of phenytoin and primidone would 
produce a synergistic effect (as may happen with phenytoin 
and phenobarbitone) due to the action of phenytoin in 
increasing serum concentrations of phenobarbitone. However, 
studies in rats have suggested that primidone itself 
probably does have some anticonvulsant activity since the 
drug is more effective than phenobarbitone in raising seizure 
threshold with comparable or even lower phenobarbitone serum 
levels (Gallagher et al, 1970). PEMA has also been shown to 
have anticonvulsant activity in rats, even at a low dose at 
which phenobarbitone would have no effect (Baumel et al,
1972). If primidone has a greater anticonvulsant activity
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than PEMA and phenobarbitone metabolites, it would be 
expected that administration of phenytoin will lower the 
therapeutic effect of the drug; also, since the drug 
induces its own metabolism there may be little value in 
high doses.
In the present study it has been shown that the PEMA/ 
primidone ratio is increased in patients receiving phenytoin 
and it is also suggested that the ratio increases with 
increasing primidone dose. This would suggest that the 
metabolism of primidone to PEMA is dependent on the com­
bined doses of enzyme-inducing drugs that the patient is 
receiving. In Chapter 12 a method for calculating 'Drug 
Units' according to the potential enzyme-inducing effect of 
a given drug regime is described; a significant positive 
relationship is found between the PEMA/primidone ratio and 
the Drug Units.
SUMMARY
1. Serum concentrations of primidone and its two
metabolites (phenobarbitone and PEMA) have been 
measured in patients receiving either primidone 
alone or primidone plus phenytoin.
2. There was no significant difference between the
mean concentrations of phenobarbitone for patients 
receiving primidone alone and for patients 
receiving primidone plus phenytoin. However, some 
patients on primidone alone showed unexpectedly 
low phenobarbitone concentrations. There may be 
an effect of phenytoin in inhibiting metabolism
of phenobarbitone.
3. There was some evidence for non-linearity in the
relationship between primidone dose and serum con­
centration, particularly in samples obtained some 
time after the previous dose. This may be explained 
by an inducing effect of primidone on its metabolism 
to PEMA.
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There appeared to be an inducing effect of phenytoin 
on metabolism of primidone to PEMA. The PEMA/ 
primidone ratio in serum was significantly higher 
( p < 0.005) in patients receiving phenytoin than in 
patients receiving primidone alone.
Concentrations of primidone and its metabolites 
were measured in 24-hour urine samples obtained 
from 10 patients. Evidence was found that the PEMA/ 
primidone ratio and phenobarbitone/primidone ratio 
in serum were accurate reflections of the relative 
concentrations in urine.
In conclusion, administration of phenytoin to 
patients receiving primidone may increase serum 
concentrations of PEMA and possibly also of 
phenobarbitone, and decrease serum concentrations 
of primidone. This may be of therapeutic 
importance depending on the relative anticonvulsant 
activities of primidone and its metabolites.
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CHAPTER 6
HOW DOES THE THERAPEUTIC EFFECT OF CLONAZEPAM CORRELATE 
WITH SERUM LEVELS AND DO DRUG INTERACTIONS ALTER THE 
EFFECTIVENESS OF THE DRUG?
"But I was thinking of a plan 
To dye one's whiskers green 
Then always use so large a fan 
That they could not be seen"
- The White Knight in
"Alice's Adventures Through the 
Looking Glass" by Lewis Carroll
INTRODUCTION
Chapters 4 and 5 have shown that drug interactions may 
affect serum levels and hence presumably the therapeutic 
response to the commonly used anticonvulsant drugs 
phenytoin, phenobarbitone and primidone. It is particularly 
important to investigate the possibility of drug inter­
actions in assessing the value of new anticonvulsants, when 
these are given to patients already receiving drug therapy.
Clonazepam, 5-(2-chlorophenyl)-1,3 dihydro-7-nitro-2H- 
benzodiazepine-2-one (Rivotril (Fig 6.1), is a new 
benzodiazepine anticonvulsant recently introduced into 
Britain and America. It was shown to be a more effective 
intravenous anticonvulsant than its benzodiazepine 
analogues diazepam and nitrazepam (Gastaut, 1971) and 
subsequent studies have shown that clonazepam is effective 
against a wide range of seizures (Browne and Penry, 1973; 
Lund, 1973; Scollo-Lavizzari et al, 1974).
However, there has been a lack of controlled trials of 
clonazepam and the value of the drug has not been clearly 
shown. The effect of simultaneous administration of other 
anticonvulsant drugs has not been investigated and a 
therapeutic range of serum concentrations of clonazepam 
has not been established. This Chapter describes the
Fig 6.1 Chemical structure of clonazepam
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effect of clonazepam in patients with various forms of 
epilepsy and receiving different anticonvulsant therapies 
and also the relationship of serum concentration to 
seizure frequency. The effects of clonazepam upon serum 
concentrations of other anticonvulsants have also been 
studied.
Both a double-blind trial and an open trial have been 
conducted to assess the value of clonazepam therapy. The 
double-blind trial extended over a period of nine weeks 
and the patients received a fixed dose of the drug; 
the patients were later followed up for a period of 21 
months. The open trial extended over a period of 22 
months. Nearly all the patients were receiving, in 
addition to clonazepam, one or more of the standard 
anticonvulsants.
PATIENTS AND METHODS
PATIENTS
Double-blind trial against placebo : Thirty patients,
22 male and 8 female, aged 11 - 40 years (mean 26 years) 
were studied. Fifteen patients had myoclonic epilepsy 
(nyoclonic jerks and tonic-clonic seizures) , four suffered 
from atypical absences and eleven patients had temporal 
lobe epilepsy. Twenty-five patients were receiving 
various combinations of phenytoin, phenobarbitone and 
primidone and five patients with myoclonic epilepsy were 
not receiving any medication. Details of the concurrently 
used anticonvulsant drugs are given in Table 6.1. Twenty 
were inpatients in a residential centre and ten were 
treated as outpatients.
Open trial : The 36 patients in the open trial of
clonazepam, 19 male and 17 female, aged 11 - 44 years 
(mean 27 years), were treated as outpatients. Seven 
patients had myoclonic epilepsy, seven had photo­
sensitive epilepsy, six had generalised tonic-clonic 
seizures and sixteen had temporal lobe epilepsy. All
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patients were receiving various combinations of phenytoin, 
phenobarbitone and primidone; the patients with myo­
clonic and with photosensitive epilepsy were generally 
receiving low doses of single drugs whereas those with 
tonic-clonic and temporal lobe epilepsy were generally 
receiving combined therapy of high doses of drugs.
METHODS
In both trials clonazepam was added to the existing anti­
convulsant regime. In the double-blind trial the initial 
dose of clonazepam was Img/day, increasing every third 
day by Img/day to 3mg/day (Img morning and 2mg at night). 
Matched placebo tablets were used. At the end of 4-6 
weeks the first tablets were reduced gradually while 
the second unknown tablet was introduced.
In the open trial, the clonazepam does was also increased 
to an initial dose of 3mg/day, and the dose later 
increased or decreased as required. Those patients who 
benefitted during the double-blind trial were also 
managed in the same way. All outpatients recorded the 
frequency of their seizures and side-effects on a chart. 
Seizures and side-effects in inpatients were recorded 
by the nursing staff.
Blood samples for measurement of anticonvulsants were 
taken before and during clonazepam treatment. In 
addition to measurement of phenytoin, phenobarbitone and 
primidone by gas chromatography, clonazepam was measured 
by a radioimmunoassay technique (see Appendix ) in 19 
patients in the double-blind trial and 8 patients in the 
open trial on 3mg clonazepam daily. In addition, 
clonazepam levels were measured in 18 of these patients 
after one year of treatment, when they were receiving 
various doses of the drug. It was not possible to 
measure clonazepam in patients receiving other benzo­
diazepines such as diazepam or nitrazepam since they 
interfered with the assay.
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RESULTS
Seizure Frequency
The effect of clonazepam on seizure frequency for the 
patients in the double-blind trial, both during the trial 
and after 21 months of therapy, is shown in Table 6.2.
In the fifteen patients with myoclonic jerks, twelve of 
whom also had major (tonic-clonic) seizures, clonazepam 
caused suppression of jerks in twelve patients and 75% 
reduction in the other three; major seizures ceased to 
occur in eight patients and were reduced by 50% in the 
other four. The effectiveness of clonazepam therapy in 
the patients who improved was the same after 21 months 
as during the trial, but in four cases the clonazepam 
was increased to maintain effectiveness, doses of up to 
12mg daily (one patient) being given without side- 
effects. It was possible to reduce or stop other anti­
convulsants in four patients.
Four patients in the double-blind trial had temporal 
lobe epilepsy with psychomotor attacks and major seizures. 
There was no effect of clonazepam on the minor seizures 
although there was a reduction in major seizures in the 
four patients affected. After 21 months only two patients 
were still being treated with clonazepam.
For the patients in the open trial, the effect of 
clonazepam on seizure control after 22 months is shown 
in Table 6.3. The drug was again found to be effective 
in myoclonic attacks and major seizures. The drug was 
also highly effective in photosensitive epilepsy, with 
six patients showing abolition of seizures and the 
seventh showing marked improvement.
The sixteen patients in the open trial with temporal 
lobe epilepsy again showed little improvement on 
clonazepam. Within a year the drug was withdrawn in 
seven patients, in two patients because seizures increased 
and in five patients because they showed no improvement 
and suffered from side-effects.
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Six patients had generalised epilepsy with only tonic- 
clonic seizures. Clonazepam was somewhat ineffective 
and was stopped in two patients, in one case because an 
increase in seizure frequency and in the other due to 
side-effects.
Side Effects
The main side-effect with clonazepam was drowsiness 
(67% of patients receiving 3mg/day), especially during 
the introduction of the drug. After two to three weeks 
only six patients receiving 3mg of clonazepam (all in the 
open trial) continued to complain of drowsiness. These 
six patients were also ataxic and clonazepam was reduced 
and then stopped. None of the patients who continued to 
receive 3mg clonazepam for 21 or 22 months (45 patients) 
complained of any side-effects at the end of this time, 
even the four patients in whom doses were increased 
above 6mg to up to 12mg/daily (one patient).
Electroencephalogram (EEC)
Ten of the patients with myoclonic epilepsy showed 
generalised polyspike-wave seizure discharges and this 
paroxysmal activity was not recorded in seven patients 
during clonazepam therapy. Two patients had progressive 
myoclonic epilepsy (Unverricht's Syndrome) and showed 
theta rhythms and spike wave activity in their EEC's; 
there was no change in their EEC's during clonazepam 
therapy. The other ten patients with myoclonic epilepsy 
showed no abnormalities. All patients with photosensitive 
epilepsy showed seizure activity with photo stimulation; 
clonazepam therapy suppressed this photosensitive 
response in all EEC's recorded during the trial. In all 
other patients EEC's were unchanged on clonazepam.
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Effect of Clonazepam on Serum Concentrations of other 
Anticonvulsants
Phenytoin (Fig 6.2a) : The mean value of serum phenytoin
in 16 patients was 4 9 umol/1 (+ 37 SD) before and 5 3 pmol/1
(+ 42 SD) after 4 - 6  weeks on 3mg of clonazepam daily.
The difference in the levels was not significant on a 
paired 't ' test or a Wilcoxon signed-ranks test.
Phenobarbitone (Fig 6.2b) : The mean value of serum
phenobarbitone in 14 patients was 56 pmol/1 (+ 28 SD) 
before and 59 pmol/1 {+ 31 SD) after 4 - 6  weeks on 3mg 
of clonazepam daily. This difference was not significant.
Primidone (Fig 6.2c) : In the ten patients taking this
drug the mean serum level before treatment was 4 0 pmol/1 
(+ 28 SD) . After clonazepam the mean was 42 jumol/1
(+ 30 SD). There was no statistically significant
difference.
Serum Concentrations of Clonazepam
Serum concentrations of clonazepam were measured in 19 
patients in the double-blind trial and these are shown 
in Fig 6.3. A wide range of values was obtained and it 
was found that the patients with myoclonic epilepsy, 
who were mainly receiving only one drug other than 
clonazepam, and some of whom were on single therapy with 
clonazepam, showed higher levels than patients with 
temporal lobe epilepsy, who were receiving combined 
therapy with phenytoin and phenobarbitone or primidone.
In particular, a significant negative correlation was 
found, in the sixteen patients receiving phenobarbitone 
or primidone, between clonazepam levels and pheno­
barbitone levels (p<0.01) Fig 6.4. Since there was no 
effect of clonazepam on phenobarbitone levels, this 
would suggest that phenobarbitone has a depressive effect 
on clonazepam levels.
The initial response to clonazepam therapy in relation 
to serum levels of the drug is shown in Fig 6.5 for 19 
patients in the double-blind trial and 8 patients in the
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primidone. A significant negative 
relationship (p<0.01) was found
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open trial who were receiving 3mg of clonazepam. It 
was found that patients showing complete abolition of 
seizures or a significant (>50%) reduction in seizures 
tended to show serum levels higher than in those who 
showed little or no improvement. Patients showing 
abolition of seizures had a mean serum clonazepam con­
centration of 58 nmol/1 (+ 30 SD); those showing 50% 
reduction in seizures had a mean concentration of 
49 nmol/1 (+ 15 SD); those showing no improvement had 
a mean concentration of 9 nmol/1 (+ 8 SD). Serum levels 
of clonazepam after one year of therapy, in 18 patients 
in whom dose was adjusted (2 - 12mg daily) to give maxi­
mum benefit, are shown in Fig 6.6; these were generally 
higher^with a mean of 116 nmol/1.
DISCUSSION
The results of these trials indicate that clonazepam 
is very effective in the treatment of myoclonic epilepsy. 
This is of considerable importance as this form of 
epilepsy was previously very difficult to treat 
(Van Woert and Sethy, 1975). The value of clonazepam 
in myoclonic epilepsy has previosuly been demonstrated 
only in uncontrolled studies (Barnett, 1973; Edwards 
and Eadie, 1973; Huang et al, 1973; Rett, 1973;
Goldberg and Dorman, 19 76). Clonazepam was also 
particularly effective in photosensitive epilepsy, 
which is in line with its potency in the Papio papio 
model of light-sensitive seizures (Killam et al, 1973). 
The drug was also found to be of value in patients with 
atypical absences and this has been found by other 
workers, .
Results from both the double-blind trial and open trials 
suggest that clonazepam is of little value in the treat­
ment of temporal lobe epilepsy (either for the major or 
the minor seizures), and there was only limited benefit 
in the small number of patients with generalised 
epilepsy with tonic-clonic seizures. This lack of 
benefit of clonazepam in the treatment of grand mal
CLONAZEPAM
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Fig 6,6 Serum clonazepam concentrations 
after one year of therapy in 18 
patients in whom dose was adjusted 
(2-12mg daily) to give maximum 
benefit
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seizures is in line with its low effect!venss in the 
prevention of maximal electroshock seizures in mice.
Other clinical trials of the effectiveness of clonazepam 
in grand mal seizures have, however, yielded conflicting 
results. In ten uncontrolled studies with ten or more 
patients in whom clonazepam was added to the existing 
therapy, 10% to 70% (median 37%) had their grand mal 
attacks completely controlled and 10% to 96% (median 
64%) had a 50% or greater reduction (Bergamini et al,
1970; Huang et al, 1973; Lehtovaara, 1973; Mikkelsen 
et al, 19 73; Munthe-Kaas et al, 19 73; Rosenmayr and 
Groh, 1973).
The total lack of effect of clonazepam in psychomotor 
seizures in patients in the present study with 
temporal lobe epilepsy is somewhat in conflict with 
findings by other workers. Seven large (17 or more 
patients) uncontrolled studies of clonazepam as an 
anticonvulsant adjunct have reported complete suppression 
of psychomotor in 26% to 57% (median 34%) of patients 
and a 50% or greater reduction in 35% to 89% (median 65%) 
(Boudin et al, 1972; Cass et al, 1973; Kick and Dreyer, 
1973; Lehtovaara, 1973; Mikkelsen et al, 1973; Huang 
et al, 1974; Scollo-Lavizzari et al, 1974). It is 
possible that the daily dose of 3mg of clonazepam in the 
trials reported here was insufficient for control, as a 
higher dosage was reported as being necessary in temporal 
lobe epilepsy (Huang et al, 1973), There appeared to be 
a greater action of clonazepam against psychomotor 
seizures when 6mg of the drug was used to treat patients 
in a double-blind trial against sodium valproate and 
this is described in Chapter 7.
Conflicting reports have previously suggested that 
clonazepam may either raise or lower phenytoin or 
phenobarbitone serum concentrations (Edwards and Eadie, 
1973; Daurella, 1974; Hara et al, 1976), but it has 
also been concluded (Huang et al, 1973) that there is 
no constant effect of clonazepam medication upon serum 
concentrations of other anticonvulsants and that an
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increase in phenytoin concentrations might be due to more 
constant drug intake because of closer supervision. The 
observations in the present study indicate that serum 
concentrations of phenytoin, phenobarbitone and primidone 
are not altered by the addition of clonazepam. It is 
unlikely that any of the therapeutic or toxic effects of 
clonazepam administration were due to alteration in the 
serum levels of other drugs.
Administration of other drugs did appear to have an effect 
on serum levels of clonazepam. The results suggest that 
treatment with other anticonvulsants, particularly pheno­
barbitone or primidone, lowers serum concentrations of 
clonazepam presumably via enzyme induction. This may be 
of therapeutic importance since the patients in the 
double-blind trial with temporal lobe and tonic-clonic 
epilepsy, who responded poorly to clonazepam therapy, 
were being treated with high doses of other anticon­
vulsants and showed high serum concentrations of pheno­
barbitone and low concentrations of clonazepam. It has 
previously been reported (Naestoft et al, 1973; Dreifuss 
et al, 1975) that, after daily oral doses of 1.5mg - 4mg 
in patients taking clonazepam alone, serum concentrations 
ranged from 40 - 240 nmol/1. It was found that patients 
in the double-blind trial who showed clonazepam con­
centrations below 4 0 nmol/1 were those who responded 
poorly to the drug.
Several reports of clonazepam therapy have mentioned the 
relatively high frequency of side-effects as a major 
problem (Edwards and Eadie, 1973; Huang et al, 1973;
Lund, 19 73), although these may disappear as treatment 
is continued. In the present study, as in others, the 
most frequent side-effects were various degrees of 
drowsiness and ataxia which necessitated dose reduction 
and eventual discontinuation in some patients. In 
general, side-effects appear to be dose-related since 
there was more of a problem in patients on multiple anti­
convulsant therapy receiving 6mg clonazepam daily 
(see Chapter 7) than in the patients receiving 3mg daily. 
However, patients receiving lower or no doses of other
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anticonvulsants were able to tolerate doses of up to 12mg 
without problems.
There appeared to be a negative correlation between 
serum levels of clonazepam and side-effects, since 
patients on high doses of other anticonvulsants showed 
reduced serum levels but increased side-effects. Previous 
studies have shown that side-effects can be reduced by 
reducing doses of phenytoin (Huang et al, 1973) or 
barbiturates (Edwards and Eadie, 1973). The present 
study shows that the side-effects are not due to an 
increase in serum levels of phenytoin or phenobarbitone 
with clonazepam therapy, but it is possible that there 
is a combined sedative effect of the drugs. However, an 
alternative hypothesis is that clonazepam is converted 
to a toxic metabolite in the presence of enzyme- 
inducing drugs. There is no correlation between side- 
effects of clonazepam and its major metabolite,
7-amino-clonazepam, but treatment with phenytoin lowers 
levels of this metabolite (sjü et al, 1973) and it
is likely that enzyme induction causes the involvement 
of some other metabolite pathway.
SUMMARY
1. A double-blind and an open trial have been con­
ducted to assess the value of clonazepam therapy 
in patients with epilepsy. Clonazepam was 
found to be particularly effective in myoclonic 
and photosensitive epilepsy.
2. Clonazepam administration did not cause any 
change in serum levels of phenytoin, pheno­
barbitone or primidone.
3. Serum levels of clonazepam were lower in patients 
receiving large doses of other anticonvulsant 
drugs and there was a negative correlation 
between serum levels of clonazepam and serum 
levels of phenobarbitone. The patients showing 
low levels of clonazepam were those who showed
no improvement in seizure control on the drug.
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4. Side -effects of clonazepam therapy were greater
in patients who were receiving high doses of 
other anticonvulsant drugs.
/ i
CHAPTER 7
HOW DOES SODIUM VALPROATE COMPARE WITH CLONAZEPAM AS AN 
ANTICONVULSANT?
INTRODUCTION
Chapter 6 described trials to assess the value of the 
newbenzodiazepine anticonvulsant clonazepam. Sodium 
valproate (Epilim^) is another new anticonvulsant 
currently under evaluation. Since its introduction in 
196 3 the drug has been widely used as an anti-epileptic 
drug in European continental countries, but has only 
recently been introduced into Britain and has not yet 
been introduced into America.
Whereas most of the currently available anticonvulsant 
drugs have chemical features in common, sodium valproate 
is a different entity with a simple chemical structure 
(Fig 7.1) which (unlike other drugs) does not contain 
nitrogen. It has good anticonvulsant activity in audio­
genic seizures in mice (Simler et al, 1968) and in 
seizures induced electrically or by CO^ withdrawal 
(Swinyard, 1964). A study in rats (Godin, 1968) suggested 
that the anticonvulsant effect of sodium valproate is 
related to an increase in the level of -y-aminobutyric 
acid (GABA), by an inhibition of GABA-transaminase.
The introduction of new anticonvulsants requires their 
assessment both individually and comparatively. Although 
sodium valproate and clonazepam have been tested 
independently in a number of trials, comparative assess­
ment of their value is desirable. One comparative trial 
has been reported (Lance and Anthony, 1977) but it was 
carried out as an open trial and there was no study of 
effects on serum levels of other drugs. This Chapter 
describes results of a controlled crossover trial of 
sodium valproate and clonazepam in the same patients, all 
of whom were initially poorly controlled. In addition.
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serum levels of other anticonvulsants were monitored in 
order to distinguish the direct effects of these drugs 
from the secondary elevation of other anticonvulsants.
In particular, sodium valproate has been reported to 
increase phenobarbitone serum concentrations (Richens 
and Ahmad, 1975? Schobben, 1975; Vakil et al, 197 ), 
and it was attempted to keep phenobarbitone concentrations 
relatively constant by reducing the dose when necessary.
In Chapter 6 it was found that clonazepam in a dose of 
3mg daily was ineffective in patients with temporal lobe 
epilepsy. In the comparative trial a higher dose of 6mg 
was given to determine whether this produced a better 
response.
PATIENTS AND METHODS
Thirty-two adult epileptic patients who were resident in 
Quarrier's Homes were studied in the double-blind trial. 
There were 15 males and 17 females aged 21 -\63 years 
(mean 36 years). The drugs which they were receiving 
were phenytoin (20 patients), phenobarbitone (17 patients), 
primidone (14 patients), carbamazepine (10 patients) 
ethotoin (2 patients) and pheneturide (1 patient). The 
criteria of selection was that they were having more 
than five seizures per month for the preceding three months 
and that two estimations of anticonvulsant serum levels 
should have been carried out in that period, the values 
being within the therapeutic ranges for phenytoin 
(40 - 80 /amol/1) or phenobarbitone (>40 p.mol/1) . Twenty 
nine patients had frequent major seizures (generalised 
tonic-clonic fits) and the patients all suffered from 
minor seizures (absences or focal attacks). The patients 
were classified on the basis of the EEC abnormalities 
into generalised or focal epilepsy.
The trial consisted of three consecutive periods each of 
twelve weeks and the design is shown in Fig 7.2, Initially 
the patients were observed for twelve weeks during which 
serum concentrations of anticonvulsants were measured 
twice. The 32 patients were then randomly divided into
CHg - CHg
CH3 - CHg
CH
CH
 - COONa
Fig 7.1 Chemical structure of sodium valproate
36 4412 164 8 20 403224 28
Clinical examination
Anticom-ulsants
EEC
Haeinalolopy and Biochemistry
Fit frequency nJSti»
Fig 7.2 Design of cross-over trial of 
sodium valproate and clonazepam
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two groups, each of 16 patients. One received sodium 
valproate (400mg four times daily) and the other 
received clonazepam (2mg three times daily). In some 
patients the dose of clonazepam was later reduced 
because of side-effects. After 12 weeks each group 
crossed over to the other drug over 6 weeks using a 
placebo matching the first additional drug they received. 
Serum concentrations of anticonvulsants were measured 
at 4 week intervals. The seizures were recorded by the 
nursing staff as major and minor fits.
Serum concentrations of phenytoin, phenobarbitone, 
primidone and PEMA were measured by gas chromatography and 
clonazepam was measured by radioimmunoassay as before.
In addition, sodium valproate was measured by a gas 
chromatographic technique (see Appendix).
RESULTS
Seizure Frequency
Fifteen patients completed all parts of the trial. The 
remaining seventeen patients completed one part of the 
trial only, twelve completing the sodium valproate 
treatment period and five the clonazepam treatment period 
only. Eight of these patients left the trial after the 
first drug period for various reasons unrelated to drug 
therapy. Another nine patients stoppped taking the trial 
drug because of side-effects; eight were on clonazepam 
and one on sodium valproate.
When the average number of seizures per month before and 
after treatment are compared for the fifteen patients who 
completed the trial, sodium valproate (p<0.005, Wilcoxon 
signed-ranks test) and clonazepam (p<0.02) both reduced 
the frequency of minor seizures but with sodium 
valproate having the greater effect (Fig 7.3). Major 
seizures were also reduced with sodium valproate but this 
failed to reach significance. The effects of treatment 
are summarised according to the percentage improvement for
Seizures/ 
Patient/ 
Month 
201
1 5 -
1 0 -
5 -
n- 15
Major
Minor
p 0.02
p < 0.005
Observation Clonazepam Sodium Valproate
Fig 7.3 Effects of clonazepam and sodium 
valproate on mean frequencies of 
major and minor seizures in 15 
patients who completed comparative 
trail
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all the patients treated in Table 7.1 and for the 15 
patients who completed the trial in Table 7.2.
Side Effects
The main side-effects with sodium valproate were 
drowsiness (25% of patients) and ataxia (17% of patients). 
These were abolished in all but one patient by reducing 
the dose of phenobarbitone or primidone. In one patient 
the drug was stopped because of drowsiness.
Side-effects were more of a problem with clonazepam, 
with 65% of patients showing drowsiness and 55% of 
patients showing ataxic symptoms. Because of side- 
effects it was necessary to reduce the clonazepam dose 
in 17 of the 29 patients in whom treatment was started 
from 6mg/day to 1 - 5 (mean 2.9) mg/day and the drug was 
eventually stopped in eight of these patients.
Serum Concentrations of Sodium Valproate
The mean serum concentrations of sodium valproate for 
patients on the trial, all receiving 16 00mg daily, was 
497 + 184SD pmol/1. The variation was generally 
reasonably small, with 21 of the 26 patients (blood 
samples were not obtained from one patient) showing 
concentrations within the range 350 - 700 ;umol/l . The 
variation in serum concentrations could not be explained 
in terms of variation in weight of the patients ; no 
correlation was found between serum concentrations and 
weight, which ranged from 47 - 76Kg (mean 62Kg). There 
was no apparent relationship between serum concentrations 
and therapeutic effect : 18 patients who showed a 
significant (>50%) reduction in the total number of 
seizures had a mean serum concentration of 490 ^umol/l 
and 8 patients who showed no improvement had a mean 
concentration of 513 pmol/1.
Serum.Concentrations of Clonazepam
The serum concentrations of clonazepam showed rather 
more variation than sodium valproate. The mean serum
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concentration for 23 patients in whom blood samples 
were obtained while they were receiving 6mg daily 
was 82,3 + 37,BSD nmol/1, but a number of patients 
actually showed lower serum concentrations of 
clonazepam throughout the major part of the trial 
period since doses were reduced. Twelve patients on 
doses ranging from 1 - 5mg daily (mean 2.9mg) showed 
a mean level of 29.1 + 19.1SD nmol/1. There appeared 
to be some relationship between serum concentrations 
and the therapeutic effect of clonazepam. The serum 
concentrations for the 20 patients treated are shown 
in Fig 7.4, for patients showing significant improve­
ment ( > 50% reduction in seizures) and patients showing 
no improvement. For patients in whom the initial dose 
was reduced during the first month the improvement in 
seizure control has been assessed during the second 
two months only and it is the serum concentration 
obtained on the lower dose that is given.
Although patients generally responded better to sodium 
valproate, some of the patients in whom high serum 
concentrations of clonazepam were obtained did show 
considerable improvement on this drug. Fig 7.5 shows 
the effect of clonazepam on minor seizures in an 
individual patient - the seizure frequency is shown 
not only for a three month period before the trial but 
for the entire period during which the drug regime was 
unchanged. This patient was receiving only 3mg of 
clonazepam after the first two weeks of the trial but 
showed a relatively high serum concentration (67.2 
nmol/1) on this dose. It is notable that, although this 
patient was on reasonably high doses of anticonvulsant 
drugs (200mg phenytoin, 120mg phenobarbitone) there was 
no enzyme-inducing effect as measured by raised serum 
concentrations of ( yGT 17U/1) - the possible significance 
of this is discussed in Chapter 12.
Serum
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Fig 7.4 Serum concentrations of clonazepam 
and therapeutic effect for 20 
patients in comparative trial
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Fig 7.5 Effect of clonazepam therapy on 
frequency of minor seizures in 
an individual patient
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Serum Concentrations o;f Other Drugs
Doses of other anticonyulsants were reduced during the 
trial if, on administration of the trial drug, there was 
an increase of 15% in serum concentration. Dose reduction 
was necessary during sodium valproate treatment in seven 
patients who showed an increase in phenobarbitone serum 
concentrations (five were receiving phenobarbitone and 
two were receiving primidone) and one patient also showed 
an increase in phenytoin serum concentration. There were 
no significant effects of clonazepam treatment on serum 
concentrations of other drugs.
Overall, on first administration of sodium valproate there 
was a significant increase in phenobarbitone concentrations 
in patients receiving phenobarbitone (p<0.05, Wilcoxon 
signed-ranks test) but there was no effect in patients 
receiving primidone (Fig 7.6a, b) Two patients were 
receiving phenobarbitone plus primidone - these both showed 
a 10% rise in serum concentrations of phenobarbitone.
In patients receiving primidone, there was also no 
noticeable effect of sodium valproate on serum concentrations 
of primidone nor, in the three patients in whom this 
metabolite was measured, PEMA.
In 14 patients in whom serum phenytoin concentrations were 
measured after sodium valproate administration (blood samples 
were not obtained from one patient), there was a significant 
fall (p<0.05) in concentrations (Fig 7.6c). This effect 
was generally most marked in patients in whom the pheno­
barbitone serum concentrations did not rise; indeed, in one 
patient in whom the phenobarbitone concentration increased 
the phenytoin concentration also increased and it was 
necessary to reduce the phenytoin dose.
No significant effects on serum concentrations of other anti­
convulsants were observed with clonazepam therapy.
henobarbitone
300-1
,'(376)
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n = 7
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100 -
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Valproate
Phenytoin
A im ol/l n = l4
100 -
O-j
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OnSodium
Valproate
A -  Patients on Phenobarbitone B -  Patients on Primidone C -  Patients on Phenytoin
Fig 7.6a,b,c Effects of sodium valproate therapy on 
serum concentrations of phenobarbitone 
(patients on phenobarbitone and patients 
on primidone)and of phenytoin . There 
was a significant rise (p<0.05) in serum 
phenobarbitone concentrations in 13 patients 
receiving phenobarbitone. There was a sig­
nificant fall (p<0.05) in serum phenytoin 
concentrations after sodium valproate 
administration
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DISCUSSION
Both sodium valproate and clonazepam significantly reduced 
the frequency of minor seizures when added to the existing 
therapy of 27 patients whose fits had proved difficult to 
control. Major seizures were also reduced by sodium 
valproate, but this did not reach a level of significance. 
Clonazepam was generally less effective than sodium 
valproate although it appeared to be of value in a few 
patients. The lack of effect of clonazepam in patients 
on multiple drug therapy, particularly on psychomotor 
seizures in patients with temporal lobe epilepsy, 
corresponds with results found in other trials using a lower 
dose which are discussed in the previous Chapter,
Sodium valproate appeared to be more effective in reducing 
seizures in patients whose EEGs showed generalised 
abnormalities than in those with focal abnormalities, and 
this accords with results in other studies. A number of 
open trials, particularly in children, have reported sodium 
valproate to be less effective in focal epilepsy and 
especially psychomotor seizures (Kerfriden et al, 1970;
Vülzke and Doose, 1973; Jeavons and Clark, 1974; Barnes 
and Bower, 19 75), although other investigators have reported 
the drug to be equally effective in temporal lobe epilepsy 
(Beaumanoir, 1973 ; Salzarula and Dairy, 1974; Espir et al, 
1976; Grant and Barot, 1976; Hassan et al, 1976). Sodium 
valproate was more effective than clonazepam in this study, 
both in the treatment of generalised and of temporal lobe 
epilepsy. This is in conflict with findings in another 
comparative trial (Lance and Anthony, 1977), in which 
clonazepam was more effective than sodium valproate in 
temporal lobe epilepsy. However, this was an uncontrolled 
trial and the drugs were not in most instances compared in 
the same patients. Also, in 70% of patients the most 
recently added drug was withdrawn as clonazepam was added 
and this may have produced an overall lower level of 
medication than in the patients in this study, which might 
have increased the effectiveness of clonazepam (see Chapter 6).
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These investigators used lower doses of sodium valproate 
than in the present trial.
Variations in response to sodium valproate therapy between 
different patients did not appear to be related to 
variations in serum concentrations of the drug. The serum 
concentrations of sodium valproate are fairly highly 
correlated with the daily dose of the drug (see Chapter 3) 
and there was a fairly small variation in serum concen­
trations in patients in the trial who were all receiving 
the same dose. Most patients in the trial showed serum 
levels of sodium valproate in the range 350 - 700 /imol/1, 
and other workers(Meinardi et al, 1974; Chard et al, 1976; 
Espir et al, 1976; Grant and Barot, 1976) have found that 
therapeutic levels lie in this range. There was no apparent 
effect of administration of other anticonvulsant drugs on 
serum concentrations of sodium valproate. By comparison, 
serum concentrations of clonazepam showed wide variation 
between different individuals and the therapeutic response 
to the drug appeared to be related to the serum concen­
trations. Administration of other anticonvulsant drugs 
appears to lower serum concentrations of clonazepam and this 
effect is discussed in Chapters 6 and 12,
Administration of other anticonvulsants did not affect serum 
concentrations of sodium valproate, but sodium valproate 
affects serum concentrations of phenobarbitone and possibly 
also of phenytoin. In this trial doses of phenobarbitone 
or primidone were reduced in patients who showed an increase 
in serum concentrations of phenobarbitone of more than 15% 
on administration of sodium valproate. This occured in 7 
patients, of whom five were receiving phenobarbitone and 
two were receiving primidone. Six of these patients showed 
drowsiness on first administration of sodium valproate which 
was abolished by reducing the serum concentration of pheno­
barbitone or primidone. The mechanism of the effect of 
sodium valproate on phenobarbitone levels is unknown, but 
the most likely hypothesis is that sodium valproate, being 
a fatty acid and therefore binding strongly to hepatic 
microsarnes, blocks the metabolism of phenobarbitone in the 
liver.
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There was a significant overall increase in serum concen­
trations of phenobarbitone in patients receiving pheno­
barbitone itself but not in patients receiving primidone. 
This suggests the possibility that sodium valproate may 
inhibit the metabolism of primidone to PEMA so that less 
of the drug is converted to phenobarbitone. No influence 
of sodium valproate was found on the PEMA ; primidone 
ratio in serum and this might suggest that sodium 
valproate inhibits primidone metabolism to phenobarbitone. 
No effect of sodium valproate on primidone serum concen­
trations was found, but since only about 25% of the drug 
is metabolised to phenobarbitone, an inhibition of this 
metabolism would produce a larger increase in phenobarbi­
tone serum concentrations than it would a decrease in 
primidone serum concentrations.
Since the phenobarbitone or primidone dose was reduced 
in patients in the trial in whom serum concentrations of 
phenobarbitone showed a significant increase, it is likely 
that most of the therapeutic benefit obtained with sodium 
valproate therapy was due to the action of the drug itself. 
However, evaluation of the drug in individual patients 
should take the possibility of drug interactions into 
account. For example. Fig 7.7 shows serum drug concen­
trations and seizure control for a patient in whom the 
phenobarbitone serum concentration showed a dramatic 
increase on sodium valproate administration ; the period 
before the phenobarbitone dose was reduced showed the 
lowest seizure frequency.
Conflicting reports have previously suggested that admini­
stration of sodium valproate may reduce (Per^ ry et al, 19 76; 
Vakil et al, 1976)or increase (Windorfer et al, 1975;
Vajda et al, 1976) serum concentrations of phenytoin, 
although these effects may be temporary. It has been 
suggested that sodium valproate may displace phenytoin 
from its plasma protein binding sites (Patsalos and 
Lascalles, 1977). A significant decrease in phenytoin 
concentrations was found in the present study, particularly 
for the patients in whom phenobarbitone serum concen­
trations did not increase - of nine patients receiving
Phenytoin 250m g /d ay
Phenobarb 180mg/day mg/day
Ç MB. 38years
Sodium Valproate
Serum Level 
ju mol/l
300-
Phenobarb
Phenytoin
200-
too-
Seizures
] Major10- Minor
Four Week Periods
Fig 7.7 Effects of sodium valproate therapy on 
seizure frequency and serum concentrations 
of phenytoin in an individual patient. This 
particular patient showed a large increase 
in serum phenobarbitone concentration on 
first administration of sodium valproate, 
accompanied by toxic symptoms. These toxic 
symptoms disappeared when the phenobarbi­
tone dose was reduced
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phenytoin the phenytoin serum concentration was reduced 
in eight and unchanged in one. However, in five patients 
receiving phenytoin in whom phenobarbitone serum concen­
trations were raised by more than 15% the serum concen­
tration was reduced in one, unchanged in two and raised 
in two; one of these patients indeed showed a 100% 
increase in phenytoin concentration and toxic effects 
which required dose reduction. It is possible that in 
these patients the raised phenobarbitone concentrations 
may cause inhibition of phenytoin metabolism (as described 
in Chapter 4) and this counteracts the action of sodium 
valproate.
In conclusion, sodium valproate is generally a more 
useful anticonvulsant than clonazepam when given to 
patients on multiple drug therapy. However, it is 
important to monitor serum concentrations of other anti­
convulsants during treatment with sodium valproate as 
these may influence seizure control or cause side effects. 
It is possible that some of the therapeutic effect of 
sodium valproate in patients in this trial may have been 
due to a displacement of phenytoin from its plasma 
protein binding sites ; the clinical importance of 
variations in protein binding of drugs is discussed in 
the following section.
SUMMARY
1. A cross-over trial has been conducted to compare 
the effectiveness of clonazepam and sodium 
valproate therapy in epileptic patients already 
receiving other anticonvulsant drugs. Both drugs 
produced a significant reduction (sodium valproate 
p <0.005, clonazepam p<0.02) in minor seizures, 
with sodium valproate having the greater effect.
2. Administration of other anticonvulsants did not 
affect serum concentrations of sodium valproate 
but sodium valproate caused a significant rise in 
phenobarbitone concentrations in several patients.
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The phenobarbitone dose was reduced in patients 
in whom phenobarbitone serum concentrations 
showed an increase of more than 15%. With 
sodium valproate treatment, phenobarbitone con­
centrations increased significantly (p<0.05) 
in patients receiving phenobarbitone but not in 
patients receiving primidone. Phenytoin con­
centrations were reduced (p<0.05) during treatment 
with sodium valproate.
3. Side-effects were a problem in patients receiving 
clonazepam and the dose of the drug had to be 
reduced or even stopped in many patients. This 
may have lowered the value of clonazepam therapy, 
since the effectiveness of the drug appeared to be 
related to serum levels.
4. It is concluded that sodium valproate is generally 
a more valuable drug than clonazepam in patients 
on multiple drug therapy.
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CHAPTER 8
PROTEIN BINDING OF PHENYTOIN AND PHENOBARBITONE
INTRODUCTION
Most drugs are carried from their sites of absorption to 
their sites of action by the circulating blood. Some drugs 
are simply dissolved in serum water, but many others are 
partly associated with plasma proteins, particularly 
albumin. Only free drug can reach the site of action and 
exert a pharmacologic effect and it would be expected that 
the action of a drug would depend on the degree of protein 
binding, although there are a few studies of this relation­
ship in man (Kunin, 1966; Borga et al, 1970).
Chapters 3 - 7  have shown that determination of anticon­
vulsant serum concentrations is of value in the management 
of epilepsy, but it was the total serum concentration 
which was measured. If there is much variation among 
patients in the degree of anticonvulsant protein binding, 
and if the binding determines brain concentration, it is 
likely that the free concentration will correlate more 
accurately than the total concentration with clinical 
effectiveness. There have been a considerable number of 
studies of phenytoin binding in man (Table 8.1) which have 
shown that phenytoin is highly bound to plasma proteins 
and the binding may be affected by many factors including 
protein levels (Porter and Layzer, 1975), disease states 
(Reidenberg et al, 1971; Hooper et al, 1974; Blasche et al, 
1975; Olsen et al, 1975) and the presence of other drugs 
(Lunde et al, 1970),
In the previous Chapter it was shown that sodium valproate 
administration reduced serum concentrations of phenytoin 
and it was suggested that this may be due to displacement 
of phenytoin from plasma proteins.
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YEAR AUTHOR % BOUND METHOD TEMPERATURE
1960 Svensmark et al 75 CSF/Plasma
1960 Triedraan et al 88 CSF/Plasma -
1963 Firemark et al 80 Ultrafiltration 37C
1969 Viukari and Tammisto 45 CSF/Plasma -
1970 Lunde et al 94 Ultrafiltration Room Temp
Lunde et al 91 Equilibrium dialysis Room Temp
19 71 Reidenberg 93 Ultrafiltration Room Temp
1971 Ehrnebo et al 89 Equilibrium dialysis 37C
1971 Conard et al 96 Equilibrium dialysis 4C
1972 Blum et al 90 Ultrafiltration 37C
1972 Reynolds et al 85 CSF/Plasma -
1972 Lund et al 90 CSF/Plasma -
Lund et al 90 Ultrafiltration 37C
1973 Booker and Darcey 91 Ultrafiltration Cones 22C
1974 Vajda et al 88 CSF/Plasma -
1974 Hooper et al 89 Ultrafiltration 37C
1974 Kurata and Wilkinson 95 Ultrafiltration Room Temp
Kurata and Wilkinson 91 Equilibrium dialysis Room Temp
1975 Blaschke et al 90 Ultrafiltration 37C
1975 Porter and Layzer 91 Ultrafiltration 25C
1975 Olsen et al 94 Ultrafiltration Room Temp
1976 Sherwin et al 89 Equilibrium dialysis Room Temp
1976 Odar-Caderldf and Borga 87 j Equilibrium dialysis 37C
Table 8.1 Summary of Previous Data on Phenytoin Binding 
in Normal Adult Man
This Chapter describes a study of plasma protein binding of 
phenytoin and phenobarbitone in epileptic patients receiving 
these drugs. Values obtained for binding obtained by 
different techniques have been compared and the degree of 
variation in binding of these drugs between different 
individuals have been assessed. In addition, in vitro 
studies have been carried out to examine the effects of 
temperature, plasma dilution and sodium valproate admini­
stration on protein binding. The degree of binding of 
phenytoin to albumin relative to other proteins has been 
measured by separation of the protein fractions on Sephadex 
and the importance of variations in albumin concentrations 
between different patients is shown.
PATIENTS AND METHODS 
CSF Concentrations of Anticonvulsants
CSF was obtained from 39 epileptic inpatients on phenytoin 
therapy, Phenytoin concentrations in the CSF and in serum 
were measured by a radioimmunoassay technique (Paxton et al, 
1976; see Appendix) requiring only small volumes of fluid.
In some patients sufficient CSF was obtained for measurement 
of anticonvulsant concentrations by GLC, and phenobarbitone 
(17 patients) and primidone (13 patients) concentrations 
were measured and compared with serum concentrations.
Protein Binding of Phenvtoin and Phenobarbitone
Protein binding was measured both by ultrafiltration using 
the method of Lunde et al (1970) and by equilibrium dialysis, 
The plasma was labelled with radioactive phenytoin and 
phenobarbitone and drug concentrations in the ultrafiltrate 
or dialysate were determined by scintillation counting. In 
addition, the effect of sodium valproate in vitro on protein 
binding of phenytoin and phenobarbitone was measured by 
ultrafiltration but using an Amicon ultrafiltration cell 
rather than filtration through cellulose tubing. Details of 
all these methods are given in the Appendix.
Protein binding in serum from 6 3 epileptic patients was 
determined by ultrafiltration at room temperature. In 2 8
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of these patients, serum albumin concentrations were 
determined.
In vitro studies were performed using the equilibrium 
dialysis technique, with plasma obtained from a blood 
bank. The effects of temperature and plasma dilution 
(diluting plasma with isotonic phosphate buffer) were 
determined.
Binding of Phenytoin to Plasma Proteins Separated on 
Sephadex GlOO
1ml of human plasma was equilibrated for 1 hour at room 
temperature with 20 pg ^^C-labelled phenytoin (Radiochemical 
Centre, Amersham), Sephadex G-lOO (Pharmacia Fine Chemicals 
Ltd)) pre-equilibrated with 0,IM phosphate buffer (pH 7.2) 
was packed in a column (30cm long x 1cm diameter) and 0.5ml 
of labelled plasma was applied to the column. The protein 
was eluted with phosphate buffer (flow rate 0.5ml/min) and 
the eluant collected in 0.5ml fractions.
0,2ml of each fraction was diluted with 2.8ml distilled 
water and the UV light absorbance was measured at 2 8 0nm. A 
further 0.2ml of each fraction was added to 5ml NE260 
scintillation fluid (Nuclear Enterprises Ltd) and the radio­
activity measured by scintillation counting.
RESULTS
CSF Concentrations of Anticonvulsants
The CSF concentrations of phenytoin, phenobarbitone and 
primidone gave a good correlation with serum concentrations 
(Figs 8.1a,b,c), The CSF concentrations were found to be 
on average 12% of the total serum concentrations for 
phenytoin, 47% for phenobarbitone and 100% for primidone.
Protein Binding of Anticonvulsants In Vivo
The plasma protein binding of phenytoin and phenobarbitone
was measured by ultrafiltration in 63 patients receiving
one or both of these drugs.The mean percentage free phenytoin 
in 63 patients was 10.5 ± 2.5 SD; percentage free phenobarbi­
tone in 32 patients was 52.9 ± 5.5 SD.
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Fig 8.1a Relationship between serum and CSF
concentrations of phenytoin in 40 
patients
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Fig 8.1b Relationship between serum and CSF
concentrations of phenobarbitone in 17 
patients
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Fig 8.1c Relationship between serum and CSF
concentrations of primidone in 13 
patients
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Serum albumin concentrations were measured in 2 8 of these 
patients. Fig 8.2 shows a graph of percentage free 
phenytoin plotted against serum albumin level. A significant 
positive relationship was found (p<0.05), suggesting that 
patients with reduced albumin levels show reduced binding 
of phenytoin. There was no significant relationship 
between age and binding of phenytoin or phenobarbitone in 
the patients described above, although there was a trend 
towards reduced binding in the elderly. There was also a 
trend towards reduced albumin levels with age and it appears 
likely that phenytoin binding is reduced in the elderly 
only if there is a reduced serum albumin level.
Effect of Plasma Dilution on Plasma Protein Binding of 
Phenytoin and Phenobarbitone
This was investigated at 37^C using equilibrium dialysis, 
adding labelled phenytoin and phenobarbitone such that the 
concentration of both was negligible to the plasma or 
diluted plasma. The results are shown in Pig 8.3,
Effect of Increasing Drug Concentrations on Plasma Protein 
Binding of Phenytoin and Phenobarbitone
This was investigated using both ultrafiltration and 
equilibirium dialysis through cellulose tubing at room 
temperature. Phenytoin and phenobarbitone were added at 
a range of concentrations 0-200 pmol/1; small concen­
trations of the labelled drugs were then added. There was 
no effect of increasing drug concentration on protein binding 
over this range. The mean percentage bound phenytoin and 
phenobarbitone measured by the ultrafiltration technique 
were 88.5 and 50 and by the equilibrium dialysis technique 
they were 82.5 and 33 respectively.
Effect of Temperature on Plasma Protein Binding of Phenytoin 
and Phenobarbitone
The protein binding of phenytoin and phenobarbitone (at a 
plasma concentration of 20 pg/ral of each) was measured in 
vitro by equilibrium dialysis at three temperatures, 2.^ , 22° 
and 37^C. The results are shown in Fig 8.4. The binding of 
phenytoin was strongly temperature dependent within this range
and decreases with increasing temperature,
ree phenytoin 
n serum
n -  28
20-
• «
10-
Serum Albumin g / l
Fig 8.2 Relationship between percentage free 
phenytoin in serum and the serum albumin 
concentration in 28 patients. A significant 
negative correlation (p<0.05) is found
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Fig 8.3 Effect of plasma dilution on 
protein binding of phenytoin and 
phenobarbitone measured by 
equilibrium dialysis
Percentage
Free
Drug
60
40"
20—
1 PB
DPH
I
22
Temperature
37
Fig B.4 Effect of increasing temperature 
on protein binding of phenytoin and 
phenobarbitone measured by 
equilibrium dialysis
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the free concentration being 21% greater at 37^C than at 
22^C. There was no significant variation in binding of 
phenobarbitone over the temperature range 0-37^C.
Effect of Sodium Valproate on Protein Binding of Phenytoin 
and Phenobarbitone
Fig 8.5 shows the results of an initial in vitro study to 
determine the possible displacing effects of sodium valproate 
on binding of phenytoin and phenobarbitone. Binding was 
determinea using an Amicon ultrafiltration cell and the 
drug concentrations in the ultrafiltrate were measured by 
radioassay, using a double labelling method (see Appendix). 
The drugs were added to 10ml plasma in the ultrafiltration 
cell such that a concentration of 20 jug/ml of each was 
obtained. The drugs were allowed to equilibrate and then 
sodium valproate was added, to give a concentration of 
iOO ug/ml. The percentage bound phenytoin decreased from 
90.7 to 83.7 and the percentage bound phenobarbitone 
decreased from 51.7 to 43.7,
Sephadex Fraction of Protein Bound Protein
The results are shown in Fig 8.6. Plasma proteins 
separated on Sephadex G-lOO are eluted as two protein 
fractions, of which the first is the globulin and the 
second the albumin fraction. Approximately half the 
radioactively labelled phenytoin was found by this 
technique to be bound to the albumin fraction.
DISCUSSION
In previous studies, four methods have been generally used 
to determine phenytoin binding to plasma proteins : 
measurement of the ratio of CSF to total plasma phenytoin 
concentrations; equilibrium dialysis; ultrafiltration with 
cellulose tubing and ultrafiltration with non-cellulosic 
polymeric membrane (Amicon) filtration cones (Table 8.1).
The latter technique was not used in this study as other 
workers have shown that these non-cellulosic ultra­
filtration cones permit the leakage of 2-6% of the albumin 
into the filtrate (Porter and Layzer, 1975) and further error
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Fig 8.5 Effect of sodium valproate (lOOug/ml) 
on plasma protein binding of phenytoin 
and phenobarbitone. This was measured 
in vitro using an Amicon ultrafiltration 
cell
cpm
1500
-1000
-5 0 0
—
5 201510
Elution Volume (ml )
Fig 8.6 Sephadexfractionation of C-labelled
phenytoin bound to plasma proteins. The 
protein concentration in the fractions 
collected was measured by the UV absorbance 
at 280nM: protein concentration is shown
by the uninterrupted line (----). C-phenytoin
was measured by scintillation counting and 
is shown by the interrupted line (---- )
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would be expected from the fact that the membranes bind 
7% of phenytoin in the unfiltrated plasma (Shah et al,
1974). However, a related technique using an Amicon 
ultrafiltration cell offers a rapid method for examining 
possible displacing effects of drugs and has been used for 
study of the effect of sodium valproate on protein binding 
of phenytoin and phenobarbitone in vitro.
In the present study the protein binding of phenytoin was 
measured directly by ultrafiltration and equilibrium 
dialysis through cellulose tubing and the values obtained 
were similar to those found by other workers (Table 8,1), 
with the equilibrium dialysis technique showing higher free 
concentrations as has been described elsewhere (Lunde, 19 70; 
Kurata and Wilkinson, 19 74), While measurement of the 
free concentration of the drug in plasma is preferable to 
measurement of the total concentration, such an assay 
involves additional méthodologie compexity. As CSF is in 
effect an ultrafiltrate of plasma (its protein content 
usually less than 50mg/100ml, phenytoin concentration is 
CSF has been taken as a measure of the free concentration 
(Triedman et al, 1960; Viukari and Tammisto, 1959;
Lund et al, 1972). The present study shows that CSF con­
centrations of phenytoin and phenobarbitone do indeed 
appear to reflect free concentrations; primidone is un­
bound in plasma and CSF concentrations are similar to total 
plasma concentrations. Obviously lumbar punctures cannot 
be performed routinely only for the purpose of measuring 
protein binding on drugs. However, a related method which 
may be suitable for routine purposes is the measurement of 
drug concentrations in saliva; a study of salivary con­
centrations of phenytoin is described in the following 
Chapter.
There were significant variations in the free fraction of 
phenytoin between different patients, but the binding of 
phenobarbitone was relatively constant. There was no 
relationship between the degree of binding of phenytoin 
and the total serum concentration of the drug and in vitro 
studies showed that there was no significant variation in ■ 
the binding over the concentration range 0-200 /imol/1.
91
There was, however, a significant trend towards lowered 
binding in patients with lower plasma concentrations of 
albumin although there was no relationship between phenytoin 
binding and total protein concentration. Other workers 
have found a significant relationship between albumin 
level and plasma phenytoin binding (Porter and Layzer,
1975) but a lack of dependency on total serum protein 
concentration has also been reported (Olsen et al, 1975).
The effect of a reduced albumin level would appear to be 
surprisingly large in view of the fact that in vitro studies 
showed relatively little effect of plasma dilution over a 
reasonable range. Also, a study of the binding to individual 
protein fractions by Sephadex fractionation showed that only 
about half of the protein-bound phenytoin is bound to albumin 
Other workers have shown that phenytoin is bound to alpha 
globulins in addition to albumin (Lightfoot and Christian, 
1966). A study of phenytoin binding to ■ particular albumin 
fraction; in uraemic patients (Shceman et al, 197 3) has 
suggested that a small reduction in total albumin concen­
trations in particular patients may cause considerably 
reduced phenytoin binding because of a large reduction in 
concentrations of the albumin fractions that account for most 
of the binding. It is possible that a higher proportion of 
the phenytoin is bound to albumin at 37° - Sephadex fraction­
ation in this study was carried out at room temperature.
The variation in binding of phenytoin should also be taken 
into account in comparing protein binding measured by 
equilibrium dialysis or ultrafiltration, at room temperature 
with the protein binding measured as the CSF/serum ratio.
A mean of 10.5% of phenytoin was free at 22° as measured by 
ultrafiltration; at 37° this would be expected to increase 
to 14.9%.
In the previous Chapter it was suggested that sodium 
valproate may displace phenytoin from its plasma protein 
binding sites. An initial in vitro study described here 
suggested that this may indeed be the case and that sodium 
valproate may also displace phenobarbitone. This was con­
firmed in an in vitro study by other workers (Jordan et al,
1976) and an in vivo study in rats (Patsalos and Lascalles, 
1977),
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has also suggested the possible importance of a displacing 
effect of sodium valproate on phenytoin binding. There is, 
however, still a need for a study of the importance of this 
effect in the clinical situation.
Determination of free levels of drugs in plasma in individual 
patients is of value if the degree of protein binding 
determines the degree of entry of the drug into the brain, 
and hence the therapeutic and toxic effects. This was 
suggested to be the case at least for phenytoin by a study 
in rats; phenylbutazone was found to increase the potency 
of phenytoin by displacing it from plasma protein (Shoeman 
and Azarnoff, 1975). No study in human patients has yet 
been carried out to demonstrate that the variation in 
protein binding is indeed of clinical significance, but it 
seems likely that this will be found to be the case. It is 
particularly important to study the protein binding of drugs 
such as phenytoin which are highly bound, since it would be 
expected that they would show particularly wide degrees of 
variation. There is a need for in vivo studies of the 
protein binding in human patients of the new anticonvulsants 
clonazepam and sodium valproate. Variations in protein 
binding might alter the therapeutic effectiveness of these 
drugs and particularly clonazepam, which is present in low 
concentrations, might be susceptible to displacement from 
its binding sites by other drugs. Displacement by phenytoin 
and phenobarbitone of clonazepam from plasma proteins would 
be another explanation of the increased toxic effects of 
clonazepam in patients on multiple drug therapy (described 
in Chapter 6) and this would also be expected to lower serum 
concentrations of clonazepam, as was found. However, this 
would not explain the reduced therapeutic effectiveness of 
clonazepam in patients on multiple drug therapy.
SUMMARY
1. The plasma protein binding of phenytoin shows
significant differences between different patients 
and this may be of therapeutic importance in 
altering tissue levels of the drug.
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2. Binding of phenytoin to different plasma protein
fractions was studied by Sephadex fractionation. 
Approximately half the bound phenytoin was bound 
to the albumin fraction .
3. Protein binding of phenytoin was lower in patients
showing low serum albumin concentrations but a 
relatively large plasma dilution was required to 
produce a comparable effect.
4. Protein binding of phenytoin but not phenobarbitone
was lower at 37°C than at room temperature.
5. Sodium valproate was found to displace phenytoin 
and phenobarbitone from their plasma protein binding 
sites in vitro.
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CHAPTER 9
THE VALUE OF MEASURING PHENYTOIN IN SALIVA
INTRODUCTION
Chapter 8 has shown that plasma protein binding of 
phenytoin may vary widely in different patients. However, 
the techniques which were used to measure free levels of 
phenytoin - equilibrium dialysis, ultrafiltration, 
measurement of CSF concentrations - are unsuitable for 
routine use. It has been suggested that salivary phenytoin 
concentration is dependent on the free concentration 
(Bochner et al, 1974) and this offers a readily obtainable 
measure of the biologically available drug.
A new radioimmunoassay technique has recently been 
produced which is sufficiently sensitive to measure low 
concentrations of phenytoin in small quantities of fluid 
(Paxton et al, 1977). In this Chapter the value of this 
technique in the measurement of saliva concentrations of 
phenytoin has been studied and the results for saliva 
concentrations have been compared to concentrations in 
serum and CSF.
METHODS
Simultaneous samples of blood and saliva were obtained 
from 104 in-patients for analysis of phenytoin. In 
addition, CSF was obtained from 33 of these patients.
All patients were receiving phenytoin and in most cases 
one or more other drugs, usually phenobarbitone or 
primidone. Blood samples were allowed to clot, serum 
separated and stored at -20^C. CSF and saliva specimens 
were deep frozen until assayed. The mixed saliva samples 
were centrifuged at 2500g for 15 minutes to remove any 
debris. Phenytoin in serum, saliva and CSF was measured 
by a new radioimmunoassay technique (Paxton et al, 19 76) 
(see Appendix) which is more sensitive than existing
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methods and requires only 20 } i l of fluid. Phenytoin con­
centrations in serum were also measured by GLC; there was 
good correlation between the GLC and radioimmunoassay 
methods for assaying phenytoin in serum (r = 0.95). 
Measurements of phenytoin by this radioimmunoassay 
technique were carried out by Dr J W Paxton in the 
Department of Materia Medica.
RESULTS
The mixed salivary concentrations of phenytoin gave a 
good correlation with serum concentrations in 104 patients 
(r = 0.93, the equation of the line being sali\a con­
centration = -0.002 + 0.095 serum concentration) and an 
even better correlation with CSF concentrations in the 33 
patients in whom lumbar punctures were performed 
(r = 0.98, the equation of the line being saliva concen­
tration = 0.03 + 0.80 CSF concentration). The relation­
ship between saliva and CSF concentrations is shown 
graphically in Fig 10.1 and the results are summarised 
in the Table below.
Fraction Ratios No of Patients
Range
{%)
Mean
Ration (%) SD
Mixed salivary 
cone : Total 
serum cone
104 5.1-18.3 9.6 2.6
CSF cone :
Total serum cone
33 9.8-25.0 12.0 2. 8
Mixed salivary 
cone :
CSF cone
33 66-111 82.3 11. 3
Table 9.1 Phenytoin concentration ratios in 
epileptic patients
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Fig 9.1 Relationship between saliva and 
CSF concentrations of phenytoin
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DISCUSSION
The previous Chapter described assay of phenytoin in 
CSF, which is in effect an ultrafiltrate of plasma, 
as a measure of the free concentration. This approach 
is not suitable for routine use, but it is known that 
the concentrations of drugs in saliva (mean protein 
content 262mg/100ml) may also reflect the free concen­
trations in plasma. Bochner et al (1974) have measured 
phenytoin concentrations in saliva and they found that 
they were similar to plasma free concentrations measured 
by ultrafiltration. However, saliva concentrations were 
measured by a gas chromatography technique which required 
volumes of at least 2ml. Volumes as large as this may be 
difficult to obtain from all but the most co-operative 
of patients and in this study a radioimmunoassay 
technique has been used to measure phenytoin salivary 
concentrations in microlitre volumes. The correlation 
found between saliva, CSF and serum concentrations 
would be expected to be of value in situations, such as 
uraemia, where serum protein binding is abnormal. In 
addition, the technique is non-invasive and may be 
valuable in paediatric practice and in pharmacokinetic 
studies in which multiple venepunctures would otherwise 
be required.
When this work was begun, literature regarding the 
correlation between plasma and saliva levels for 
phenytoin was fragmentary. Svensmark et al (1960) 
reported no relation between the concentration of phenytoin 
in serum and saliva, and Ciancio et al (1972) found a 
significant correlation only at low serum and salivary 
concentrations of the drug. Recently, other studies have 
confirmed that measurement of phenytoin concentrations in 
saliva is of value. Other workers have found that saliva 
levels give an accurate indication of phenytoin available 
in CSF (Troupin and Friel, 1974; Schmidt and Kupferberg,
1975) and of free phenytoin in plasma (Reynolds et al,
19 76) and there has been another study in which phenytoin 
was measured by a radioimmunoassay technique in small
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volumes of saliva (Cook et al, 1975), Primidone, pheno­
barbitone, carbamazepine and ethosuximide concentrations 
in saliva have also been shown to reflect plasma free 
concentrations (Horning et al, 1977; McAuliffe et al, 
1977) but salivary concentrations of sodium valproate 
are much lower than expected because the transfer into 
saliva is pH-dependent and this drug has a low pKa,
SUMMARY
1. A new radioimmunoassay technique has been used 
for the measurement of phenytoin in small 
volumes of saliva.
2. Highly significant correlations were found 
between phenytoin concentrations in serum and 
saliva (r = 0.93) and particularly between CSF 
and saliva (r = 0.98). Assay of phenytoin con­
centration in saliva offers a simple measure
of the plasma free concentration.
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CHAPTER 10
UPTAKE OF DRUGS BY RED BLOOD CELLS AS A MEASURE OF 
BIOLOGICALLY AVAILABLE DRUG
INTRODUCTION
In Chapter 8 it was shown that the degree of plasma protein 
binding of phenytoin may vary between different patients 
and it might be desirable to measure protein binding 
routinely in the clinical situation; in the previous 
Chapter a simple method for measuring protein binding of 
phenytoin was described, using a radioimmunoassay technique 
to measure concentrations of phenytoin in saliva. However, 
this radioimmunoassay technique is not widely available and 
also it might be desirable to have a method which could be 
readily adapted to the measurement of free concentrations 
of other anticonvulsants; it would of course be possible 
to measure saliva concentrations by GLC (McAuliffe et al, 
1977) but the fairly large volumes of saliva required may 
be difficult to obtain from any but the most obliging of 
patients.
Kurata and Wilkinson (19 74) have suggested that determination 
of the RBC/plasma concentration ratio may serve as a simple 
and rapid technique for the screening of abnormal protein 
binding in routine clinical samples. The assumption is that 
the RBC concentration depends on the free rather than the 
total concentration in plasma. This Chapter describes a 
method whereby the uptake of phenytoin and phenobarbitone 
can be determined simultaneously using doubly labelled radio­
isotopes. In addition, whole blood concentrations of these 
drugs and of primidone and PEMA have been measured by GLC.
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PATIENTS AND METHODS 
RBC Binding of Anticonvulsants In Vivo
1. Heparinised blood was obtained from a group of 
epileptic patients receiving one or more of the anti­
convulsants phenytoin, phenobarbitone or primidone. 
Gas-liquid chromatography was used to determine anti­
convulsant concentrations in whole blood and in 
plasma. In 6 patients PEMA concentrations were also 
measured,
2. The erythrocyte/plasma concentration ratios for
phenytoin and phenobarbitone in 41 patients were
obtained by a radioassay technique (see Appendix)
3after adding small concentrations of H-labelled 
phenytoin and ^^C-labelled phenobarbitone to whole 
blood. After equilibration for 30 minutes at 22^C, 
the plasma was removed and the drug concentrations 
determined by scintillation counting. In order to 
determine the uptake of these drugs by RBC‘s from 
buffer, they were washed twice in their own volume 
of phosphate buffer and the packed cells resuspended 
to twice their own volume. 0.1ml of the previous 
washing and of the resuspended RBC’s were taken for 
counting. The uptake of the drugs by RBC's from 
plasma is calculated using the equation
c = B/P - (1 - H)
P H
where C is the red blood cell concentration, B is the 
known whole blood concentration, P is the plasma con­
centration and' H is the haematocrit.
RBC Binding of Anticonvulsants In Vitro
Heparinised blood was obtained from normal volunteers and 
centrifuged and the plasma and buffer layers removed. The 
RBC's were washed twice with isotonic phosphate buffer 
(K^HPO^ 1.41, NaH^PO^ 0.26, NaCll8.10g/l : pH 7.4) and the 
packed RBC's resuspended to twice their own volume with 
varying dilutions of plasma containing 20 pg/ml each of 
radioactively labelled phenytoin and phenobarbitone. After 
equilibration, for thirty minutes, the drug
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concentrations in plasma and RBC's were measured by 
scintillation counting.
RESULTS
Concentrations of phenytoin, phenobarbitone, primidone and 
PEMA were determined by GLC in plasma and whole blood, 
and the concentrations in RBC's were determined by sub­
traction. Primidone and PEMA are unbound in plasma and 
RBC concentrations were approximately equal to plasma con­
centrations. The results are shown in Table 10.1 below.
....... .........................—
DRUG
" . ..............-  "
No of 
Patients
m b r
Phenytoin 40 0.755 1.4 0.924
Phenobarbitone 40 0.738 12.5 0. 859
Primidone 17 0.92 5.5 0.948
PEMA 6 0.90 j 3.9 0.947
Table 10.1 Relationship between whole blood and plasma 
concentrations of phenytoin, phenobarbitone, 
primidone and PEMA according to the equation 
y = b + mx, where y is whole blood concen­
tration and X  is plasma concentration in 
pmol/1 and r is the correlation coefficient
Primidone and PEMA are unbound in plasma and the values 
obtained for RBC concentrations by subtraction suggest that 
there is a simple equilibration between plasma and RBC's, 
with the concentrations being approximately equal.
The uptake of phenytoin and phenobarbitone by RBC's was 
determined by a radioassay technique. The uptake of these 
drugs from isotonic phosphate buffer was also determined. 
The results are shown in Table 10.2.
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DRUG RBC/PLASMA(a)
RBC/BUFFER
(b) a/b
Phenytoin
Phenobarbitone
0.58 ± 0.08 
0.88 ± 0.08
2.8 ± 0.3 
0.99± 0.19
0.21 ± 0.3 
0.88 ± 0.13
Table 10.2 Uptake of phenytoin and phenobarbitone 
by RBC's obtained from 41 patients.
All values are means ± standard 
deviation
It would be expected that the ratio a/b would be approxi­
mately equal to the free fraction of these drugs in plasma. 
In fact, the values obtained for this ratio either for 
phenytoin or phenobarbitone are somewhat higher than the 
values obtained by ultrafiltration for the protein free 
drug (described in Chapter 8). This may be explained by 
the swelling of the RBC's in buffer, in the absence of 
protein, which may reduce the uptake of the drug.
That the RBC concentration is related to the free rather 
than the total concentration can be shown by the effect of 
plasma dilution. Fig 10.1 shows the effect of plasma 
dilution on the uptake of phenytoin and phenobarbitone by 
RBC's. Comparing this figure to Fig 8.3, in which the 
effects of plasma dilution on protein binding are shown, 
it can be seen that the RBC uptake increases as protein 
binding decreases.
DISCUSSION
Phenytoin, phenobarbitone, primidone and PEMA all accumulate 
in human RBC's, and uptake appears to be a function of 
the concentration of unbound drug in the plasma. A constant 
RBC/unbound plasma concentration partition coefficient with 
little interindividual variability exists. Perturbations 
in the unbound fraction of phenytoin and phenobarbitone 
produced by plasma dilution do not appear to affect the 
coefficient. Such results have been found previously for
RBC Cone. 
Plasma Cone.
Phenobarb.
Phenytoin
1
Plasma Dilution
Fig 10.1 Effect of plasma dilution on the
RBC uptake from plasma of phenytoin 
and phenobarbitone
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phenytoin (Borondy et al, 197 3; Kurata and Wilkinson . 1974; 
Sherwin et al, 1976) propranolol (Jellett and Shand, 1974, 
quinidine (Hughes et al, 1975) and haloperidol (Hughes et al,
1976). Direct measurement of the phenytoin content of 
RBC's by the method described here may provide a useful 
index of percentage free drug in plasma. However, the 
protein binding of phenobarbitone varies only slightly 
between different patients and there would be little value 
in measuring RBC uptake of this drug. It should be noted 
that because of the variation in plasma protein binding of 
phenytoin with temperature, the uptake of the drug by RBC's 
varies with temperature. If there is no effect of tempera­
ture over the range 22°C - 37^C on the uptake of the free 
drug by the RBC and, as was shown in Chapter 8, the free 
fraction of drug in plasma increases over this temperature 
range, then it would be expected that more of the phenytoin 
in a blood sample will be bound in the RBC's at 37°C than 
at 20^0. This is of importance since blood samples are 
normally spun down and the plasma or serum removed for 
anticonvulsant analysis at room temperature. The phenytoin 
in plasma or serum will be greater at room temperature 
than in the in vivo situation, since there will be less 
bound in the RBC's. If the haematocrit is 0.50, it can be 
calculated that the measured serum concentration will be 
approximately 10% greater than the in vivo concentration.
This has also been suggested recently by other workers 
(Ehrnebo and Odar-Cederlôf, 1977). Thus the CSF/serum 
or saliva/serum ratios as measured will be 91% of the true 
values. This may at least partly explain why the values 
for protein binding obtained in Chapter 8 by equilibrium 
dialysis or ultrafiltration were greater than the values 
obtained for the CSF/serum or saliva/serum phenytoin 
concentration ratios. The true mean CSF/serum ratio 
obtained from the results described in Chapter 8 would then 
be 13.3, which compares reasonably well with a percentage 
free phenytoin at 37^ measured by ultrafiltration of 14.9.
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SUMMARY
1. Phenytoin, phenobarbitone, primidone and PEMA 
concentrations in whole blood from epileptic 
patients have been measured by GLC- In all cases 
the whole blood concentration was directly propor­
tional to the plasma concentration.
2. A simple radioassay technique has been developed 
for the simultaneous determination of uptake by 
RBC's of phenytoin and phenobarbitone. This 
provides a readily available index of the percentage 
free drug in plasma.
3. Uptake of phenytoin by RBC's does not vary with 
temperature. However, since protein binding 
decreases with increasing temperature, a higher 
concentration of the drug is bound in the RBC's at 
37°C than at 22°C.
Iü4
CHAPTER 11 
ANTICONVULSANTS AND FOLATE METABOLISM 
INTRODUCTION
'Folate' is a general term for a group of pteridines 
which are required in the diet for normal metabolism. 
Deficiency of folate leads to the development of 
megaloblastic anaemia, morphologically identical to that 
of vitamin B^^ deficiency. Investigations of 
megaloblastic anaemias not associated with low serum 
vitamin B^ ^^  showed that certain of them were related to 
anticonvulsant therapy and that the effect was due to a 
secondary fall in serum folate (Kohn et al, 1961; Druskin 
et al, 1962). When other workers studied groups of 
non-anaemic patients receiving anticonvulsants, however, 
it became apparent that low serum folate concentrations 
were present in a large percentage of the epileptic 
population varying from 27% to 91% (reviewed by 
Reynolds, 19 73). Other studies have shown that sub­
normal serum folate levels are accompanied by correspond­
ing lowering of RBC folate (Preece et al, 1971) and of 
CSF (Wells and Casey, 1967 ; Reynolds et al, 1969, 1972).
The clinical importance of the lowered serum folate 
concentrations is not clearly defined. There have been 
various reports of worsening of seizures in patients 
who received therapeutic administration of folate 
(Chanarin et al, 1960; Reynolds, 1967; Wells, 1968; 
Dennis and Taylor, 1969; Lanzkowskyet al, 1969), but 
a series of controlled trials to study the effect of 
folic acid administration on seizure control all 
produced negative results (Grant and Stores, 1970;
Jensen and Olesen, 1970; Ralston et al, 1970; Norris 
and Pratt, 1971; Mattson et al, 1973). However,
Mattson et al (1973) found no rise in CSF folate during 
folic acid administration and suggested that anticon­
vulsants interfere with conversion of folic acid to
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,5-methyl te trahydrof Ola, te, which is the form of folate 
which enters the CSF, Administration of 'Leucovorin' 
(5“formyltetrahydrofolate) to a group of six patients 
produced a significant rise in CSF folate but there was 
no change in seizure frequency. 5-formyltetrahydrofolate 
is a reduced folate which is rapidly converted to 
5-methyltetrahydrofolate (Nixon and Bertino, 19 72).
Low folate concentrations have been related to treatment 
with the three major anticonvulsant drugs (phenytoin, 
phenobarbitone and primidone) and Reynolds et al (196 6) 
found that the incidence rose with the number of drugs 
that the patient was receiving. However, Klipstein 
(1964) reported that the incidence of low concentrations 
was the same in patients on phenytoin alone as in 
patients on phenytoin plus other drugs. The relationship 
between lowered folate and the anticonvulsant regime 
remains unclear and therefore this Chapter describes 
measurements of serum folate in patients on various 
drug therapies in order to study the relative effects.
In addition, a double-blind trial has been conducted 
in which the effects of folic acid and 'Leucovorin' 
administration on serum and CSF concentrations of 
folate, serum concentrations of anticonvulsants and 
seizure control have been assessed and compared.
The effects of anticonvulsant and folate administration 
on concentrations in CSF of 5-hydroxyindoleacetic acid 
(5-HIAA) and homovanillic acid (HVA), the acid 
metabolites of serotonin and dopamine respectively, 
have also been studied. It is known that pharmacological 
agents that decrease endogenous brain amines increase 
the susceptibility to experimental seizures, while 
agents that increase biogenic amines decrease the 
susceptibility to convulsions. There is a possibility 
that the action of anticonvulsant drugs may involve an 
effect on the brain amines, and this may be reflected 
in the CSF concentrations of HVA and 5-HIAA. Much 
evidence supports the view that the concentrations of 
these metabolites reflect the turnover of their parent 
amines (Moir et al, 1970). Folate may be involved in
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the metabolism of these amines (Laduron, 1972; Banerjee 
and Snyder, 1974) and it is possible that an effect of 
anticonvulsants on brain amine metabolism may be 
mediated via an effect on tissue folate. It would in 
that case be expected that administration of folate 
would reverse the biochemical effect of anticonvulsants 
and worsen seizure control.
PATIENTS AND METHODS
The subjects studied were 61 male and 50 female epileptic 
In-patients, with ages ranging from 18 - 66 years (mean 
37 years). All patients had been receiving various 
combinations of phenytoin, phenobarbitone and primidone 
for at least one year. In addition some patients were 
receiving other anticonvulsant drugs - carbamazepine (17), 
sodium valproate (11), clonazepam (5), valium (5), 
sulthiame (2) and ethosuximide (1). Blood samples for 
analysis of serum folate and anticonvulsant concentrations 
were obtained from all patients on at least one occasion 
and in 75% of patients on two or more occasions. In 
addition, serum B^^ concentrations were measured in 10 3 
of the patients.
Tumbar punctures were performed for analysis of CSF 
concentrations of folate from 4 3 patients; in addition 
to folate, CSF concentrations of HVA (24 patients) and 
5—HIAA (30 patients) were measured. Nineteen patients 
who showed low CSF concentrations of folate were 
selected for a double-blind trial of the effects on 
seizure control of administration of folic acid and 
'Leucovorin'. All these patients had low levels of 
serum folate also. Fourteen patients were receiving 
phenytoin combined with phenobarbitone or primidone, 
four patients were receiving phenobarbitone or primidone 
and one patient was receiving phenytoin alone. Folic 
acid (5mg intramuscular daily) and 5-formyltetrahydro- 
folate (3mg intramuscular daily) were administered for 
a period of one month, after which time a second lumbar 
puncture was performed. Ten patients received 
'Leucovorin; and nine patients received folic acid.
107
CSF concentrations of folate, HVA and 5-HIAA were 
measured both before and after folate administration. 
Serum concentrations of folate and anticonvulsants 
(phenytoin, phenobarbitone, primidone and PEMA) were 
measured at the same time as lumbar punctures were 
performed and in addition serum folate concentrations 
were measured three months after the start of folate 
therapy. Seizures were recorded by the nursing staff 
as major or minor seizures and the frequencies were 
computed for three months before the trial and three 
months after the start of folate therapy.
RESULTS
Serum folate concentrations in 111 patients receiving 
various combinations of anticonvulsant drugs are 
summarised in Table 7.1. 7 3% of patients were found to
have folate concentrations below the normal range 
(3.2 - 17 pg/1). There was no significant difference 
between single treatment with phenytoin and treatment 
with phenobarbitone or primidone, and there was no 
significant difference between single treatment and 
combined treatment with these drugs. However, higher 
serum concentrations of folate were found in patients 
on low doses of phenobarbitone only - five patients with 
doses in the range 60 - 120mg daily showed a mean of
5.2 pg/1 and the concentrations were significantly 
higher (p<0.G01, t-test, comparing the log serum con­
centrations) than in other patients receiving anti­
convulsant therapy. Also, there appeared to be a trend 
towards lower folate concentrations with higher pheno­
barbitone serum concentrations in the 11 patients on 
phenobarbitone alone (r - 0.672, p <0.05, correlating 
log folate concentrations with phenobarbitone concen­
trations) .
A small but significant positive correlation (r = 0.211, 
pCO.OS) between serum concentrations of folate and serum 
concentrations of vitamin found in 10 3 patients
(correlating the logarithms of the concentrations). 
However, none of the patients showed concentrations
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below the normal range (160 - 96 0 pg/ml).
That anticonvulsants lower folate concentrations in CSF 
as well as in serum was confirmed in the 43 patients 
in whom lumbar punctures were performed - 65% of 
patients showed CSF concentrations below the normal 
range (12.6 - 67 jag/1) . There was a significant 
correlation (r = 0.472, p <  0.01) between serum and 
CSF concentrations.
Administration of either folic acid or 5-formyltetra- 
hydrofolate raised both serum and CSF levels of folate 
(with 5-formyltetrahydrofolate having a somewhat 
greater effect on CSF folate concentrations relative 
to serum concentrations). These effects are summarised 
for fifteen patients in Table 11.2 - for four patients 
on the trial it was not possible to perform a second 
lumbar puncture and these patients have not been 
included. Serum folate concentrations were still 
raised three months after the start of folate therapy 
(ie two months after the end of folate administration); 
in nine patients who received folic acid the mean serum 
folate concentration was 3.9 + 1.6 SD pg/1 after three 
months as compated to 2.1 + 1.2 SD pg/1 before therapy; 
in nine patients who received 5-formyltetrahydrofolate 
(a later blood sample was not obtained from one patient) 
the concentration was 3.7 + 1.8 SD pg/1 as compared to
2.2 + 0.7 SD pg/1 before therapy.
There was no significant effect of administration of 
either folic acid or 5-formyltetrahydrofolate on the 
frequency of either minor or major seizures as shown 
on Table 11.3 below
Seizures FolicBefore
Acid
After
5-formyltetrc 
Before
ahydrofolate
After
Major
Minor
3.2 
21. 8
2.7
22.9
5.2
7.7
4.7
7.9
Table 11.3 Effects of treatment with 5-formyltetra­
hydrofolate (10 patients) or folic acid 
(9 patients) on the mean seizure 
frequencies per month.
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However, a significant reduction in serum concentrations 
of phenytoin (p<0.01, Wilcoxon signed-ranks test) 
was found as serum folate was raised comparing con­
centrations of phenytoin before and after one month of 
folate therapy (Table 11.4 and Fig 11.1). Although 
there was no overall effect of folate therapy on 
seizure control there was a possible effect on control 
of major seizures in patients in whom serum concen­
trations of phenytoin fell - of nine patients in whom 
there was a fall in serum concentrations there was an 
increase in major seizures in five and seizures were 
unchanged in four (five of these patients were previously 
not suffering from major seizures, of whom two had 
major seizures during folate therapy). There were no 
significant effects of folate therapy on serum concen­
trations of phenobarbitone, primidone or PEMA.
Brain Amine Metabolism
CSF concentrations of HVA 64 patients) and 5-HIAA 
( 30 patients) were measured in a group of epileptic 
in-patients receiving chronic anticonvulsant therapy 
in whom the seizure frequency had been assessed over 
the previous six months. All patients were receiving 
phenytoin and in most cases were in adddition 
receiving one or more other drugs, generally pheno­
barbitone or primidone. The mean phenytoin serum con­
centration in these patients was 42.2 pmol/1 (range 
6 - 109 pmol/1 ) • Both HVA and HIAA concentrations were 
low in these patients - the mean HVA concentration was
0.11 pmol/1 ±0.11 (normal range 0. 22-0. 44 pmol/1) and 
mean HIAA concentration was 0. llpmol/1 + 0.8SD(normal range 
Q 8-0.13 ) - with the HIAA concentrations in 53%
of patients showing values at the lowest limit of 
sensitivity of the assay005pmol/l . No correlation was 
found in these patients between either the HVA or HIAA 
concentrations and the serum phenytoin concentration, 
serum or CSF folate concentration, seizure frequency or 
age of the patients.
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Fig 11.1 Effect of folate therapy on serum
phenytoin concentrations in 14 patients 
A significant fall (p < 0.01) was found
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The effects of folate administration as folic acid or 
5-formyltetrahydrofolate on CSF concentrations of HVA 
(7 patients) and HIAA (8 patients) are shown in 
Table 11.2. There were reductions in concentrations 
of these metabolites but it is likely that these 
changes were not significant and they were due to 
errors in the assay - the measurements were performed 
on different occasions to determine the levels before 
and after therapy and there may have been differences 
in the standardisation of the assay between these two 
occasions; also there are considerable errors in the 
assay in measuring the low concentrations of HVA and 
5-HIAA found in these patients. However, a definite 
conclusion can be made that there were no increases 
in levels of HVA or 5-HIAA with folate therapy.
DISCUSSION
The results in these patients confirm that anticon­
vulsant administration lowers serum folate concen­
trations. There was no signi'fkant difference in folate 
concentrations between patients receiving phenytoin and 
patients receiving phenobarbitone or primidone, 
although a few patients receiving low doses of pheno­
barbitone had higher folate levels. Other workers 
have suggested that phenytoin has a greater effect than 
these other drugs in lowering serum folate (Reynolds,
19 72), but this is probably only the case if the effect 
of high doses of phenytoin is compared with the effect 
of low doses of phenobarbitone or primidone. Reynolds 
et al (1966) found that the incidence of low folate 
concentrations rose with the number of drugs being 
taken by the patient but Klipstein (1964) reported that 
the incidence of low concentrations was the same in 
patients on phenytoin alone as in patients on phenytoin 
plus other drugs. In the present study, serum folate 
concentrations in patients receiving multiple anticon­
vulsant therapy was only slightly and not significantly 
lower than in patients receiving single drug therapy, 
and it appears that, once a low folate level is attained
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with a reasonably high dose of a drug, the addition of 
other drugs has no significant effect. This is similar 
to results of a study of the effects of administration 
of phenobarbitone or phenytoin to rats fed on vitamin 
Bi2“-deficient or vitamin B^g^supplemented diets 
(Williams and Spray, 19 76) - the anticonvulsants failed 
to reduce further the already lowered liver folates 
resulting from feeding of the vitamin 
diet, although there was significant depletion in 
animals taking the supplemented diet.
An inverse correlation between phenytoin and pheno­
barbitone in serum and folate levels has been found by 
other workers (Reynolds, 1972b) but in the present study 
this was found only for phenobarbitone concentrations 
in patients on low doses of the drug (none of the 
patients receiving phenytoin or primidone were on 
comparably low doses of the drug).
The proposed mechanisms for lowered serum folate in 
patients receiving anticonvulsants include impairment 
of folate (monoglutamate) absorption (Meynell,
196 6 ) . This has not been confirmed ( Doe et al, 1971; 
Fehling et al, 1973 ) , and neither has the hypothesis 
that phenytoin inhibits the deconjugation of poly­
glutamates to the glutamate form, which is absorbed 
Oaugh, 1969 ) . Displacement of folate from plasma
protein by anticonvulsants (Markkanen et al, 19 73) 
would lower serum folate but would probably not account 
for the reduction in RBC folate also observed (Preece 
et al, 1971). Possibly the most likely hypothesis 
(Maxwell et al, 1972) is that lowered serum folate is 
related to an effect of anticonvulsants on the drug- 
metabolising system in the liver. This possibility is 
discussed in the following Chapter.
The concentrations of folate in CSF in patients in the 
present study were also lower than normal, and there was 
a significant relationship between serum and CSF concen­
trations of folate. The serum and CSF concentrations 
were raised both by administration of folic acid and
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5-formyltetrahydrofolate. Other workers (Mattson et al, 
1973) found that folate concentrations did not rise in 
CSF in patients who received folic acid although the 
concentrations rose in serum, presumably because folate 
must be converted to 5-methlytetrahydrofolate before 
appearing in the CSF (Levitt et al, 1971). It was 
assumed that anticonvulsants interfere with this con­
version. In conflict with this, folic acid administration 
did raise CSF concentrations in the present study, 
although the effect on CSF concentrations compared to 
serum concentrations was less than with 5-formyltetra­
hydrofolate administration.
Increase in serum folate concentrations in patients 
receiving treatment with either folic acid or 5-formyl­
tetrahydrofolate was accompanied by a fall in serum 
phenytoin concentrations particularly in patients 
showing previously high concentrations. This confirms 
previous observations (Jensen and Olesen, 1970; Baylis 
et al, 1971; Mattson et al, 19 73) and may provide an 
explanation for the conflicting views on the effect of 
folate therapy on seizure control. It is possible that 
some of the reports of a worsening of seizures, 
particularly that by Reynolds (19 67), may have been due 
to the effect of folate in reducing phenytoin concen­
trations. In the present study, there appeared to be 
an increase in major seizures in the patients in whom 
phenytoin concentrations fell and this is in line with 
the findings in Chapter 4 that increase of phenytoin 
serum concentrations into the therapeutic range reduces 
the frequency of major but not minor seizures. It seems un­
likely that the antifolate effect of anticonvulsants is 
a major factor in the control of epilepsy. Although 
folic acid and its derivatives act as convulsants 
when injected into the cerebral cortex of rats or cats, 
millimolar concentrations of these compounds are required 
to elicit such effects (Maugiere et al, 1975).
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Folate is involved as a cofactor in drug hydroxylation 
and it is likely that the effect of folate treatment in 
reducing serum phenytoin concentrations is due to an 
increased metabolism of the drug. Kutt et al (1966) 
have previously demonstrated accelerated metabolism 
of phenytoin to HPPH during folic acid treatment in 
a patient with phenytoin intoxication. This effect of 
folate on phenytoin metabolism offers a mechanism 
whereby administration of a second drug may indirectly 
increase serum levels of another drug, rather than by 
competitive inhibition of metabolism. For example, 
an effect of phenobarbitone in increasing phenytoin 
serum concentrations (which is suggested to be a 
possibility in Chapter 4) may be due to a lower serum 
folate concentration in patients receiving combined 
therapy, although it seems likely that this would happen 
only if the patient was receiving a low dose of phenytoin 
Also, the non-linear relationship between phenytoin dose 
and serum concentration may at least partly be due to a 
lowering of the serum folate concentration as the 
phenytoin dose is increased.
Brain Amine Metabolism
It has been reported that 5-methyltetrahydrofolate may 
be an active methyl donor for biogenic amines such as 
dopamine and serotonon (Laduron, 19 72; Banerjee and 
Snyder, 19 74) and this raised the possibility that the 
effect of anticonvulsants in causing lowered serum and 
tissue concentrations of folate may in turn cause 
altered monoamine metabolism. There is some evidence 
from animal studies that anticonvulsants may produce 
changes in monoamine metabolism (Bonnycastle et al, 1957; 
Chase et al, 1969) and this may in part be related to 
their effects (Meyer and Frey, 19 73). Other workers 
(Reynolds et al, 19 75) have found a negative correlation 
in a group of treated epileptic patients between CSF 
folate and 5-HIAA or HVA, the metabolites of serotonin 
and dopamine. In a study of the effect of folic acid 
in five drug treated epileptics. Hunter et al (1971)
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found a slight but not significant fall in HVA though 
there was a significant drop in HVA in 11 psychiatric 
patients.
In the present study there were no significant effects 
on CSF levels of HVA and 5-HIAA when either folic acid 
or 5-methyltetrahydrofolate were administered. Also, 
there were no correlations between CSF concentrations 
of folate and HVA or 5-HIAA in the group of epileptic 
patients studied, in conflict with previous results, 
(Reynolds et al, 1975). HVA and 5-HIAA concentrations 
were lower in epileptic patients as compared to normal 
controls, whereas a previous report described raised 
levels especially in patients with high levels of serum 
anticonvulsants (Chadwick et al, 1975). No correlation 
was found in the present study between serum anticon­
vulsant concentrations and the monoamine metabolites 
in CSF. Other workers, in a study of children with 
epilepsy, found reduced CSF concentrations of HVA and 
HIAA afterprobenicid loading, with no relationship to 
serum anticonvulsant concentrations (ShayWitz et al,
19 75); a number of investigations have noted reduced 
base-line concentrations of one or both of HVA and 
5-HIAA in patients with epilepsy (Barolin and Hornykiewicz , 
1967; Dubowitz and Rogers, 1969; Papeschi et al, 1972; 
Garelis and Sourkes, 19 73). Shayfitz et al (19 7 5) 
suggested that the altered brain amine metabolism is 
related to epilepsy rather than to anticonvulsant medi­
cation. Chadwick et al (1975) did not find any difference 
in CSF amine metabolite levels between neurological 
controls and untreated epileptics but found that treat­
ment with high serum concentrations of phenytoin and 
phenobarbitone tended to raise CSF levels of HVA and 
5-HIAA, the latter to a significant degree.
A hypothesis which might explain these conflicting results 
is that there is an abnormality in amine metabolism 
associated with epilepsy which tends to lower CSF con­
centrations of HVA and 5-HIAA, and this tends to be 
reversed by anticonvulsant administration. That Chadwick 
et al, (1975) did not find lowered concentrations of
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HVA and HIAA even in untreated epileptics could be 
explained by the fact that the patients investigated 
were out-patients who were presumably suffering from 
fewer seizures than the in-patients who were 
investigated in the present study. However, if this 
was the case one might expect to find a relationship 
between the lowered levels of HVA and 5-HIAA and the 
seizure frequency but no relationship was found in the 
patients examined in the present study. It should also 
be taken into consideration that these patients, apart 
from suffering from more seizures than an out-patient 
epileptic population would be expected to, were also in 
most cases suffering from some degree of mental 
deficiency usually associated with brain damage.
Thus this in-patient population might not be directly 
comparable with other groups of patients and there might 
be a greater degree of abnormality in amine metabolism 
than is usual.
SUMMARY
1. Serum folate concentrations were measured in 111
patients receiving anticonvulsant therapy. Most 
patients showed concentrations below the normal 
range. There was no significant difference in 
folate concentrations between patients receiving 
phenytoin and primidone and between patients 
receiving single or multiple drug therapy, but 
patients receiving phenobarbitone alone showed 
higher levels.
2'. Folate concentrations in CSF in 4 3 patients in
whom lumbar punctures were performed were also 
low. There was a significant correlation 
(p <  0.01) between serum and CSF concentrations.
3. Folate was administered, either as folic acid or
5-formyltetrahydrofolate to 19 patients showing 
low serum and CSF folate concentrations. Both 
groups of patients showed increases in serum and 
CSF folate concentrations but there was no effect 
on seizure control.
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4. Serum concentrations in 14 of these patients who 
were receiving phenytoin showed a significant 
fall (p< 0 .01) when folate was administered.
5. Patients treated with anticonvulsants show 
lowered CSF concentrations of HVA and HIAA but 
there was no relationship with folate concen­
trations and folate administration had no effect 
on levels of these metabolites.
6 . It is concluded that there is no relationship 
between the antifolate effect of anticonvulsants 
and their therapeutic action or brain amine 
metabolism. Effects of folate administration
in worsening seizure control may be explained 
by lowered serum concentrations of phenytoin.
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CHAPTER 12
THE LIVER ENZYME-INDUCING EFFECTS OF ANTICONVULSANTS
INTRODUCTION
In Section 1 of this thesis it was shown that serum con­
centrations for a number of anticonvulsants show wide 
variations between different patients. This was suggested 
to be frequently due to variations in the rate of metabol­
ism of the drugs, particularly due to variations in the 
level of enzyme induction. Most anticonvulsant drugs are 
metabolised by the P enzyme system of the liver. The
basis for induction is an increase of liver size and weight 
with proliferation of endoplasmic reticulum and increase 
in enzyme activity per mg of microsomal protein; this can 
be demonstrated by an increase in cytochrome P45Q content. 
The Km is usually not greatly altered by induction but the 
Vmax may become increased manifold (Conney, 1967). If 
enzyme induction could be measured it might be possible to 
predict more accurately for a given patient the serum con­
centration obtained with a given dose of drug.
Direct proof of liver microsomal enzyme induction depends 
on showing that administration of an inducing agent results 
in an increase of enzyme activity. Enzyme levels can be 
assessed directly in liver tissue but liver biopsy is rarely 
justified for this purpose alone. Indirect evidence comes 
from the finding of a shortening in plasma half-lives and 
lowered steady state concentrations in the plasma of drugs 
metabolised by these enzymes. But the disappearance rate 
of test drugs such as antipyrine does not necessarily 
reflect the total activity of drug-hydroxylating enzyme in 
patients on multiple drug therapy because these drugs may 
compete with the test drug for the same metabolising enzyme 
system. Genetic differences in human drug metabolism 
also complicates the interpretation of drug disappearance 
rates (Vessell et al, 1969, 1971).
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Recently, increases in the activity of the enzyme 
y  -glutamyl transpeptidase (yGT) in human serum after 
administration of phenobarbitone and phenytoin have been 
reported (Rosalki et al, 1971; Whitfield et al, 1973). 
Hepatic GT is located primarily in the microsomal 
fraction (Szewczuk, 19 66) and administration of pheno­
barbitone to rats is accompanied by an increased activity 
(Ideo et al, 1971). It is likely that the effect of a 
drug on serum y GT levels may be related to the drug's 
ability to promote hepatic enzyme induction.
In this Chapter the measurement of serum levels of yGT  
in epileptic patients has been used to assess the relative 
enzyme-inducing properties of anticonvulsant drugs and to 
quantify the induction produced by multiple drug therapy. 
This may allow the prediction of the stimulatory effect on 
metabolism of a drug due to induction either by itself or 
by other drugs that the patient is receiving. Also, some 
of the biochemical effects of anticonvulsants may be due to 
their enzyme-inducing properties, and attempts have been 
made to correlate serum y GT levels with serum concentrations 
of calcium and triglycerides. In Chapter 11 it was 
suggested that the effect of anticonvulsants in lowering 
serum folate concentration•may be related to an induction 
of folate metabolism; in this Chapter the relationship 
between y GT and folate levels is described.
PATIENTS AND METHODS
Serum levels of yGT were measured in 40 male and 38 female 
epileptic inpatients and outpatients receiving anticon­
vulsant therapy, their ages ranged from 17 to 71 years 
(mean 35 years). Twenty five patients were receiving 
phenytoin, six were receiving phenobarbitone, ten were 
receiving primdone, two were receiving sodium valproate 
and the remainder were receiving various combinations of 
these anticonvulsant drugs. Thirteen patients were also 
receiving carbamazepine. In twelve of these patients ^GT 
levels were measured on a second occasion, after being on
therapy with sodium valproate. Serum levels of alkaline
+-hphosphatase, Ca and triglyceride were measured in 24 of 
the patients.
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In addition, in this Chapter results for serum concen­
trations of PEMA' and primidone and of clonazepam in 
patients described in Chapters 5 - 7  have been further 
analysed and interpreted. Results for folate serum con­
centrations in patients described in the previous Chapter 
are also analysed here in terms of the level of enzyme 
induction; further folate concentrations were measured 
in 24 patients in whom drug doses had been increased or 
decreased, so that folate concentrations have been 
measured in a total of 111 patients on 135 dose regimes.
41 of these were patients in whom -yGT levels were 
measured.
RESULTS
The GT levels in six patients receiving phenobarbitone 
alone, were significantly lower (p<0.05, t-test, comparing 
the logarithms of the ^GT levels) than in patients receiving 
phenytoin or primidone as a single drug; also 14 patients 
receiving combined therapy with phenytoin and primidone 
showed higher levels (p<O.Ol) than 22 patients receiving 
phenytoin alone. The serum levels of yGT for patients 
with varying anticonvulsant therapies are given in Table 8.1 
On the basis of the levels obtained in patients on single 
drug therapy, correlating the yGT levels with the drug 
doses the patients were receiving, it was possible to 
quantify the effect of a given dose of a drug in raising 
yGT levels. 'Drug Units' were allocated as follows :
50mg of phenytoin equals 1 unit; 60mg of phenobarbitone 
equals 1.5 units; 250mg of primidone equals 1.5 units.
The combined doses of anticonvulsant drugs in patients on 
multiple drug therapy can then be described in terms of 
their ability to increase yGT levels by calculating the 
Drug Units received. Fig 12.1 shows a plot of serum yGT 
levels against Drug Units for 78 patients. A linear plot 
is obtained when the logarithms of the yGT levels are 
plotted against Drug Units, there being significance 
difference in yGT levels between male and female patients; 
the equation of the line is 
log yGT = 1.32 + 0.0567 Drug Units.
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DRUG THERAPY No of 
PATIENTS
MEAN
SERUM
y GT
SD RANGE
Phenytoin 25 62 50 10-189
Phenobarbitone 6 28 10 12- 44
Primidone 10 65 41 13-164
Phenytoin & Phenobarbitone 20 62 22 17- 101
Phenytoin & Primidone 14 93 40 42“164
Phenobarbitone & Primidone 1 48 - -
v.Sodium Valproate 2 15 — 9- 21
Table 12.1 Serum levels of yGT in 78 patients receiving 
anticonvulsant therapy
yGT
• Male 
o Fem ale 
n=78200-
• *
100-
o *
o*
$o
8 160
Drug Units
Fig 12.1 Relationship between the serum yGT
levels and the 'Drug Units' that 78 
epileptic patients on anticonvulsant 
therapy were receiving
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Administration of sodium valproate to twelve patients 
produced no change in the yGT levels. The mean level before 
treatment was 95.9 U/1 and after treatment was 85.2 U/1 - 
there was no significant difference between the means.
Serum Calcium and Alkaline Phosphatase
Serum calcium and alkaline phosphatase were measured in 24 
patients. The mean serum calcium concentration was 2.34 
± 0.11 SD mmol/1 (normal range 2.12 - 2.62 mmol/1); only 
one patient showed a level below the normal range. The 
mean serum alkaline phosphatase ^ level was 34.2 ± 10.5 SD 
U/1 (normal range 12 - 30 U/1);^patients showed levels 
above the normal range. There was a significant negative 
correlation (r = 0.477, p<0.05) between the serum calcium 
and alkaline phosphatase levels.
There was no obvious relationship between the raised 
alkaline phosphatase levels and the drugs received.
Fifteen patients receiving phenytoin (with or without 
other drugs) had a mean alkaline phosphatase level of 
36.1 U/1 and nine patients receiving other drugs only had 
a mean of 31.0 U/1; there was no significant difference 
between these means. There was no correlation between 
alkaline phosphatase levels and yGT levels. There was 
also no significant correlation between calcium concen­
trations and the Drug Units received, although there was 
a possible inverse relationship (r = 0.201). However, 
there was a significant positive correlation (r = 0.454, 
p 0.05) between the logarithm of the yGT level and the 
serum calcium level; the equation of the line was 
serum calcium = 2.02 + 0.170 log yGT. In fact, the one 
patient showing abnormally low serum calcium had the 
lowest yGT level (17 U/1) .
Serum Triglyceride
Serum trigylceride levels were measured after an overnight 
fast in the same 24 patients as those above. The levels 
ranged from 0,77 to 2.62 mmol/1 with a mean of 1.66± 0.54 
SD mmol/1. There was no correlation between triglyceride 
levels and levels of yGT.
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Serum Folate
Serum folate concentrations were measured in 41 of the 
patients in whom yGT levels were measured and the results 
are shown graphically in Fig 12.2. The serum folate con­
centrations appear to decrease initially as the yGT levels 
increase but the concentrations then level off as shown. 
Plotting the logarithm of the folate concentration against 
the logarithm of the yGT level, a negative straight line 
correlation was found which only just failed to reach 
significance at the 0.05 level (r = 0.297) ; the equation 
of the line was log folate concentration = 0.58 - 0.135 log 
y G T  level. A significant negative correlation was found 
when log folate concentration was plotted against Drug Units 
for 111 patients (in 24 of whom folate concentrations were 
measured on two different drug regimes) - the equation of 
the line was log folate concentration = 0.54 - 0.0179 Drug 
Units (r = 0.283, p <  0.001).
DISCUSSION
The data presented here suggest that both phenytoin and 
primidone treated subjects show a more severely raised GT 
level than those treated with phenobarbitone. This is in 
line with findings by other workers (Rundle and Sudell, 1973), 
It might, in fact, be expected that the patients receiving 
primidone would show higher yGT levels than the patients 
receiving phenobarbitone since the former had a higher 
mean serum concentration of derived phenobarbitone, but it 
may be that primidone itself has an effect since even with 
doses producing equivalent serum levels of phenobarbitone 
there appeared to be a greater elevation of yGT levels, 
lOOOmg of primidone produces a mean serum level of pheno­
barbitone approximately equal to that produced by ISOmg of 
phenobarbitone itself - the former dose is equal to 6 Drug 
Units whereas the latter is equal to 4.5 Drug Units. This 
provides an explanation of the results described in 
Chapter 3 for serum concentrations of phenytoin in patients 
receiving phenytoin alone and in patients receiving combined 
therapy with phenobarbitone or primidone. Patients receiving
Serum  
Folate jjg/l
6-1
n = 41
4 -
2 -
200
yG T U/1
Fig 12.2 Relationship between serum folate
and yGT levels in 41 patients on 
anticonvulsant therapy
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primidone appeared to show reduced serum concentrations 
of phenytoin but this did not occur with phenobarbitone; 
it is likely that this is due to a higher level of enzyme 
induction and hence increased phenytoin metabolism in 
patients receiving primidone.
Patients treated with phenytoin plus primidone showed 
significantly higher y GT levels than patients treated with 
phenytoin alone and thus the effects of these drugs appear 
to be additive, which suggests that it is reasonable to 
describe the combined dose of drugs in a patient on multiple 
therapy according to the potential effect on GT levels and 
hence presumably their enzyme-inducing properties. The Drug 
Units ascribed in this study to doses of phenytoin, 
phenobarbitone and primidone are similar to those ascribed 
by Richens and Rowe (1970).
The low yGT levels in the two patients receiving sodium 
valproate and the lack of elevation in patients on other 
anticonvulsants who had the drug added to their therapy, 
suggest that sodium valproate is not an enzyme inducer.
This is in line with a study in rats (Jordan et al, 197 6) 
in which there was found to be no effect of sodium 
valproate administration in rats on levels of cytochrome 
^450 other liver microsomal enzymes. Thus it is
unlikely that the effects of sodium valproate in causing 
higher serum levels of phenobarbitone and lower serum 
levels of phenytoin (see Chapter 7) are due to an increase 
or decrease in the level of induction.
In Chapter 5 it is suggested that phenytoin may induce the 
metabolism of primidone to PEMA and also that primidone 
may induce its own metabolism. This is in line with the 
enzyme-inducing properties of these drugs as measured by 
their effect on yGT levels. Fig 12.3 shows a plot of the 
Î PEMA/Primidone ratio against the Drug Units received 
for the patients described in Chapter 5. Theie is found 
to be a significant correlation (r = 0.403, p < 0.01) 
between the PEMA:primidone ratio and the Drug Units for the 
40 patients described in Chapter 5 in whom PEMA concen­
trations were measured. The Drug Unit concept may be
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useful in predicting the serum concentrations of primidone 
and PEMA obtained in patients on multiple drug therapy.
Similarly, the use of Drug Units may be valuable in pre­
dicting serum levels of clonazepam obtained in patients on 
multiple drug therapy. In Chapters 6 and 7 it was found 
that patients receiving other drugs generally showed lower 
clonazepam serum concentrations. Fig 12.4 shows a plot of 
serum clonazepam concentrations against Drug Units for 
patients on 3mg clonazepam daily and patients on 6mg 
clonazepam daily who were described in Chapters 6 and 7 
respectively. There is found to be a significant 
correlation (p<0.01) between the serum concentrations and 
the Drug Units for both groups of patients. An individual 
patient who showed good therapeutic response to clonazepam, 
described in Chapter 7, had a high serum concentration of 
the drug, although he was receiving fairly high doses of 
phenytoin and phenobarbitone. This patient showed a 
normal level of yGT, suggesting that there was no enzyme 
induction. Thus in some patients the calculation of Drug 
Units may not accurately predict enzyme-inducing effects 
and it may be desirable rather to measure serum GT in the 
individual patients.
Calcium Metabolism
Osteomalacia has been recognised as a complication of 
anticonvulsant therapy (Dent et al, 1970) and has been 
attributed to induction of the liver microsomal enzymes 
which convert cholecalciferol and 25-hydroxycholecalciferol 
into inactive metabolites (Hahn et al, 19 72). Low serum 
calcium and raised levels of alkaline phosphatase in treated 
patients have been described (Richens and Rowe, 1970;
Hunter et al, 19 71) as have low levels of 25-hydroxychole- 
calciferol (Hahn et al, 1975). If enzyme induction was 
responsible for the disordered calcium metabolism, one might 
expect to find a negative correlation between serum yGT 
activity and the serum calcium level.
Richens and Rowe (1970) produced a system for scoring anti­
convulsant drugs - one unit was allowed for every SOmg of 
phenytoin or 30mg phenobarbitone and 1.5 units for every
Serum ^^^ /^P rim id on e n=40
2
1
Drug Units
Fig 12.3 Relationship between the serum PEMA/
primidone ratio and the 'Drug Units' 
that 40 patients on primidone therapy 
were receiving. A significant positive 
relationship (p<0.01) is shown
Serum Clonazepam 
nm ol/l
6 mg/day
1504
1004
P<001
50
3 mg/day150"!
1004
504 p<0 01
10
Drug Units
Fig 12.4 Relationship between serum clonazepam
concentrations and the 'Drug Units' 
that the patients were receiving
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250itig of primidone - and found a significant inverse 
correlation between these Drug Units and the serum 
calcium level. The system for scoring Drug Units devised 
from the present study is similar, but only 0.75 units is 
allowed for every 30mg of phenobarbitone. Using this 
system, the negative correlation although non-significant 
(r = 0.201) was in fact higher than in the larger group 
of patients investigated in the previous study (r = 0.17). 
Thus the present study would appear to provide further 
evidence that the disturbance of calcium metabolism in 
epileptics is related to an effect of anticonvulsants on 
liver enzyme induction being an increased breakdown of 
vitamin D. However, in the present study a significant 
positive relationship was found between the yGT levels and 
the serum calcium, which is the opposite of what would be 
expected. This would suggest that, while the lowered 
serum calcium may be related to the total doses of drugs 
that the patient is receiving, it is not due to an 
enzyme induction effect; it is possible that enzyme 
induction may in fact raise serum calcium levels.
Serum Triglycerides
A correlation between the concentration of serum trig­
lycerides and of serum yGT within the general population 
has been reported (Martin et al, 1975). It was suggested 
that induction of a microsomal enzyme on the biosynthetic 
pathway for triglycerides may cause elevated serum trig­
lyceride. In addition, there has been a report that 
administration of oral contraceptives may produce raised 
levels of both serum triglyceride and yGT (Martin 
et al, 197 6) and a study of a few patients on anticon­
vulsant therapy found raised serum triglyceride and yGT 
(Annoni et al, 1976). Patients in the present study did 
not show serum triglyceride levels outwith the normal 
range and there was no correlation with serum and GT 
concentrations. This accords with studies by other 
workers of the effects of administration of phenobarbi­
tone to normal subjects, there being no significant 
change in total triglyceride (Durrington et al, 1976;
Ohnhaus et al, 1977). Another study has shown an
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increase in serum triglyceride after the start of phenytoin 
therapy but this change was a temporary one (Reunanen and 
Sotaniemi, 1975), The results in the present study suggest 
that there is no permanent change in serum triglyceride 
in patients on chronic anticonvulsant therapy.
Serum Folate
The finding of an association between the serum yGT level 
and the level of serum folate is evidence that the folate 
deficiency in patients on anticonvulsant therapy may be 
related to the induction of hepatic drug-metabolising 
enzymes. Similarly Maxwell et al (1972) have found a 
linear relationship between D-glucaric acid excretion 
when plotted logarithmically against the serum folate in 
a group of children. It appears that there is a relation­
ship between serum folate and the drug dose but only at 
low concentrations of enzyme-inducing drugs; the folate 
tends not to fall below a certain point and levels off 
with high drug doses.
However, it remains uncertain whether the lowered folate 
is really due to induction of folate metabolism in the 
liver. There may be no direct casual relationship 
between the level of enzyme induction and the serum 
folate concentration. However, studies in rats (Spray 
and Burns, 1972; Williams and Spray, 19 76) have shown 
that administration of phenobarbitone or phenytoin 
significantly increased the liver activities of glutamate 
formimino-transferase and methylene tetrafolate dehydro­
genase, enzymes involved in folate metabolism.
SUMMARY
1. Serum levels of yGT were assayed in 78 patients
receiving anticonvulsant therapy as a measure of 
the level of enzyme induction. The p>GT levels 
appeared to be related to the number and doses of 
drugs that the patient was receiving and it was 
possible to quantify the enzyme-inducing effect 
of a given dose of a drug in terms of 'Drug Units'.
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Serum calcium and alkaline phosphatase levels 
were measured in 24 patients. A number of patients 
showed raised alkaline phosphatase levels and 
there was a significant negative correlation 
(p<0.05) between alkaline phosphatase and calcium 
levels although only one patient showed an 
abnormally low serum calcium level. The serum 
calcium levels appeared to be inversely related to 
the Drug Units but there was a significant positive 
correlation (p<0.05) between serum calcium and 
the GT level.
Serum triglyceride levels were measured in 24 
patients. They were all in the normal range and 
there was no correlation with yGT levels.
The use of Drug Units may be valuable in predicting 
serum concentrations of primidone or clonazepam 
in patients on multiple drug therapy. Significant 
correlations were found between the PEMA;primidone 
ratio (p<0.01) or clonazepam serum concentrations 
(p<0.01) and the Drug Units that a patient was 
receiving.
A significant correlation was found between serum 
folate concentrations and the Drug Units that the 
patients were receiving ( p < 0.001). Lowered 
serum folate in patients receiving anticonvulsant 
therapy may be due to induction of folate 
metabolism.
It is concluded that the rate of metabolism of 
clonazepam and primidone and the lowered 'Èolate 
levels in patients on anticonvulsant therapy may be 
related to enzyme. However, there was no apparent 
effect of enzyme induction on serum calcium or 
triglyceride levels.
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CHAPTER 13
THE EFFECTS OF ANTICONVULSANTS ON SERUM IMMUNOGLOBULIN 
LEVELS
INTRODUCTION
Abnormally low levels of serum IgA have been found in 
patients receiving phenytoin (Slavin et al, 1974; Aarli 
and Tender, 1975; Sorrell and Forbes, 1975; Seager et al, 
1975; Fontana, 1976). In some patients also low IgG has 
been reported both in serum (MacKinney and Booker, 197 2; 
Aarli, 1975) and in CSF (Fossan, 1976). It remains un­
clear whether there is a specific effect of phenytoin, or 
whether other anticonvulsants also reduce levels of IgA 
and possibly other immunoglobulins. This Chapter describes 
immunoglobulin levels in patients receiving differed anti­
convulsant regimes; IgA levels have been compared in 
patients receiving phenytoin and patients receiving other 
drugs only. The possible mechanisms for a lowering of IgA 
levels are discussed and particularly the relationship 
between immunoglobulin metabolism and serum folate concen­
trations. The effect of folate administration on immuno­
globulin levels in the patients described in Chapter 11 is 
described.
PATIENTS AND METHODS
The patients studied were 83 epileptic inpatients who had 
been on anticonvulsant therapy for at least one year. Of 
these, 56 were receiving phenytoin and 27 were receiving 
other anticonvulsants only. All the patients were 
receiving at least one of the anticonvulsants phenytoin, 
phenobarbitone or primidone; in addition some patients 
were receiving other drugs - carbamazepine (15), sodium 
valproate (3), clonazepam (2), diazepam (1),sulthiame (1).
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Serum immunoglobulin (IgG, IgA and IgM) levels were 
measured in all patients on one occasion and in most 
patients on two occasions. In addition, serum concen­
trations of anticonvulsants and of folate were measured 
in these patients.
Serum immunoglobulin levels were measured in the 19 patients 
described in Chapter 11 who received therapy with folic 
acid or 5-methyltetrahydrofolate. Levels were measured 
before and one month after the start of folate therapy.
RESULTS
The 10 0% mean normal values for IgG, IgA and Igm in the 
laboratory in which the serum immunoglobulin measurements 
were carried out are IgG 947mg/100ml, IgA 248mg/100ml,
IgM 94mg/100ml and the normal range is regarded as 50- 
175% MNA (Hobbs, 1971) with a log-normal distribution.
The serum immunoglobulin levels for 82 patients receiving 
anticonvulsant therapy are summarised in Table 13.1 and 
the IgA levels are shown in Fig 13.1. The serum levels 
of IgG and IgM were generally within the normal range 
(although five patients showed somewhat lowered IgM levels) 
but thirteen of the patients receiving phenytoin (23%) had 
serum levels of IgA below 50% MNA. Only one of the patients 
not receiving phenytoin had a slight reduction, but there 
was no significant difference in the mean IgA level between 
patients receiving phenytoin and patients receiving only 
phenobarbitone or primidone (t =1.94, p<0.1, comparing the 
log values of the IgA levels). There was no correlation 
between serum IgA levels and levels of IgG or IgM.
The serum anticonvulsant levels in these patients are 
summarised in Table 13.2. The serum phenobarbitone levels 
in 4 patients with low IgA were significantly higher than 
in 24 patients with normal IgA (p<0.05, t-test) who were 
also receiving combined therapy with phenytoin and pheno­
barbitone. In addition, in patients receiving primidone 
and phenytoin, there was a significantly lower (p<0.05) 
serum primidone concentration in seven patients who were 
igA deficient compared to 16 patients with normal IgA, 
although the phenobarbitone concentrations in the two
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Fig 13.1 Serum IgA levels in 56 patients on
phenytoin therapy and 27 patients 
receiving other anticonvulsants only
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groups were the same. There was no apparent relationship 
between the reduced IgA levels and serum concentrations 
of phenytoin.
Patients receiving phenytoin had lower serum folate con­
centrations than patients receiving other anticonvulsants 
only, but the higher occurrence of abnormally low serum 
levels of IgA did not appear to be related to this. There 
was no correlation between reduced serum folate concen­
trations and low IgA levels; in fact, there was a nega­
tive trend between serum folate and IgA levels. There 
V7as also a negative trend which just reached significance 
between serum folate and IgG levels (r = 0.237, p< 0.05, 
correlating the log values of the folate and IgG levels.
In order to investigate the relationship between the 
immunoglobulin levels and the number and doses of drugs 
that the patients were receiving, immunoglobulin levels 
were correlated with 'Drug Units' (the method for cal­
culating Drug Units is described in the previous Chapter), 
There were negative trends between Drug Units and immuno­
globulin levels for IgG, IgA and IgM but this did not 
reach significance in any instance.
Serum immunoglobulin levels were measured in 19 patients 
who received folate therapy. There was a significant fall 
in levels of both IgA and IgG (p <0.01, Wilcoxon signed- 
ranks test) but not of IgM after folate therapy.
DISCUSSION
The incidence of IgA deficiency in the normal adult 
population is one in 500-700 individuals (Hobbs,1971 ).
In the present study, abnormally low serum IgA was found 
in 23% of patients receiving phenytoin, which correlates 
well with the findings of other workers (Slavin et al,
1974; Sorrell and Forbes, 1975; Aarli, 1976). The higher 
incidence of low IgA levels in patients on phenytoin relative 
to patients on other drugs would suggest that there is a 
specific effect of phenytoin on IgA metabolism. However, 
there was no significant difference between the mean serum 
IgA levels for patients receiving phenytoin and patients
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receiving other.drugs ; also, it should be noted that the 
patients receiving phenytoin were generally receiving higher 
combined doses on anticonvulsant drugs, being treated with 
phenytoin and phenobarbitone or primidone in combination.
If there is a specific effect of phenytoin on IgA levels, 
then a negative relationship between serum phenytoin and 
IgA levels might be expected; this was not found.
The reduction of IgA levels may be a consequence of 
reduced production or of increased breakdown. It is 
possible that anticonvulsants might cause increased break­
down of IgA (and possibly of other immunoglobulins) by
their effects on liver growth and enzyme induction. Little
is known about immunoglobulin catabolism but it is known 
that 30% of IgG is broken down in the liver and high doses 
of corticosteroids can increase breakdown.
In patients in the present study receiving primidone, there 
were significantly higher phenobarbitone concentrations 
and lower primidone concentrations in patients with low 
IgA levels; a positive relationship between serum primidone 
and IgA levels has also been reported by Slavin et al (1974). 
The increased phenobarbitone: primidone ratio in patients 
with low IgA levels could be explained by an increased 
metabolism of primidone in these patients (see Chapter 5) 
and this would be in line with the hypothesis that there is 
higher enzyme induction in these patients, which increases 
the metabolism of IgA in the liver. However, no correlation 
was found between the IgA levels and the enzyme induction as 
measured by increased serum levels of yGT. In addition, 
although there was a negative trend, there was no correlation 
between IgA (or IgG and IgM) levels and the combined doses 
of enzyme - inducing drugs as expressed in 'Drug Units’.
It was noted that there were negative trends towards lower 
levels of IgA and IgG (significant in the case of IgG) in 
patients with higher serum concentrations of folate. This 
is other than might be expected since patients show low 
concentrations of folate on high doses of anticonvulsants 
(see Chapter 11) and patients on phenytoin showed lower 
folate concentrations than patients receiving other anti­
convulsants only. When folate was administered to patients
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on anticonvulsant therapy, significant reductions in levels 
of IgA and IgG were observed. The most likely explanation 
for these findings is that folate is involved in immuno­
globulin catabolism and that the low folate concentrations 
obtained in patients on anticonvulsant therapy inhibit 
metabolism. It is thus hypothesised that there are two 
opposing effects of anticonvulsants on immunoglobulin 
metabolism - they directly increase breakdown by their 
enzyme-inducing effects but indirectly also decrease 
their breakdown via their effects in lowering folate 
concentrations. It may be that there are also more wide­
spread effects of anticonvulsants on serum protein 
metabolism. For example there has been a report of 
decreased serum haemopexin and concentrations and 
increased serum caeruloplasmin after phenytoin therapy 
(Seager, 1977); it is possible that these conflicting 
effects may reflect similar effects of phenytoin on 
protein catabolism to those suggested for immunoglobulins, 
although it is also possible that phenytoin may induce 
protein synthesis by the liver.
S U M M A R Y
1. Serum immunoglobulin levels were measured in 83
patients receiving anticonvulsants. 23% of patients 
receiving phenytoin showed serum IgA levels below 
the normal range.
2. There was no apparent relationship between serum
phenytoin levels and levels of IgA but there were 
significantly lower serum primidone levels in 
patients who were IgA deficient. It is suggested 
that this may reflect an increased rate of 
metabolism, both of IgA and of primidone in these 
patients.
3. There was a significant negative relationship
(p<0.05) in these patients between serum folate 
and IgG levels and administration of folate to the 
19 patients described in Chapter 11 significantly
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reduced serum levels of IgG and IgA {p<0,01). 
It is possible that the low serum folate concen­
trations in patients on anticonvulsant therapy 
may inhibit immunoglobulin breakdown. -
APPENDIX
METHODS USED IN THIS THESIS
In Chapter 2 brief summaries of the methods used in this 
thesis for measurement of anticonvulsants were given. More 
extensive descriptions are given here of these methods.
In addition, this Appendix includes details of methods 
used for measuring protein binding of drugs and of methods 
for assay of various enzymes and metabolites in body fluids
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Extraction of Phenytoin, Phenobarbitone, Primidone, HPPH 
and PEMA from Biological Fluids
The method was based on that of Goudie and Burnett (1973) 
and was basically the same for plasma, whole blood, urine 
or CSF samples. HPPH was present in measureable quantities 
only in urine.
Materials
1. Img/ml solutions in MeOH of the above drugs and
metabolites stored at 4^0
2. Internal standard. Stock solution Img/ml p-tolyl
phenytoin in MeOH
3. Dichloromethare (Analar)
4. Cycllohexane (Analar)
5. lOmM NaOH
6. IM HCL
7. 9cm phase-separating paper (Whatman)
Standardisation 
Working standards
1. Drugs. Pipette 1ml of each of the relevant stock
solutions into a volumetric flask and make up to
2 0ml with lOmT-l NaOH (50 ;jg/ml)
2. Internal Standard. Dilute 1ml of stock solution with
4ml of lOmM NaOH
Procedure
1. Preparation of Standard Curve. Make up the following
dilutions with lOmM NaOH of the working standard :
0,5,10,20,30,40,50 pg/ml of drug. Pipette 1ml of each
of these dilutions into test tubes and add 1ml of 
horse serum
2. Preparation of Specimens. Add 1ml specimen and 1ml
lOmM NaOH to test tubes
3. Extraction. To standards and tests add 0.1ml internal
standard and 0.1ml IM HCI. Add 5ml cyclohexane and mix 
for 5 minutes by shaking. Centrifuge briefly and 
discard upper cyclohexane phase.
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Add 10ml dichloromethane and mix for 5 minutes. 
Remove aqueous phase using phase separating paper 
(which has been previously washed with dichloro­
methane) . Evaporate the extract to dryness at 
50^ in water bath under nitrogen. The residues 
can be stored in fridge for up to one week prior 
to chromatography.
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Gas Chromatographic Analysis of Phenytoin, Phenobarbitone 
Primidone and HPPH
The method is based on that of Goudie and Burnett (1973) 
but using a gas chromatograph with flame ionisation 
detectors rather than nitrogen detectors. The method has 
been extended to include assay of HPPH. A Pye Unicam 10 4 
gas chromatograph equipped with dual flame ionisation 
detectors and temperature programming was used. The drugs 
were chromatographed on 3-foot long coiled glass columns 
packed with 3% OV-1 on chromsorb mesh WCHP (Pye Unicam)
1. Add 0.1ml of 25mM trimethylphenyl-ammonium hydroxide
(TMPAH) to dried extract in conical tube immediately 
before chromatograph. Mix on vortex mixer for 15 
seconds and inject 2 ;al into GLC.
2. Gas chromatography conditions :
Column oven programmed 1 min at 2 00°C then 10^/min 
to 275°C
Detector oven 300°C
Injection point heater 275^C
Nitrogen carrier flow rate 60ml/min
3Attenuation 1 x 10
The peaks obtained are shown in the accompanying 
figure. Peak heights due to the drugs are measured 
in relation to the internal standard (p-toly- 
phenytoin)
Note : Administration of carbaraazepine was found to inter-
,,fere slightly with the assay of primidone
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Gas Chromatographic Analysis of PEMA
The method is based on that of Baumel et al (19 72). The 
gas chromatograph and column used were as for the previous 
assay.
1. Add 0.2ml of n ,N - Dimethylformamide to 1ml of bis
(trimethylsilyl acetamide. Add 20 pil of this to 
residue (5 minutes before injection) and mix on 
vortex for 15 seconds. Inject 2 ;ul.
2. Gas chromatography conditions :
Column oven programmed 2 minutes at 190°C, then 
15^C min to 240^C. Detector oven 300^C.
3Nitrogen flow rate 60ml/min. Attenuation 1 x 10 . 
The peaks obtained for primidone and PEMA are 
shown in the accompanying figure. The peak due to 
PEMA is measured in relation to the peak due to 
primidone, the concentration of the latter being 
measured by the method above.
Note : Administration of ethotoin was found to interfere
markedly with this assay.
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■Assay of Sodium Vaproate by Gas Chromatography
The method used was similar to that of Chard (1976). A Pye 
Unicam 104 gas chromatograph with flame ionisation detectors 
was used as in the previous assays but there was no 
requirement for temperature programming.
Standardisation
1. Sodium valproate standard solution - Img/ml in horse
serum
2. Internal standard solution - Img/ml cyclohexane 
carboxylic acid in HgSO^
3. Preparation of standard curve. Make up the following
dilutions with horse serum of the sodium valproate 
standard solution - 0,20,50,100,150,200 pg/ml
Extraction
Pipette 100 pi serum (for both standards and tests), 100 ul 
internal standard solution and 100 pi dichloromethane into 
a small glass tube. Mix on vortex for 30 seconds and 
centrifuge (1 minuted at 2000 rpm) to give a clear lower 
organic layer. Inject 2 pi into GLC.
Gas Chromatography
Column 3ft x 2mm packed with 2% W/11 on Chromasorb W(HP) 
80-100 mesh (Perkin-Elmer Limited). Oven temperature 
150^C. Detector temperature 250^C . Nitrogen flow rate
3
30ml/min. Attenuation 2 x 10
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Radioimmunoassay of Phenytoin
This was used to measure phenytoin concentrations in saliva, 
described in Chapter 9. The method was a specific double­
antibody radioimmuniassay using an antiserum raised against 
phenytoin-valerate-BSA (Paxton et al, 197 6) and an iodinated 
tracer (Paxton et al, 1977). 20 pi of sample (serum, saliva
or CSF) is incubated with an appropriate dilution of phenytoin 
antiserum, donkey anti-rabbit precipitating serum (Wellcome) 
and trace amounts of -phenytoin for 1 hour at 37^C.
After centrifugation of the incubate at 4^C for 30 minutes
at 2500g the supernatant is aspirated and the precipitate
12 5(containing the antibody bound I -phenytoin) counted
for 10-20 seconds on a counter.
The detection limit of the assay was approximately 0.4 nmol/1 
and there was a good correlation with the gas chromato­
graphic method )r = 0.9 5 with gradient = 1.13) used in this 
study in a double-blind comparison on 200 serum samples 
obtained from epileptic patients over a six month period 
(Paxton et al, 1977).
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Plasma Protein Binding of Phenytoin and Phenobarbitone
Heparinised blood was obtained from patients receiving 
one or more of the anticonvulsants phenytoin, phenobarbi­
tone or primidone. The plasma was removed and small con­
centrations of ^H-labelled phenytoin and ^^C-labelled 
phenobarbitone (see following section) were added. Ultra­
filtration through cellulose tubing was carried out by the 
method of Lunde et al (1970) in cellophane dialysis tubing 
(Visking) with a flat diameter of 6mm. The tubing was first 
soaked in isotonic saline for 15 minutes and the excess 
water squeezed out. One end was carefully double knotted 
and 2ml of labelled plasma was added to the bag, which was 
then suspended in a 10ml glass centrifuge tube. The bags 
were centrifuged twice at 800xg for 10 and 20 minutes 
respectively. The filtrate obtained after the first centri­
fugation, corresponding to the water content of the bag, 
was discarded. The drug content in 50 pil of the second 
filtrate was determined by radioassay as described in the 
following section. This filtrate was routinely screened 
for protein by observing the precipitation upon adding one 
drop of concentrated perchloric acid. All studies were 
carried out at room temperature.
Equilibrium Dialysis
Equilibrium dialysis was also carried out using 6mm cello­
phane dialysis tubing. 1ml of labelled plasma was inserted 
into a bag, which was knotted at both ends. The bag was then 
placed in a small stoppered plastic tube containing 2ml of 
isotonic phosphate buffer (pH 7.4) such that the top of the 
buffer solution in the tube just covered the top of the plasma 
in the bag. The tube was stoppered and placed on a rotating 
mixer. Equilibration was allowed to take place for 16 hours 
at a constant temperature. The drug content in 10 0 jul of 
the dialysate was determined by radioimmunoassay.
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Measurement of Protein Binding using Ultrafiltration Cell
In Chapter 8 a study to determine the effects of sodium 
valproate on protein binding of phenytoin and phenobarbitone 
is described. An 'Amicon' Model 12 ultrafiltration cell 
was used (volume 10ml), the plasma being filtered through a 
'Diaflo* UM-10 membrane. Rotary stirring is provided by 
means of a magnet and the driving force for ultrafiltration 
is nitrogen gas.
The cell was initially charged with 10ml of plasma. Small 
volumes of radioactively labelled phenytoin and pheno­
barbitone were added to give a concentration of 20 pg/ml of 
each. The cell was immediately pressurised and the filtrate 
collected. Fractions collected at approximately 10,20 and 
30 minutes were taken for analysis by scintillation counting. 
Immediately after the last fraction was collected, 
pressurisation was removed and sodium valproate was added 
to the plasma in the cell to give a concentration of 100 
;ug/ml. The cell was re-pressurised and further fractions 
for analysis obtained at 40,50 and 60 minutes. The total 
filtrate volume obtained throughout the experiment was less 
than 10% (ie 1ml) of the cell charge. The experiment was 
carried out at room temperature.
It is theoretically possible using this method to determine 
the binding kinetics of drugs to proteins. However, it was 
found that the rates of binding of phenytoin and pheno­
barbitone to plasma proteins were too rapid for this to be 
accomplished.
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Radioassay of Phenytoin and Phenobarbitone
This assay was used in studies described in Chapters 8 and 
10 involving measurement of drug binding in plasma or 
uptake by RBC's. The radioactively labelled drugs were 
added to plasma or whole blood in vitro.
Materials
3
1. H-labelled phenytoin (5 Ci/mmol) (Radiochemical
Centre, Amersham) 25 iiC dissolved in 10ml ethanol.
2. ^^C-labelled phenobarbitone (20 Ci/mmol) (Radio­
chemical Centre) 50 /iCi dissolved in 10ml ethanol.
3. NE 260 scintillation fluid (Nuclear Enterprises Ltd)
4. 0.9% saline.
5. Glacial acetic acid.
6. 70% hydrogen peroxide (HgOg).
Method
1. 1ml of stock solution,of each labelled drugs are
combined and made up to 5ml with isotonic saline 
to make working solution.
2. For measurement of uptake by RBC, 0.1ml of working
solution is added to 4ml whole blood. Both 0.1ml of 
plasma and 0.1ml of RBC (resuspended to original 
volume in isotonic saline) are taken for counting.
3. For measurement of protein binding by ultrafiltration
of equilibrium dialysis, 0.1ml of working solution
is added to 2.5ml plasma, 0.05 ml of ultrafiltrate or
0.1ml of dialysate are taken for counting.
4. For labelled plasma ultrafiltrate or dialysate, add
to 5ml of scintillation fluid and count for 5 minutes.
5. For labelled RBC, add 0.1ml glacial acetic acid and
0.1ml H2O2 to 0.1ml RBC in scintillation vial to 
decolourise RBC. Heat open vials at 70^ for 30 
minutes. Add 5ml scintillation fluid and count for 
5 minutes.
6. ^H and '^^ C are both counted in Channel 1 while ^^C 
alone is counted in Channel 2. A ^^C standard is
used to calculate the ratio of ^^C counts in Channel 1 
to ^^C counts in Channel 2, Channel 1-Channel 2 x ratio
gives the counts.
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Enzymes and Metabolites in Body Fluids 
Folate
Chapter 11 involves a study of folate concentrations in 
serum and CSF. A modification of the L.casei method 
(Herbert, 1966) was used. This was carried out in the 
Department of Haematology of the Southern General Hospital, 
Glasgow,
KVA and 5-HIAA
Measurements of these amine metabolites in CSF are described 
in Chapter 11. They were estimated spectrophotofluori- 
metrically by the method of Ashcroft et al (196 8) . The 
fluorimeter used was an Aminco-BowmanSPFl25 fitted with an 
off-axis ellipsoidal condensing system.
Immunoglobulins
Serum immunoglobulin (IgG, IgA, IgM) concentrations 
described in Chapter 13 were measured by nephelometry using 
the technicon AIP system. These measurements were performed 
in the Department of Haematology.
Serum Albumin
Albumin concentrations described in Chapter 8 were measured 
colorimetrically by a method based on the binding of the dye 
broracresol green (Doumas and Biggs, 1972).
The following enzymes and metabolites were determined using 
Boehringer Test Combination Kits.
y  Glutamyl Transferase
Chapter 12 involves studies of serum levels of yGT, which 
were measured colorimetrically by a method based on hydrolysis 
of the substrate.
Alkaline Phosphatase
Alkaline phosphatase levels in serum, described in Chapter 
i2 were measured colorimetrically by a method based on the 
hydrolysis of the substrase p-nitrophenylphosphate.
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Triglycerides
Serum triglyceride concentrations, also described in 
Chapter 12 were measured spectrophotometrically by a 
method involving saponification and then assay of the free 
glycerol by the NAD produced in its reaction with 
glycerokinase.
Creatinine
Chapters 4B and 5 include studies of concentrations of 
drugs and metabolites in 24-hour urine specimens. 
Completeness of collection was checked roughly by measuring 
creatine production. Creatinine in urine was measured 
colorimetrically by a method involving the reaction with 
picric acid.
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